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ABSTRACT 
 
Past research efforts have focused on the energy difference between altered 
locomotion methods in fractional gravity at different speeds, suggesting that skipping is 
energetically more efficient than walking and running in these environments. While 
skipping may be more beneficial from an energy standpoint, the full range of reasons 
behind the gait transition and locomotion selection have not been researched. This 
includes damage to the muscles of the leg, which is partially prevented by a transition 
from walking to running. In a space environment, these factors will play a role in 
astronaut health and injury prevention. For this study, participants walked, ran and 
skipped on a treadmill while being supported by an analog for activity on other planets 
called the Active Response Gravity Offload System (ARGOS). These intervals were 
performed under 1g, and then under simulated .38g, and .17g conditions to simulate 
gravity conditions on Mars and the Moon, respectively. Electromyography was used to 
monitor muscle activation, along with the Vicon motion capture system for 3D motion 
analysis. Results show that there are significant changes (p <.05) in activation energy in 
the tibialis anterior and medial gastrocnemius under simulated Martian and Lunar gravity 
conditions, as well as significant changes (p <.05) in dorsiflexion and plantar flexion. 
These findings suggest that there are fundamental changes in the way humans move in 
these fractional gravity environments, and that the effect these changes have on the body 
should be included in the development of astronaut training regimen development. 
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CHAPTER I. INTRODUCTION 
 
The efforts of space exploration have recently turned back to a sustained human 
presence on the Moon, as well as our first crewed mission to Mars. Shifts in space policy 
and new commercial ventures have spurred the announcement of the Artemis program, 
NASA’s multi-phase path from the Moon to Mars. Artemis 1 will be the next human 
mission back to the Moon, will see the first woman step foot on the lunar surface, and is 
set to land by 2024. With this new push back to the Moon and beyond it is important to 
reconnect with the lessons learned from Apollo, and how training needs to be updated to 
reflect the current scientific knowledge base.  
One area that has been studied pre and post-Apollo is how humans move around in 
lower gravity environments, such as on the Moon or Mars. NASA developed a Reduced 
Gravity Walking Simulator to study human movement and give astronauts the ability to 
practice moving in reduced gravity before they ever stepped foot on the moon (Hewes, 
1969).  Though this simulator provided a way for researchers to study possible movement 
in lunar gravity levels, it restricted movement to forward momentum (Hewes, 1969) and 
was not used to develop a locomotion training regimen. Later on, video of Apollo 
astronauts moving on the moon in what appear to be skipping gaits resulted in post-
Apollo studies on the efficiency of skipping in these environments. The idea of skipping 
being the preferred method of locomotion in these environments based on efficiency has 
dominated subsequent research.  
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While the energy efficiency of locomotion method is inherently coupled with the gait 
choice, familiarity and training will undoubtably also play a role in selection. When 
asked about his locomotion selection on the moon during a Question and Answer session 
at the Fiske Planetarium located at the University of Colorado, Boulder, Apollo Astronaut 
Harrison “Jack” Schmitt noted that he selected an apparent skipping gait because it was 
familiar to him, as it was similar to the leg motions he had become accustomed to as an 
avid cross-country skier (Schmitt, 2018). He further went on to suggest a study on cross-
country movements over skipping in reduced gravity environments. This revelation that it 
was not necessarily a new gait, but a gait that he had become accustomed to through 
years of practice and chose to use on Moon, shines light on the importance of training for 
these missions. Future missions to the Moon and Mars should have locomotion training 
that takes energy efficiency and biomechanics of locomotion into account.   
 
1.1 Background 
1.1.1 Human Locomotion 
There are three locomotion methods being explored in this experiment: walking, 
running and skipping. Walking and running are commonly utilized depending on the 
speed of the individual, with a preferred transition speed between the two occurring at 
approximately 4.5 mph for most people (Hreljac, 1995). Skipping is considered a novel 
gate by most and is usually only observed in children or during play to signify joy. Most 
people do not consciously think of the mechanical differences between walking and 
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running (or skipping, for that matter), but these differences are essential for both their 
selection at certain speeds on Earth, understanding their energy expenditures, and for the 
consideration of locomotion methods on other planets due to reduced or increased gravity 
levels.  
Locomotion methods, or gaits, are differentiated by the difference in stride, step, 
and stand and swing phases.  Figure 1 from Minetti (1998) shows the cadence of walking, 
running, and skipping, including when either foot is in contact with the ground 
(rectangles) and when they are in float/flight (no rectangle). 
Gait Terms (Enoka, 2002): 
• Stride- a full gait cycle, from event on one foot to the same event on the 
same foot 
• Step– half of a stride, a cycle of an event on one foot to the same event on 
the opposite foot 
• Stance phase - when a foot is experiencing support from the ground, 
beginning at heel strike and ending with toe-off. 
• Swing Phase – when a limb is not experiencing support from the ground. 
This begins with toe-off and ends at heel strike.  
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1.1.1.1 Walking 
As the primary locomotion method for humans on a daily basis, walking is the 
lowest energy cost locomotion method at these speeds in the 1g environment, as well as 
being the smoothest locomotion method to reduce jostling of the brain and other tissues 
(Perry, 1967). Mechanically, walking is characterized by at least one foot being on the 
ground at a time, which is accomplished by an overlapping of stance time between limbs 
and is usually utilized at slower speeds compared to running (Olympic style race walking 
speeds can reach over 12 mph, but this is atypical).  
1.1.1.2 Running 
Utilized at higher speeds, running involves no overlap of stance phases between 
limbs and includes a phase where both limbs are entirely off the ground, known as the 
float or flight phase.  
1.2.1.3 Skipping 
There are two types of skipping: unilateral and bilateral. Unilateral skipping 
occurs when a person keeps the same foot forwards during the skip, while bilateral 
skipping occurs when there is an alternation between the left and right foot skipping. 
Bilateral skipping is the method we normally think of on Earth (such as skipping 
children), while unilateral skipping is the observed form in videos of astronauts on the 
moon (Minetti, 1998). While walking and running have consistent stance and swing 
phases, skipping alternates between a shorter and longer stance phase with the order of 
foot contact depending on whether unilateral or bilateral skipping is being employed. 
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Skipping also has ipsilateral foot-ground contact events, unlike walking and running 
which have contralateral foot-ground contact events (Ackermann and van den Bogert, 
2012). This means that during skipping, each foot has two ground-contact events before 
the opposite foot touches the ground.   
 
Figure 1. Locomotion Cadences (Minetti 1998) 
Depiction of walking, running and skipping cadences. Reprinted from “The Biomechanics of Skipping 
Gaits: A Third Locomotion Paradigm?” by A.E. Minetti, 1998, Proceedings: Biological Sciences 
265(1402), 1227-1235 
 
 
1.1.1.4 Preferred transition speed 
When moving from slower to faster speeds, humans switch from walking to 
running at the cleverly named walk-run transition. This transition occurs at the preferred 
transition speed, or PTS, when it seems like less effort to run than walk. Whether it is 
triggered by an actual metabolic reduction or by other biomechanical means is hotly 
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contested, as will be discussed in the literature review. The cause of PTS will be a 
contributing factor to the selection of gait type on other planets.  
1.1.2 Movement 
1.1.2.1 Muscles 
Muscles are responsible for the movement of the human body. The brain signals 
the contraction of muscle fibers, which cause the movement of organs and the skeletal 
system. Of the three types of muscle, two are autonomous (cardiac and smooth muscle), 
while skeletal muscle is voluntary. Skeletal muscle contractions move limbs by pulling 
on the muscle attachment point known as the insertion, with help from another muscle 
attachment point called the origin, which is where the muscle is anchored to the part of 
the bone that does not move during the contraction.   
1.1.2.1.1 Tibialis anterior 
The tibialis anterior is the strongest dorsiflexor (extension) muscle and is active 
during the swing phase, and the heel strike through flat foot section of the stance phase. 
This activation is used to reduce the slapping impact of the foot on the ground, and to 
raise the toes to avoid tripping (Brockett & Chapman, 2016). The tibialis anterior is 
located on the anterior side of the leg (See Image 1) 
1.1.2.1.2 Medial gastrocnemius 
The gastrocnemius and soleus are responsible for the majority of plantar flexion 
and come together to form the Achilles tendon. The medial gastrocnemius was selected 
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for this study because the muscle belly had less obstruction for surface EMG electrodes, 
as the gastrocnemius and Achilles tendon lays between the soleus muscle and the skin 
(See Image 1).  The Medial gastrocnemius was chosen over the lateral gastrocnemius 
because of the position of the tibialis anterior electrodes, as to avoid crosstalk. 
A B  
 
 
Image 1. Tibialis anterior and medial gastrocnemius muscles 
 A Tibialis anterior (A), medial gastrocnemius, which lies on the inner side of the leg (C), and a cross-
section of where the muscles occur in the leg (B).  Adapted from Netter’s Anatomy Coloring (3-29,3-30), 
by J.T. Hansen, 2014, Philadelphia, PA: Saunders Elsevier. 
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1.1.2.1.3 Muscle Activation  
Like all muscles, the tibialis anterior and medial gastrocnemius muscles are 
controlled by nerve impulses. These impulses, also known as muscle fiber action 
potential in this situation, are based on the rapid changes in electrical potential across the 
muscle cell membranes. The result of this action potential is the contraction of the 
muscle, with the intensity of this contraction increasing proportionally to the action 
potential exhibited upon it. The application of Ohm's law:  
𝐼 = 𝑔 ∗ 𝑉 
(Equation 1)  
where I is the current, g is the conductance and V is the potential difference. As action 
potential is a change in membrane potential difference, applying Ohm’s law shows that as 
the action potential increases so does the current associated with it. The potential 
difference within the muscle itself, not within the associated motor neurons which is 
caused by increase in current, can be detected by the electrodes used in electromyography 
(EMG) (Enoka, 2002). Simply put, EMG conveys muscle fiber activity generated as a 
result of motor neuron activation (Farina et al., 2014). 
Studies on muscle activity have demonstrated that muscle activity reductions 
varied by muscle during different levels of weighting. Mercer et al. (2013) used a lower-
body positive treadmill to support the participants during running exercises, simulating a 
reduction in weight between 50-80% during running trials at three speeds. Gastrocnemius 
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activity reduced in line with the reduction in body weight of the subject, unaffected by 
speed, while the activity of the tibialis anterior decreased with bodyweight while 
increasing with speed. They did note that the reduction in activity was not equal to the 
reduction in weight, suggesting that there is a muscle activation “floor” for running 
activities. (Mercer et al., 2013). 
1.1.2.1.4 Muscle Damage 
Muscle damage can be seen in the form of a strain, pull or tear, and can affect a 
portion of a muscle or the entire muscle and associated tendons (Laumonier and 
Menetrey, 2016). Muscle injury can cause swelling, bruising, pain, weakness, and 
complete inability to use the muscle or limb(s) associated with the muscle. This damage 
can occur due to overuse of a muscle, such as quickly lifting weights too heavy for the 
comparative strength of the muscle. 
1.1.2.1.5 Joints 
A joint is a connection between two bones on a human body, consisting of 
connective tissue, including tendons, ligaments, and cartilage. The bone structure 
prevents flexing and movement in healthy bone, so a joint is required for the everyday 
movement of the skeletal system.  
1.1.2.1.5.1 Ankle Joints 
The ankle is made up of three joints that carry many names among different 
literature: the subtalar (talocalcaneal) joint, talocrural (tibiotalar or ankle joint proper) 
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joint, and the interior tibiofibular joint, which is often considered a part of the tibiotalar 
joint. Additionally, some literature claims the transverse-tarsal (talocalcaneonavicular) 
joint is also part of the ankle (Brockett & Chapman, 2016). The ankle is considered a 
synovial hinge joint, where the tibia and fibula contact the talus and allow for 
dorsiflexion and plantarflexion. The two major movements of the ankle that occurs 
mainly at the tibiotalar joint, though all of these joints play a part in this basic movement 
(Brockett & Chapman, 2016).  
1.1.2.1.5.2 Joint Angles 
Joint angles are the degree of extension or flexion from a fixed point, which is 
usually based on a human standing. When discussing movement of the ankle, the term 
“dorsiflexion” is used for pointing the foot upwards from 90°, while “plantar flexion” is 
used to describe pointing the toe downward from 90° (See Image 2). This movement is 
along the sagittal plane of the foot and includes the tibiotalar and subtalar joints within 
the ankle. The full range of motion (ROM) of the ankle varies depending on many 
factors, including the age of a subject, geographical location, cultural influences, daily 
activity level or foot injuries (Brockett & Chapman, 2016), but is normally between 0-20° 
for dorsiflexion and from 0-55° for plantar flexion (Nordin & Frankel, 2001). However, 
the ROM exhibited by the ankle during locomotion is typically lower than the full ROM 
of the ankle, with average walking dorsiflexion peaking at 10.2° and plantar flexion 
peaking at 14.2°(Stauffer et al., 1977).   
11 
 
 
 
Image 2: Dorsiflexion & plantar flexion.  
Dorsiflexion occurs when the foot is pointed upwards, while plantar flexion occurs when the toes are 
pointed downwards.  Adapted from Netter’s Anatomy Coloring (1-30), by J.T. Hansen, 2014, Philadelphia, 
PA: Saunders Elsevier. 
 
1.1.2.1.5.3 Joint Injury  
Damage at a joint can have long rehabilitation times, varying from short stints of 
rest and elevation for a strain to surgeries for injuries that involve torn ligaments. Joint 
injuries include strains, sprains, fractures, and dislocations, and involve joint muscles, 
ligaments and bones, depending on the injury. Studies of large groups of sports injuries 
show that ankle and lower limb injuries are extremely common, with ankle ligament 
injuries being the most common (15% of all NCAA injuries between 1988-2004) and 
12 
 
50% of all injuries involving the lower limbs (Hootman et al., 2007). Another study 
focusing on high school athletes found that 52.8% of all injuries were lower extremity 
sports-related injuries, with 50% of those being sprains, 40% of all injuries occurring at 
the ankle, and 42% of all fractures occurring at the ankle (Fernandez et al., 2007).   
 
1.1.3 Fractional Gravity Environments 
 
The environment that an organism lives in defines the growth and evolution of 
muscles and the skeletal system, as well as the organ systems that it relies on to survive. 
In this respect, humans are no different from any other creature. Humans evolved in a 1g 
environment, where 1g stands for the normal gravitational force equivalent, or g-force, 
felt per unit mass on the Earth’s surface as caused by gravity. This has shaped our 
locomotion style affected the structure of our bones and the size of our vestibular organs 
and everything in between. These evolutionary adaptations show that natural selection is 
working on us, shrinking muscles and bones we do not use until they disappear without 
consequence, or growing the ones we need until they are optimal for our daily needs. 
Unfortunately for the future of human space exploration, the force of microgravity, where 
the pull of gravity is not strong enough for objects to feel like they have a weight, is so 
far below the 1g felt on Earth that human body functions could vary to an extreme level. 
One such function is the circulatory system, which exhibits fluid shifts inside the body, 
changing the distribution of blood upwards (Drummer et al., 2000, Fu et al., 2004,). This 
change can affect the perception of your surroundings and cause space motion sickness, 
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among other health problems. Other systems that rely on gravity, such as the 
musculoskeletal system, degrade to levels that render them useless upon returning to 
Earth. Between 1g and microgravity there are fractional gravity environments, such as the 
Moon and Mars, with gravity levels of .17 g and .38 g, respectively. The changes to 
human biological functions are less obvious, as there are few examples of humans in 
these environments (limited only to Apollo astronauts). Terrestrial analogs for these 
environments exist, but the time spent in these analogs and the assumptions made leave a 
question as to their fidelity to fractional gravity environments.  
1.1.3.1 Astronaut Training & Simulators 
NASA astronauts receive two years of training as Astronaut Candidates before 
their first launch. While the majority of this training is to ensure skill in their endeavors, 
much of it is focused on simulating the space environment to test physical compatibility 
with spaceflight, and to acclimatize them to the general feeling of weightlessness. 
Astronaut Candidates train in facilities that offer a range of fidelity, with no simulator 
being a perfect analog for spaceflight. The Neutral Buoyancy Lab (NBL), which has a 
large pool and a mockup of the ISS where they can practice EVA procedures in an 
environment that simulates space movement and the bulk of the spacesuits they will be 
performing them in, (Seedhouse, 2010) but does not offer accurate biomechanics or 
metabolic rates (Norcross et al., 2010). Other methods, such as parabolic flights, offer 
seconds of actual weightlessness but pose limits in the number of people and equipment 
that can be involved in the tests, not to mention the prohibitive length of these weightless 
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periods (Norcross et al., 2010). Additionally, some training and studies are being 
conducted on reduced gravity simulators such as NASA Johnson Space Center’s Active 
Response Gravity Offload System, or ARGOS, which can simulate the fractional gravity 
environments between 1g and microgravity for human and robotic testing (NASA 2013, 
Valle et al., 2011). This provides more prolonged levels of simulated micro or fractional 
gravity and proximity to testing equipment, as many of these systems are located at space 
centers. The ARGOS builds on of the Partial Gravity Simulator known as the POGO, 
which only had forward and up and down abilities (X & Z), while the ARGOS includes a 
third degree of freedom in the Y plane. Finally, field analogs allow for testing of tools 
and equipment in realistic EVA locations but are limited to 1g and therefore do not offer 
a full simulation of biomechanical moment on other planets.  (Norcross et al., 2010). The 
actual differences in fractional gravity will need to be tested and compared to the data 
collected in studies from ARGOS and other simulators, as the impact of the internal 
mechanisms of these machines on the movement of the participants  is not yet understood 
at this time, especially given differences in ground reaction force between ARGOS and 
parabolic flight trials (Crowley et al., 2014).  
 
1.1.3.2 Muscle and Bone Density Loss 
Weakness and fatigue occur after just several days in microgravity conditions 
(Leach and Rambaut, 1983), though the effects can continue to grow the longer they stay 
in a reduced gravity environment (Adams et al., 2003). In an examination of how 
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contraction methods of muscle fibers were affected by spaceflight Widrick et al. 
conducted a study comparing muscle shortening velocity and power production in soleus 
muscle fibers. After a 17-day spaceflight they observed that type I Myosin heavy chain 
muscle fibers produced less force on average than they had during preflight conditions 
and that the muscle fibers shortened at a higher velocity (Widrick et al., 1999). As the 
soleus muscle is used heavily in plantar flexion, this could impact the use of this muscle 
in gravitational environments, even with reduced gravity levels as low as on the Moon 
and Mars.  
1.2 Problem Statement 
 
Human movement on other planets can have serious implications for the health of 
astronauts on a long-duration mission. Locomotion methods need to be properly tested in 
simulated reduced gravity environments to determine how astronauts should be trained 
before their voyages. The effects of these environments on muscle activation, 
dorsiflexion and plantar flexion will be fundamental in evaluating locomotion methods 
and determining the best training regimen.  
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Chapter II.  Literature Review 
 
Human locomotion is hugely complex, so it should come as no surprise that the 
transition from 1g to lunar or Martian gravity will have a tremendous impact on 
locomotion. These effects include balance issues due to vestibular system reliance on 
gravity, changes in locomotion mechanics, and the effect of suits required in these harsh 
conditions on locomotion methods. The selection of walking, running or skipping will 
depend on the interaction of these factors. 
2.1 Gravity and the Vestibular System  
The human vestibular system has evolved to create a stronger sense of balance by 
increasing the relative size of the anterior and posterior semicircular canals, which are 
associated with balance in the vertical plane (Day and Fitzpatrick, 2005). The vestibular 
organs rely significantly on their ability to sense gravity in order to correctly signal the 
brain as to the intensity and vector of acceleration that is being exerted on the body. This 
dependence on gravity for balance could prove detrimental in microgravity and reduced 
gravity as felt during spaceflight and planetary exploration. A 2014 study by Harris et al. 
discussed the importance of gravity in calculating the perceptual upright, or how the 
human body assesses what direction is up. Through use of the Oriented Character 
Recognition Test (OCHART), they were able to establish that humans can begin to 
correctly assess the perceptual upright at gravity levels as low as 0.15, which is just lower 
than the 0.17g felt on the surface of the moon (Harris et al., 2014). Though this finding is 
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corroborated by other studies, a previous study by de Winkel et al. (2012) found a wide 
variation in the gravity needed by individuals to correctly gauge perceptual upright 
ranging from .03g to .57g. In addition to the wide range, the data they collected show that 
there was a positive correlation between the age of the participant and their dependence 
on gravity to establish the perceptual upright, where the older the participant was, the 
more they relied on it. Due to high amounts of cosmic radiation in space, the first 
missions to Mars would most likely have older crew members. This would reduce the 
risk of cancerous masses being the cause of death for said astronauts, as well as offer a 
reduced chance for reproductive issues as reproduction rates lessen at higher ages. While 
the visible effects of radiation on older astronauts are lower, the increase of age could 
have negative ramifications for movement in those environments. There is a difference in 
testing results between Harris et al. (2014) and de Winkel et al. (2012), but in this case a 
major contributor is most probably the difference in testing style. The differences in 
technique are described by Dyde et al. in 2006 indicate that, while the OCHART relies 
more heavily on the long body axis, the later study relied on the amount that subjective 
vertical (the identification of a vertical line perpendicular to the ground) depends on 
gravity (de Winkel et al., 2012). It can, therefore, be suggested that the older an astronaut 
may be, the more their body depends on the force of gravity to establish what direction is 
up. This observation hints to the effect of gravity’s increased importance in the vestibular 
system.  An older crew might, therefore, have issues with continuous activity on Mars, or 
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in space, without some sort of retraining or rehabilitation device to train/adapt the 
astronauts to function under reduced gravity for extended periods of time.  
The disturbance of the vestibular system function brings up two main dangers. 
First, the inability to adapt to a new gravitational environment such as that on Mars 
would leave an astronaut unable to perform mission essential techniques, may require 
assistance from their crewmates, and could endanger their mission. Nausea and other side 
effects of severe vestibular pathologies could cause dehydration and malnutrition, 
endangering the life of the afflicted. Secondly, as the reliance on the vestibular system 
wanes, the reliance on vision would increase. This will not be an issue for astronauts on a 
short trip to the moon, but a 6-month spaceflight to Mars puts the astronauts at risk for 
Spaceflight Associated Neuro-ocular Syndrome (SANS). A NASA Evidence report 
entitled Risk of Spaceflight Associated Neuro-ocular Syndrome (SANS) suggests that 
while the vision issues associated with SANS may be acceptable risk for mission success 
in sub-1-year microgravity missions, but longer missions and planetary missions will 
require mitigation for these issues (Stenger et al., 2017). Vision impairments may make 
locomotion difficult if other factors come into play, such as issues with leg biomechanics 
brought on by changed in gravity levels.   
Thought the level of vestibular system disturbance in lunar and Martian gravity 
levels over long periods will not be truly understood until astronauts experience it, 
current sensorimotor adaptability training has given modern astronauts the ability to 
adapt quickly to new gravity environments. NASA and the NSBRI have done extensive 
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testing on the validity of this work, with eyes forward to Martian exploration missions 
(Bloomberg et al., 2015). By using adaptive treadmill systems that mimic movement 
differences that could be encountered in the future, Bloomberg et al. were able to train 
the vestibular systems of the participants to adapt to new environments, using several 
hand-eye coordination tests to calculate their success. While this training is preventative, 
once the true distortions felt on Mars are realized the system could be programmed on-
site to reduce the transition time. Non-space related organizations have created a variety 
of vestibular rehabilitation techniques that are able to treat vestibular issues, as opposed 
to preventative training. A review by Susan J. Herdman has compiled data on the success 
of vestibular rehabilitation treatments, which were successful in some participants 
exhibiting vestibular disorders. These rehabilitation techniques utilize gait and balance 
exercises that could mirror those used in the NASA/NSBRI studies, while others are 
based on head and eye movements of the patients. Unfortunately, not all patients had the 
same degree of success, but the treatment was effective on the majority of patients 
(Herdman 2013).  
The effect of gravity on the vestibular system has the possibility of effecting 
locomotion methods and selection during movement in fractional gravity environments.  
An assessment of how the different locomotion methods are affected by vestibular 
perturbations, including base gait stability and the effects of perceived upright on stability 
during a skipping gait, should be studied before a selection of “optimal” gaits is 
solidified.  
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2.2 Gait Selection 
Humans spend little to no time thinking about whether they are going to run, walk 
or skip somewhere. Much of the gait selection calculations happen internally based on a 
complex and not yet fully understood series of calculations conducted by our central 
nervous system (CNS) (Croft et al., 2019). Locomotion, at its core, is a means to an end – 
you walk or run to get somewhere, catch something, or run away from something. With 
that in mind, it makes sense that the less energy you expend to complete these tasks, the 
longer you can continue doing them or the more energy you can spend on a more 
essential task. The evolutionary advantage to lower energy locomotion methods is 
apparent in the subconscious changes to minimize energetic costs by tweaking frequency 
of steps and limb movement.  A study by Snaterse et al. found that within walking there 
are two phases of human gait frequency selection: one that occurs quickly in response to 
changes in speed, occurring under 2 seconds from the speed change, and the second 
phase of fine-tuning the gait around the 10-second mark. They cite the apparent 
difference between a pre-programmed response to quickly change speeds in the fast 
phase and direct optimization of the chosen speed in the slower phase. These processes 
are used to find the most economical method of walking (Snaterse et al., 2011).   
2.2.1 Stability 
Human locomotion is a complex movement involving limbs and joints moving 
and rotating at different speeds. This requires extreme coordination of neurological 
signals to compensate for this movement, as well as shifts in the center of mass. A lack of 
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stability can cause tripping, falling, or injury of a joint. To be considered as a reliable 
locomotion method on Earth or in other environments, stability must be confirmed. Gait 
stability is significantly lowered when the ankle muscles, specifically dorsiflexion, are 
weakened, especially at higher walking speeds (Whipple et al., 1987). This has 
implications for muscle degradation during spaceflight with subsequent planetary 
missions, where adjusting to a novel gravity environment could put astronauts at an 
increased risk of gait instability.  
Studies have shown the connection between the effects of spaceflight on 
astronauts mirror the degradation of elderly humans on Earth (Goswami, 2017). Just as 
lessons can be learned about elderly care from spaceflight applications, lessons from 
rehabilitation and fall prevention in elderly can influence training of astronauts exhibiting 
muscle atrophy.   Weight training of the lower limb counteracts the progression of gaits 
declining into unstable, fall-prone gaits in elderly women (Persch et al., 2009). This 
change in gait kinematics may be a precursor for training suggestions for astronauts 
living in fractional gravity for long periods of time.  
2.2.2 The walk-run transition 
In 1g human bipedal locomotion has two "normal" methods; walking and running. 
The switch between the two occurs when the perceived efficiency of walking becomes 
less than that of running, at a speed known as the preferred transition speed (PTS). This 
point is typically a gradient of motion, not an abrupt change under either terrestrial 
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(Hreljac et al., 2008) or reduced gravity conditions (Sylos-Labini et al., 2014). In 
terrestrial gravity levels, the PTS is close to 2.0 m/s. 
Current research on the actual speed at which this transition occurs given 
variations in height uses a dimensionless value called a Froude Number, represented by 
the equation: 
𝐹𝑟 = 	 𝑣*𝑔𝐿 
(Equation 2) 
where v = speed of locomotion g = acceleration of gravity and L = characteristic limb 
length (usually leg length for applications to humans) (Sylos-Labini et al., 2014). The 
preferred transition is given at Fr = 0.5 (Alexander 1989). This is in contrast with the 
optimal walking speed of humans which is at Fr=0.25 (Leurs et al., 2011). These 
transitions can also be applied to locomotion on other planets using the equation: 
𝑣,-./01 = 𝑣2.3145𝑔,-./01𝑔2.314  
(Equation 3) 
where v = reference velocity and g= acceleration of gravity (Minetti, 2001). In an attempt 
to determine if Froude numbers were applicable to locomotion on other planets, Kram et 
al. performed a study where participants used a reduced gravity simulator and were asked 
to walk until they reached their PTS, at which point they should run. The results of their 
data showed that under reduced gravity, there was still a predisposition to transition at a 
Fr = 0.5, and consequentially the speeds of transition were lower (Kram at al. 1997). 
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What triggers the walk-run transition is an area up for additional research, though many 
studies have attempted to answer that question. There is a discrepancy between the 
optimal walking speed and the transition speed, which shows a decrease in energy 
efficiency prior to the transition from walking to running (Hreljac, 1993). The speed at 
which running is more energy-efficient than walking is higher than the actual preferred 
transition speed of change we observe. Hreljac demonstrated that participants perceived a 
lower level of exertion while running at the point of preferred transition speed than 
walking, even though the energetically optimal transition speed was higher than each 
individual's perceived transition speed (Hreljac, 1993). To address this, Hreljac and a 
team of researchers conducted a study in 2001 focusing on different muscle systems. This 
study concluded that the preferred transition speeds were not influenced by the actual 
metabolic energy output of the participant at that speed but instead were based on the 
force placed on the dorsiflexor muscles that cause the foot to be pulled towards the shin 
(Hreljac et al., 2001). 
Ankle plantar flexor force production has also been linked to the PTS. A 
comparison of muscle activation for several muscles of the leg, including the medial 
gastrocnemius and tibialis anterior, was conducted by Neptune and Sasaki in 2005. They 
found that the ability of the plantar flexors to generate force during walking at the PTS 
was hindered by the mechanics of locomotion at that speed. They proposed that the 
switch to running was to regain the ability of the plantar flexors to generate force, as 
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running at the same speed saw a drastic improvement in force production at the ankle 
(Neptune and Sasaki in 2005).  
2.3 Skipping as an Alternate Locomotion Method  
Walk-run transitions have been studied widely in normal gravity levels, but the 
locomotion paradigms exhibited during the Apollo missions implied that the usage of 
running might be swapped for skipping. Videos of Apollo astronauts showed skipping 
motions replaced regular walking during moon EVAs (Jones, 2010). These videos have 
fascinated researchers, who have studied the cost of skipping in fractional gravity, even 
proposing a walk-skip transition instead of a walk-run transition (Ackermann and van den 
Bogert, 2012). 
In order to address the walking and running/skipping transitions in space, the 
energy expenditures of each method in environments other than 1g have been assessed by 
several studies. The most efficient speed of each movement style can be described by 
maximum levels of the recovery of mechanical energy (R) during each cycle of 
movement. This number varies based on locomotion method, speed, and influence of 
gravity (Cavagna et al., 2000). A study by Cavagna et al. (2000) determined that the 
highest values of R corresponded with slower speeds in Martian gravity levels, and also 
suggested that higher gravity levels would show the opposite effect. In addition, they 
demonstrated that the level of gravity positively correlates with the ability to maintain 
walking mechanisms, with increased gravity enabling the participant to continue the 
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pendulum motion at higher speeds, but also increased the amount of work needed to do 
so (Cavagna et al., 2000). As locomotion is optimized to be as low energy as possible, the 
ability to walk at higher speeds may be a moot point when either running or skipping 
could reduce that cost.  
In order to determine whether the preference for skipping motion exhibited by 
Apollo astronauts on the moon could continue under Martian gravity conditions, 
researchers Ackermann and van den Bogert conducted a study using physiological 
computer modeling simulations to analyze the energy expenditure of walking, running 
and skipping under Earth, Lunar and Martian gravity levels. As previously mentioned, 
the analysis of human transitions from walking to running has shown that 2.0 m/s or 4.5 
mph is the average preferred transition speed in 1g. Using this as a reference point, 
Ackermann and van den Bogert analyzed the energy expenditures of all three locomotion 
types, focusing on the implications for effort and fatigue. Analysis of their data showed 
that while walking and running are the energy-efficient methods of locomotion on Earth, 
skipping was the most energy-efficient on the moon and all three means of locomotion 
had benefits on Mars. Under Martian gravity levels, and at the aforementioned 
transitional speed of 2.0 m/s, it was less effort to run, but less fatiguing to skip 
(Ackermann and van den Bogert, 2012). The nuances of the difference between effort 
and fatigue lies in the difference between energy expenditure (effort) and muscle fatigue 
(fatigue). They define these three terms in their paper:  
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Effort cost function:  
𝐽0 = 	 1Σ𝑉9:𝑉9𝑇 < 𝑎9*>? (𝑡)		𝑑𝑡D9EF  
 (Equation 4) 
 
where a is muscle activation and V is the volume of the muscle. 
Fatigue cost function: 
𝐽G = H:Φ9F?D9EF J
F F?⁄ ≈ 	max9 Φ9 
(Equation 5) 
 
 
where F is a measure of muscle fatigue:  
 
Φ9 = 1𝑇< 𝑎9P(𝑡)			𝑑𝑡>?  
(Equation 6) 
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with a continuing to represent muscle activation. These equations are based on 
Crowninshield and Brand’s (1981) findings that muscle fatigue is “approximately 
proportional to the cube of the muscle activation.” It is apparent that muscle fatigue 
levels would be more apparent to changes in muscle activation, given the higher power 
exhibited in the muscle fatigue equation versus the effort cost equation.  
Ackermann and van der Bogert also note that there is a spike in tibialis anterior 
activation at the 2.0m/s, as the tibialis anterior tendon works to counteract the additional 
plantar flexion caused by the tendency to land on the back portion of the foot. This 
activation was apparent in the analysis of fatigue but absent from the effort cost graphs.  
The evidence that the cost of movement is not the only factor encouraging an 
individual's specific preferred locomotion method needs to be taken into account when 
determining gait selection preferences in fractional gravity environments. A study by 
Pavei et al. in 2015 came to a similar conclusion regarding skipping and running 
selection in hypogravity. Their study determined that the metabolic rates of running and 
skipping were low in simulated Martian and Lunar conditions – about the same as 
observed in walking gaits in Earth gravity. They determined that the difference between 
metabolic requirements for running and skipping were negligible at these levels, though 
skipping was still more costly than running in both novel scenarios. This led their team to 
determine that non-metabolic reasons were responsible for the preference towards 
skipping in the Lunar environment shown in Apollo footage, as well as in Ackermann 
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and van den Bogert’s 2012 study which was the jumping-off point for their research 
(Pavei et al. in 2015). 
2.4 Suited Effects on Locomotion 
Human locomotion is impacted by spacesuit usage due to their mass (including 
mass distribution), pressurization, and mechanically induced joint stiffness (Carr and 
Newman, 2005). The mass of the suit causes the center of gravity to be shifted aft 
compared to terrestrial gravity (Mulugeta et al., 2009) and ultimately alters mobility in 
the way of muscle force and joint angles (Sridhar et al., 2017) ,  While the mass of a 
spacesuit is high, considering the requirements for personal life support systems and 
layers to protect the astronaut from the harsh environments other planets, the pressurized 
nature of the suits means that this mass is not necessarily all weighing on the astronaut. 
Pressurized suits are partially self-supporting in a vacuum, reducing the mass supported 
by the wearer. Given this reality, and expanding upon the Froude number discussed 
earlier, Carr and McGee (2009) conducted a study that demonstrated that the walk-run 
transition occurs at lower Froude numbers in the lunar environment when participants 
were compared to non-suited conditions. This study introduced a new dimensionless 
value, the Apollo Number (Ap),  
𝐴𝑝 = 	𝐹𝑟𝑀  
(Equation 7) 
29 
 
which took the Froude number and divides it by M, the ratio of human supported to total 
transported mass. They computed Fr and Ap values by taking anthropometric values from 
Apollo astronauts and comparing their walk/run/lope velocities during audio and video 
clips of those astronauts on the lunar surface. They concluded that Ap results in 60% of 
the reason for the gait transition, though they proposed these numbers could vary based 
on experiments from Kram et al. (1997) run on NASA’s POGO (estimates 38%) or 
possibly much higher given the sample bias of their tests. Their takeaway was that while 
this was a significant effect on the walk-run transition, other factors were more likely 
coming into play, such as metabolic expenditures, muscle force/activation, or stability 
(Carr and McGee, 2009).  
As with injury to the dorsiflexor muscles, the constraints put upon an astronaut by 
the design of the EVA suit must be taken into account when determining the best gait to 
use in an environment. Sparrow and Newel posed in a 1998 article that the economy of 
completing a task was easier to address than the efficiency of those tasks because 
determining total actual work completed for that task was difficult, if not impossible. 
They go further to suggest that there are three constraint systems that work against a task 
being completed: Organism constraints, where the abilities and anatomy of the organism 
such as muscle force generation, Environmental constraints, including gravitational 
constraints, where the environment poses additional metabolic energy demands, and Task 
constraints, where the regulations of the task imposed by either societal or mechanical 
(such as tool design) constraints determine forced movements or time constraints. These 
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three constraints are involved in defining the movement available to an organism where 
the efficiency of actions is used to help determine which movement set is ultimately 
chosen (Sparrow and Newell, 1998). The intersection of these restraints was expanded in 
Croft et al. (2019), where they concluded that energetic cost of motion was an outcome of 
the interaction between environmental, organism, and task requirements and constraints. 
Constraints such as suit and EVA design can impact the efficiency of movements in other 
planetary environments, even if these movements are optimized for the environment. 
This impact could increase or decrease stability depending on design interactions with the 
astronaut.  
2.4.1 Skipping, by any other name  
A significant issue within the literature at this time is the definition of locomotion 
methods. While Apollo astronauts are seen making a unilateral skipping pattern, this is 
often called loping, or just skipping, with little attention given to the difference between 
the two terms when comparing studies. Crowley at al. describe a “rolling‐loping walk 
(resembling cross-country skiing),” with no definition of what this mainly looks like or 
how it compares to bilateral or unilateral skipping. It is also worth noting that loping is 
sometimes used interchangeably with skipping in earlier studies, while loping in 
colloquial terms just means long, bounding strides and does not necessarily imply a 
skipping movement. Computer simulations, such as those done by Ackermann and van 
den Bogert (2012) focused on bilateral skipping, while others focused on unilateral 
skipping as demonstrated by Apollo astronauts.   
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In any case, over long periods of time, this change in usage towards skipping could 
exacerbate the degradation of some bones and muscles, while encouraging growth in 
others that are typically not used in 1g. This could substantially inhibit the ability of 
astronauts to walk or complete other movements when they return to Earth gravity and 
could induce injury and pathologies that could significantly cripple the astronauts. 
 
2.5 Hypothesis 
This thesis tackles four hypothesis based on electromyography and motion capture data: 
1. Mean activation energy peaks in of the tibialis anterior will vary significantly 
between Earth gravity and simulated Martian and Lunar gravity levels. 
  
2. Mean activation energy peaks in of the medial gastrocnemius will vary 
significantly between Earth gravity and simulated Martian and Lunar gravity 
levels. 
  
3. Mean dorsiflexion peaks will vary significantly between Earth gravity and 
simulated Martian and Lunar gravity levels. 
  
4. Mean plantar flexion peaks will vary significantly between Earth gravity and 
simulated Martian and Lunar gravity levels. 
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CHAPTER III. METHODS 
To explore muscle activation and ankle angles in fractional gravity, 
electromyography of the tibialis anterior and medial gastrocnemius was collected, as well 
as motion capture data. These were collected at a range of speeds in 1g and under 
simulated reduced gravity conditions equal to that of Mars and the Moon. Simulated 
conditions were made possible by the Active Response Gravity Offload System 
(ARGOS) at NASA’s Johnson Space Center. Statistical analysis was performed to 
determine whether and when significant changes in muscle activation or ankle angles 
were present, and whether these were higher or lower values.  
3.1 Variables 
Primary dependent variables include muscle activation, measured in mV, and 
angles of biomechanical movement, specifically of the ankle, measured in degrees of 
dorsiflexion or plantar flexion. Independent variables are speed of motion in m/s, and 
gravity levels in g, with Earth gravity being 1g, simulated Martian and lunar being .38 
and .17, respectively.  
3.2 Procedures 
Participants walked, ran and skipped on a treadmill at 1 MPH increments from 2 
to 6 MPH. The tests were repeated for different simulated gravity levels (Lunar and 
Martian gravity) by connecting the participants to the ARGOS via a gimbal system. The 
duration of testing was 1 minute per speed per gait, with the last 10 seconds of each speed 
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being used for analysis. This allowed the participant to get used to the speed with the 
system setup to reduce noise in the data. Speeds and gravitational constants were verified 
through the VICON system before analysis was conducted. 
3.3 Participants 
3.3.1 Sample Size 
The sample size (n) of this study is 6. This study is attempting to estimate a 
characteristic of the response measures, and is study is exploratory. This sample size fits 
within the range discussed within current literature, including other NASA studies, which 
often feature only three participants. 
3.3.2 Participant Selection 
Participants were selected based on convenience sampling. Three female 
participants and three male participants were selected based on availability and ability to 
perform the exercises required by the study without the risk of adverse health effects. 
Requirements to ensure the health of our participants were suggested by the NASA IRB 
office documentation for exercise protocols and included: 
* BMI lower than 30 
* BMI higher than 19 
* No recent smoking history 
* No history of lower back pain 
* No history of Achilles tendinitis 
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* Must be able to complete the exercise requirements of this study as listed in 
the consent form 
3.3.3 Institutional Review Board 
Institutional Review Board (IRB) approval is required for any study using human 
participants, including this thesis. IRB Applications were approved by both The 
University of North Dakota and NASA's Johnson Space Center prior to the recruitment of 
participant or any participant related testing. 
3.3.3.1 Medical Monitor: Level 3 
NASA JSC requires medical monitors to be present for any procedures where 
participants may be injured. Their system uses levels 1-4, with one being the most 
extreme level of monitoring and 4 being the lowest. The medical monitoring level of this 
study was level 3, with the following requirements list included in the IRB resources: 
* Typically for procedures that carry less risk than Level 2 procedures, for 
example, those that require sub-maximal aerobic exertion of <85% of 
maximum predicted heart rate or VO2. 
* A physician with current BLS-AED training is available within 15 minutes 
of notification. 
* Two other BLS-AED certified personnel can respond to the test site within 
two minutes. 
* An AED is located nearby and available for use within two minutes. 
3.3.3.2 Risk Assessment & Hazard Analysis 
Risk assessments and hazard analysis are required for NASA IRB applications 
and include plans for mitigation of risks and hazards. For this study risks included those 
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associated with exercise and usage of the ARGOS, and mitigations were devised to 
reduce those risks. Both the Risk Assessment and Hazard analysis are included in the 
appendix (See Appendix A). 
3.3.3.3 Consent Forms 
Consent forms outlining the tasks to be performed and the risks were outlines in a 
consent form that was given to the participants in advance, and then reread and discussed 
with the participants before their involvement in the study. Participants signed the 
consent forms before test procedures began and were provided with IRB and PI contact 
information in the event they had any issues during or after the study tests. These forms 
were approved by the UND and NASA JSC IRB Boards. The consent forms can be 
viewed in the Appendix (See Appendix B and C). 
3.4 Metrics 
3.4.1 Electromyography 
There are multiple types of EMG, including intrusive and non-intrusive methods. 
This study employs surface EMG (sEMG), a non-intrusive method using electrodes that 
are placed on the skin. This method was chosen as it reduces the risk to the participant 
caused by piercing the skin and does not require medical training to administer. These 
electrodes detect muscle activation, which is then used in statistical analysis to determine 
muscle usage.  
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3.4.1.1 BIOPAC MP150 System 
This hardware system is used to collect data about the human body for research 
purposes. It allows integration of different data acquisition modules, including the 
BIOPAC EMG100C unit used in this study, and utilizes channels to allow for multiple 
sets of data acquisition at once. The system works with BIOPAC AcqKnowledge 
software for operations, as well as some levels of data, clean up and analysis.  
3.4.1.2 BIOPAC EMG100C 
The EMG100C amplifies general and skeletal muscle electrical activity. The 
connection points were non-invasive surface electrodes (no needles or skin penetration - 
Figure 2) that effectively senses muscle activation and sends the signal to the EMG100C, 
which then integrates with the main MP150 unit. These electrodes only receive signals; 
they do not emit signals to the subject. Placement of these electrodes were placed on the 
leg on the skin above the tibialis anterior and gastrocnemius medialis. The electrodes 
have a sticker built into them, and conductive gel was used to ensure signal strength. 
Participants either removed hair from the areas of skin that had the electrodes attached to 
them, or the PI shaved the areas for them. Ace bandages and tape were used to keep the 
electrodes in place and illuminate the risk of participants tripping on the lead wires (See 
Image 3). 
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Image 3. EMG Electrode placement.  
Placement of surface electrodes before securing them to the participant’s legs with Ace bandages. 
 
3.4.1.3 BIOPAC AcqKnowledge 
This software is used to control operations of the MP150 and connected units during data 
acquisition. It is also used to clean up data with filtering algorithms and allows for quick 
access to mean, standard deviation, and maximum and minimum values for data used in 
this study. 
3.4.1.3.1 Filtering 
Raw EMG data are rectified for analysis using the Vicon average rectification 
filter, a software solution that makes the data easier to analyze. This filter takes the 
absolute value of the EMG signal, instead of leaving it in positive and negative values, 
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which makes statistical analysis simpler for this application. This is the common 
approach to cleaning up EMG data for analysis (Enoka, 2002). 
3.4.1.3.2 Additional Software 
Vicon version 1.8.5 (Vicon, Oxford, UK) Nexus software suite was used for the 
calibration, data collection, and preliminary data cleanup. Vicon Polygon 4 version 4.0.0 
was used for data visualization. Microsoft Excel was used to parse data and organize it 
for analysis. MATLAB version R2018b (MathWorks, Natick, MA, USA) was used for 
data analysis, as well as SPSS Statistics version 1.0.0.1131 (IBM, Armonk, NY, USA).  
3.4.2 Motion Capture 
Motion capture is used to translate movement in 3D space to a data set on a 
computer that can be processed by relevant software. This allows researchers to precisely 
measure kinematic data, such as ankle angle, and to extrapolate more complex 
biomechanics found in kinetic data. This system uses cameras and reflective markers to 
reduce the data cleanup compared to manual methods.   
3.4.2.1 Vicon NEXUS 
Vicon NEXUS infrared motion capture analysis system was employed during 
testing. This system consists of 10 motion-capture cameras mapped the movement of the 
participants by receiving light shining off of 35 reflective markers placed on key points of 
the participant’s body. These points are standardized as described in Vicon’s Plug-in Gait 
Models, and correct placement is critical for analysis (Vicon Motion Systems Ltd., 2017). 
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For this study used two posterior superior iliac spine markers instead of a single sacral 
marker to increase the visibility of the markers due to obstruction from the ARGOS 
gimbal. This complex system allowed for a comparison between joint angles and overall 
movement of the participant's body, with the Plug-in Gait model being easily recognized 
by the system software, as per its design. Each test was recorded and then the data were 
recorded using the Vicon analysis software (Figure 3), which allowed for analysis of gait 
variations between tests. 
3.4.2.1.1 Hardware 
This system consists of 10 infra-red motion-capture cameras that track the 
movement of the participants by receiving light shining off of reflective markers placed 
on key points of the participant’s body (these points are standardized) (See Image 4). 
This allows for a comparison between joint angles and overall movement of the 
participant’s body. 
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Image 4: Motion capture reflective marker.  
This marker has reflective coating that shines light back in the direction it originated from, allowing the 10-camera system to pick up 
the movement of the marker.  
3.4.2.1.2 Software 
Vicon Nexus 1.8 software suite was used for the calibration, data collection, and 
preliminary data cleanup. Vicon Polygon 4 was used for data visualization. Microsoft 
Excel was used to parse data and organize it for analysis. MATLAB was used for data 
analysis, as well as SPSS.  
3.4.2.1.3 Calibration 
The Vicon T wand is used to calibrate the system. This wand has five 14mm 
markers, similar to the ones used on the body of the subject. The wand dimensions are 
prerecorded into the Vicon NEXUS software, and calibration of the test area is performed 
by manually waving the wand in large circles during a calibration run.  
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3.4.2.1.4 False Markers & Interference 
As this system is participant to the reflectivity of objects in the testing area, a 
visual sweep for reflective surfaces that appeared in the software window were identified 
and mitigated. The gimbal system or the treadmill momentarily blocked the view of 
markers for certain cameras, but the number of cameras employed during this test 
reduced the amount of marker disappearance. 
3.4.2.1.5 Filtering 
A 10 hz Woltering filter was applied to the Vicon data. This filter was used to 
smooth data for processing and was specially designed to be the equivalent to performing 
a double Butterworth filter on kinematic data (Vicon).  
3.4.3 Hexoskin 
A Hexoskin Smart Shirt was used to monitor the heart rate of the participants 
during exercise. This shirt is used in conjunction with an app that receives heart rate data 
via Bluetooth from the shirt. Participants ages were used to calculate their 85% max heart 
rate. These rates were used as a basis to stop testing and allow the participants time to rest 
before resuming.  
3.5 Study Design 
Exercise protocol that is conducted over a short period of time can have the risk 
of tiring out the participants, which could skew data. This study scheduled the most 
energy substantial activities first (Earth-level gravity runs) before the second (Martian) 
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and least (Lunar) intensive runs to reduce this possibility. Participants were also given 
time to recuperate if they needed it, and there were additional breaks between the gravity 
conditions due to connecting the participants to the ARGOS gimbal. 
3.6 Statistical Analysis 
Means and standard deviations were determined from collected data using 
Microsoft Excel version 16.31. Only one round of testing, with no replications, was 
competed, as there was limited time to conduct the study due to the ARGOS schedule. 
Due to the relatively low sample size associated with studies in which an extensive 
amount of time is necessary for participant preparation and data collection, statistical 
analysis within this study was limited to non-inferential statistics. This has typically been 
the case with fractional gravity studies. Low numbers associated with these types of data 
collection require the application of non-inferential statistics are utilized in determining 
the extent to which a particular difference or association is of interest for future studies. 
Primarily, an examination of this nature is utilized to demonstrate possible avenues for 
future examination and illustrate possible hypotheses for future testing. 
This study employed two statistical methods, One-way Analysis of variance 
(ANOVA) and an Independent Sample Student's T-Tests. ANOVA tests are used to 
determine the difference in mean values of the samples were significantly different 
enough to warrant further testing; in our case this is in the form of a T-Test. The main 
difference between ANOVA and T-Tests is that ANOVA tests are used on three or more 
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sample populations, while T-Tests are only used on two sample populations. Data were 
grouped into three categories for the ANOVA: walking running and skipping. ANOVAs 
were performed in SPSS for each speed, and into either channel (for EMG) or left and 
right leg (for absolute ankle angle). It was essential to separate the ANOVA by speeds as 
different locomotion methods might be more advantageous at different speeds. This 
would have incorrectly rejected the null hypothesis, leading to an incorrect assessment of 
the effect of reduced gravity and made it impossible to determine at what speeds the 
chances in locomotion were truly different, if at all. The left and right leg were analyzed 
separately to allow for differences in each leg during unilateral skipping gaits. T-tests 
were conducted in MATLAB comparing Earth and Martian values, and Earth and lunar 
values, but not Martian and lunar values. These tests mirrored the setup of the ANOVA 
in regard to locomotion method and speed.  
3.6.1 Hypothesis testing 
T-test data will be used to test the hypotheses. P-values will be evaluated based on 
whether they are equal to or above .05 (hypothesis rejected) or below .05 (hypothesis 
supported). While these p-values may vary among locomotion methods and speeds, a 
statistically significant change in any of these sections supports the null hypothesis, as 
this thesis is looking for changes in overall locomotion, not just at one speed or under one 
locomotion method.  
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3.6.2 Bonferroni corrections 
When multiple comparisons are made during statistical analysis, corrections are 
often used to offset the chance of type I and II errors. While the Bonferroni correction has 
its merits, it is often criticized for overly decreasing the power of performed tests, 
increasing the likelihood of type II errors (failing to reject the null hypothesis) (Perneger, 
1998). As this study is exploratory in nature, and as the n value is already too low to 
make arguments based on the statistical power of these tests, I have decided to focus on 
p-values without the Bonferroni correction (P<.05). While this is fine for the EMG 
values, there is some inconsistency with the ankle angle peaks later in this document.  
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CHAPTER IV. RESULTS 
 
The Study results are displayed in graph form for reader clarity. SPSS ANOVA 
descriptives and charts, including post hoc Bonferroni corrections, can be found in the 
Appendix (See Appendix D). Values represented are the averages of participants’ 
activation energy for EMG and the average of peak values for dorsiflexion and planter 
flexion.  
 
4.1 EMG 
4.1.1 Activation Energy Trends by Gravity level 
The muscle activation energy of the tibialis anterior in 1g sees upward trends as 
speed increases, with running and skipping having similar trends under non-Earth 
conditions (See Figure 2). Walking exhibits higher activation at higher speeds (except for 
Lunar for the right tibialis anterior) under all conditions. Under Earth conditions, walking 
starts as a lower activation energy and crosses that threshold between 4 and 5 mph, 
ending at a higher activation level. This is consistent with the normally demonstrated 
preferred transition speed where the switch from walking to running occurs. The data 
corroborates the assumption that energy expenditure of the entire body may not be the 
cause of the switch from walking to running, but that there is a connection with strain on 
the dorsiflexor muscles. 
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The medial gastrocnemius also sees differences in activations among the 
locomotion methods in 1g (See Figure 5). Walking starts off as less energy and then 
surpasses that between 4 and 5 MPH for the left leg, with running and skipping being 
similar patterns. On the right leg the trend was slightly different, with running and 
skipping having slightly higher values throughout the test, ending at values similar to that 
of walking at 6MPH. For the medial gastrocnemius there is minimal change in activation 
between the locomotion methods in non-Earth conditions (See Figures 6 and 7).  
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Figure 2. Activation Energy Gravity Trends – Earth - Tibialis anterior  
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Figure 3. Activation Energy Gravity Trend – Martian – Tibialis anterior 
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Figure 4. Activation Energy Gravity Trends – Lunar - Tibialis anterior 
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Figure 5. Activation Energy Gravity Trends – Earth – Medial gastrocnemius 
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Figure 6. Activation Energy Gravity Trends – Martian – Medial gastrocnemius 
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Figure 7. Activation Energy Gravity Trends – Lunar – Medial gastrocnemius 
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Figure 8. Activation Energy Locomotion Trends – Walking – Tibialis anterior 
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Figure 9. Activation Energy Locomotion Trends – Running – Tibialis anterior 
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Figure 10. Activation Energy Locomotion Trends – Skipping – Tibialis anterior 
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Figure 11. Activation Energy Locomotion Trends – Walking – Medial gastrocnemius 
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Figure 12. Activation Energy Locomotion Trends – Running – Medial gastrocnemius 
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Figure 13. Activation Energy Locomotion Trends – Skipping – Medial gastrocnemius 
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4.1.2 Activation Energy trends by Locomotion Method 
ANOVA Data demonstrates significance in the difference between 1g, .38g and 
.17 g levels (See Table 1). There is significant difference identified under all speed and 
locomotion methods.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. EMG ANOVA Table 
Activation energy with p<.05 in green - CH1 - Left tibialis anterior, CH2 - Left medial gastrocnemius, CH3 - Right medial 
gastrocnemius, CH4 - left Tibialis anterior 
ANOVA< .05   
CH1 Walking Running Skipping 
2 0.864 0.044 0.004 
3 0.728 0.026 0.002 
4 0.269 0.001 0.002 
5 0.539 0.075 0.079 
6 0.014 0.025 0.001 
CH2    
2 0.001 0.000 0.000 
3 0.001 0.000 0.000 
4 0.006 0.000 0.000 
5 0.002 0.000 0.000 
6 0.000 0.000 0.000 
CH3    
2 0.031 0.011 0.000 
3 0.053 0.007 0.001 
4 0.055 0.002 0.001 
5 0.010 0.004 0.001 
6 0.027 0.010 0.000 
CH4    
2 0.692 0.103 0.052 
3 0.934 0.151 0.014 
4 0.762 0.040 0.026 
5 0.472 0.054 0.013 
6 0.094 0.080 0.014 
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From Figure 14 we see similar values for the same muscles on the left and right 
leg, which helps corroborate correct placement of the markers. High values of significant 
change are encouraging, so post hoc analysis was done with Student T-Tests (See Table 
2). 
 
Table 2. EMG Student's T-Tests 
Activation with p<.05 shown in green. CH1 - Left tibialis anterior, CH2 - Left medial gastrocnemius, CH3 - Right medial 
gastrocnemius, CH4 - left Tibialis anterior 
 
MARTIAN < 0.05     LUNAR       
CH1 Walking Running Skipping CH1 Walking Running Skipping 
2 0.9977 0.1656 0.012 2 0.6724 0.0304 0.0078 
3 0.5283 0.1656 0.0184 3 0.4455 0.0175 0.0038 
4 0.6746 0.0134 0.0196 4 0.1492 0.0011 0.004 
5 0.6905 0.1841 0.1114 5 0.2861 0.0588 0.0807 
6 0.2586 0.1148 0.0069 6 0.9246 0.0155 0.0018 
CH2    CH2    
2 0.0114 0.0025 1.55E-04 2 0.0038 0.0011 1.27E-05 
3 0.0172 2.83E-04 0.0022 3 0.0046 7.19E-05 5.64E-04 
4 0.0397 4.39E-04 0.004 4 0.0134 8.82E-05 0.0014 
5 0.0162 4.29E-04 0.0018 5 0.0058 9.52E-05 2.97E-04 
6 0.0025 0.0023 8.40E-04 6 0.0016 5.80E-04 7.60E-05 
CH3    CH3    
2 0.0681 0.0492 0.0046 2 0.0278 0.0215 1.30E-03 
3 0.202 0.0391 0.0126 3 0.0251 0.0156 5.20E-03 
4 0.1727 0.0185 0.0106 4 0.0352 0.0082 0.0046 
5 0.0609 0.0243 0.0127 5 0.013 0.0107 2.50E-03 
6 0.0709 0.0366 0.0048 6 0.0321 0.0233 7.71E-04 
CH4    CH4    
2 0.513 0.3175 0.0857 2 0.4277 0.0553 5.32E-02 
3 0.731 0.2311 0.0416 3 0.7733 0.1263 2.16E-02 
4 0.7216 0.1093 0.046 4 0.6767 0.0452 3.08E-02 
5 0.7793 0.1707 0.037 5 0.2541 0.0408 1.85E-02 
6 0.2673 0.2036 0.0417 6 0.0368 0.043 1.07E-02 
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Additionally, T-Tests do not tell us whether the values are lower or higher, just 
that there is a difference. For these EMG values, all the significant values are 
significantly lower than the Earth values, indicating less activation energy required for 
the movements. 
This analysis indicates that the medial gastrocnemius, acting as a plantar flexor, is 
exhibiting significantly less activation energy under all locomotion methods in simulated 
Martian and Lunar conditions (except the medial gastrocnemius of the right leg while 
walking under Martian conditions). 
However, the tibialis anterior muscles, acting as dorsiflexion, have a different 
pattern. Under Martian conditions, nine of the ten significantly lower values occur during 
skipping, with one left leg value in running. Under Lunar conditions the majority of 
running and skipping cause the muscles to exhibit lower activation energy, with the 
addition of the fastest speed of walking for the right leg. This shows that there may not be 
a difference in activation energy large enough to matter under Martian gravity conditions, 
while there is one observed under Lunar conditions. This is in line with the previous 
experiments assessing the reduced energy expenditure of skipping in lower gravity 
environments that prompted this thesis experiment. 
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4.2 Motion Capture 
 
4.2.1 Ankle Angle 
Absolute Ankle Angle data sets created through the Vicon motion capture system 
analysis software. This allows us to look at the angles of Dorsiflexion (pointing the toe 
up) and plantarflexion (pointing the toe down). For this study, peaks were selected out of 
the 10-second segments and averaged. 
4.2.1.1 Dorsiflexion 
Dorsiflexion values start off similar walking at 2 MPH but vary as speed increases 
(See Figure 14) Trend lines (dotted) indicate that as speed increases, so does dorsiflexion 
angle and difference between angles from Earth, Lunar, and Martian conditions. Though 
one might expect gravity level to be directly proportionate to dorsiflexion level, here it 
indicates that Martian gravity conditions may have an increased level of dorsiflexion vs. 
both Earth and Lunar levels. 
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Figure 14. Dorsiflexion Peaks - Walking 
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For running, Lunar conditions remain the lowest value, starting lower than both 
Earth and Martian conditions (which start at the same level) and decreasing with speed, 
while Martian and Earth levels increase with speed (See Figure 15). Here we see that 
there is a correlation with gravity levels, unlike running trials. 
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Figure 15. Dorsiflexion Peaks - Running 
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Skipping dorsiflexion values vary more intensely by leg (See Figure 18). 
Dorsiflexion best fit lines are flat for the left leg, with Earth and Martian conditions being 
very similar, while the Lunar conditions show lower levels of dorsiflexion. For the right 
leg, we see a spike in dorsiflexion degree for low levels in Earth conditions, a dip in 
dorsiflexion degree at lower speed for Martian levels. Earth levels show a slight decrease 
in levels as speed increases, while Martian conditions show a slight increase. Lunar levels 
again show a flat linear fit line close to the same level as the left leg. 
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Figure 16. Dorsiflexion Peaks - Skipping 
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Earth levels have the most variety among the gravity conditions, with distinct 
trends for each locomotion method (See Figure 19). Walking shows the lowest 
dorsiflexion values, with running coming in at the highest other than at 2MPH, where we 
see a spike from skipping. Under simulated Martian gravity levels (See Figure 20), we 
see the gap close between the locomotion methods, with running values remaining 
relatively constant, walking remaining a steady slope, and skipping either matching 
running (left leg) or walking (right leg). We see slightly higher variation between the 
right and left leg for skipping vs. walking and running in simulated Lunar gravity (See 
Figure 21), possibly because of skipping being a novel method of movement. This is 
consistent with all three gravity conditions. 
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Figure 17. Dorsiflexion Peaks - Earth 
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Figure 18. Dorsiflexion Peaks - Martian 
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Figure 19. Dorsiflexion Peaks - Lunar 
 
0
5
10
15
20
25
2 3 4 5 6
A
bs
ol
ut
e 
A
nk
le
 A
ng
le
 (D
eg
re
es
)
Speed (MPH)
Lunar Locomotion Trend  - Dorsiflexion (Left)
Walking Running Skipping
Linear (Walking) Linear (Running) Linear (Skipping)
0
5
10
15
20
25
2 3 4 5 6
A
bs
ol
ut
e 
A
nk
le
 A
ng
le
 (D
eg
re
es
)
Speed (MPH)
Lunar Locomotion Trend - Dorsiflexion (Right)
Walking Running Skipping
Linear (Walking) Linear (Running) Linear (Skipping)
72 
 
Changes in Dorsiflexion were less significantly different than EMG values, with 
ANOVA only indicating significance (p<.05) at 5 PMH for all locomotion methods, as 
well as at 6 MPH (See Table 3). 
 
 
ANOVA < .05     
Left Walking Running Skipping 
2 0.637 0.534 0.658 
3 0.806 0.4 0.386 
4 0.324 0.064 0.405 
5 0.056 0.02 0.324 
6 0.333 0.006 0.343 
Right    
2 0.981 0.336 0.071 
3 0.881 0.453 0.106 
4 0.192 0.087 0.215 
5 0.029 0.003 0.003 
6 0.091 0.001 0.661 
 
Table 3. Dorsiflexion Peaks - ANOVA 
Dorsiflexion angle values with significant differences p<.05 are shown in green.  
 
The p<.05 T-Tests show significant amounts of variation, but this does not 
exactly fit with the ANOVA results, as there are additional significances indicated for 
running at 3 MPH (See Table 4). This did, however, match the Bonferroni corrected T-
Tests (See Appendix E). It is possible that the difference between the ANOVA and T-
Tests can be a result of different degrees of freedom (T-test dof is 10, while ANOVA was 
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17) and small sampling size of 6.  In this case there are very few instances of significant 
differences after the correction, though the fast running speeds still see that difference.  
 
MARTIAN < .05     LUNAR       
Left Walking Running Skipping Left Walking Running Skipping 
2 0.3507 0.9152 0.73 2 0.4747 0.3503 0.3891 
3 0.5626 0.5108 0.9023 3 0.8813 0.1882 0.2598 
4 1.78E-01 0.3412 0.8744 4 0.4299 0.0473 0.2799 
5 0.0259 0.0797 0.6535 5 0.1137 0.0137 0.1088 
6 0.2074 0.1704 0.6388 6 0.7484 0.0064 0.1495 
Right    Right    
2 0.8238 0.7001 0.0604 2 0.9328 0.3074 0.2024 
3 0.6619 0.7132 0.2254 3 0.9897 0.268 0.0395 
4 1.47E-01 0.3818 0.2563 4 0.073 3.98E-02 0.0752 
5 0.0298 0.0266 0.1887 5 0.1724 6.50E-04 0.0014 
6 0.0876 0.2694 0.7634 6 0.7124 5.73E-04 0.2298 
 
Table 4. Dorsiflexion Peaks - T-Tests 
Ankle angle values with significant differences (p<.05) are shown in green. 
 
There were high and lower mean values of dorsiflexion peaks, though the 
majority of changes indicated lower dorsiflexion (See Table 5). 
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MARTIAN < .05    LUNAR       
Left Walking Running Skipping Left Walking Running Skipping 
2 0.3507 0.9152 0.73 2 0.4747 0.3503 0.3891 
3 0.5626 0.5108 0.9023 3 0.8813 0.1882 0.2598 
4 
1.78E-
01 0.3412 0.8744 4 0.4299 0.0473 0.2799 
5 0.0259 0.0797 0.6535 5 0.1137 0.0137 0.1088 
6 0.2074 0.1704 0.6388 6 0.7484 0.0064 0.1495 
Right    Right    
2 0.8238 0.7001 0.0604 2 0.9328 0.3074 0.2024 
3 0.6619 0.7132 0.2254 3 0.9897 0.268 0.0395 
4 
1.47E-
01 0.3818 0.2563 4 0.073 
3.98E-
02 0.0752 
5 0.0298 0.0266 0.1887 5 0.1724 
6.50E-
04 0.0014 
6 0.0876 0.2694 0.7634 6 0.7124 
5.73E-
04 0.2298 
 
Table 5. Dorsiflexion T-Test Value Comparisons 
Student's T-test chart with indication of higher (red) or lower (green) ankle dorsiflexion 
 
4.2.1.2.  Plantar flexion 
In walking on the Earth, plantar flexion starts at a much lower degree than for 
Martian or Lunar conditions and slowly converges with lunar degrees, which fall in value 
as speed increases (See Figure 20). Planter flexion in Martian conditions stay at a higher 
degree, increases until halfway through the speeds, and slightly dips back down. Degree 
values in running follow similar trends to each other under simulated Martian conditions, 
with Earth values starting lower than Martian and Lunar values but ending in a 
convergence of all three values at 6MPH (See Figure 21). Skipping demonstrates the 
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same slope in each gravity condition, with Earth values being consistently significantly 
lower than Martian and Lunar values and never converging with them (See Figure 22). It 
is interesting that in walking, there are distinct differences between the trends for each 
gravity condition, but that running and skipping show Martian and Lunar trends to be 
extraordinarily similar and different from the Earth values. The mechanical differences 
seen between the differences in gravity may happen at a much lower gravity difference 
than that seen between Earth (1g) and Mars (.38g). 
76 
 
 
Figure 20. Plantar Flexion - Walking 
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Figure 21. Plantar Flexion - Running 
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Figure 22. Plantar Flexion - Skipping 
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Figure 23. Plantar Flexion - Earth 
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Figure 24. Plantar Flexion - Martian 
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Figure 25. Plantar Flexion - Lunar 
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ANOVA results indicated that running had a very consistent amount of plantar 
flexion between gravity conditions, with variations being the most obvious in skipping 
and walking (See Table 6). The pattern for plantar flexion does not follow the same 
theme as dorsiflexion, with only walking at 2MPH and skipping at 5 MPH, showing any 
suggestion of significance. 
 
ANOVA< .05     
Left Walking Running Skipping 
2 0.017 0.292 0.544 
3 0.057 0.544 0.546 
4 0.093 0.556 0.199 
5 0.196 0.859 0.016 
6 0.85 0.982 0.077 
Right    
2 0.043 0.435 0.355 
3 0.075 0.579 0.133 
4 0.159 0.789 0.151 
5 0.515 0.712 0.04 
6 0.576 0.864 0.086 
 
Table 6. Plantar Flexion Peaks - ANOVA 
Plantar flexion angle values with significant differences p<.05 are shown in green.  
 
We see that T-Test and ANOVA discrepancies still exist as they did in 
dorsiflexion (See Table 7). All mean differences in Martian and Lunar conditions were 
higher than the Earth level. 
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MARTIAN < .05     LUNAR       
Left Walking Running Skipping Left Walking Running Skipping 
2 0.0236 0.1377 0.4911 2 0.0049 0.1582 0.2109 
3 0.0392 0.4028 0.4146 3 0.1154 0.2694 0.2175 
4 2.80E-02 0.461 0.1499 4 0.5262 0.2489 0.0291 
5 0.0258 0.6639 0.0288 5 0.9931 0.5873 0.0049 
6 0.3241 0.9291 0.1131 6 0.9182 0.9121 0.0191 
Right    Right    
2 0.0482 0.2637 0.1052 2 0.0101 0.2286 0.3059 
3 0.0545 0.3516 0.0558 3 0.0427 0.3519 0.1045 
4 3.19E-02 0.6496 0.1608 4 0.7619 4.97E-01 0.0518 
5 0.172 0.4158 0.056 5 0.5751 5.38E-01 0.0141 
6 0.2586 0.4655 0.0523 6 0.9246 7.63E-01 0.0602 
 
Table 7. Plantar Flexion Peaks - T-Tests 
Plantar flexion angle values with significant differences (p<.05) are shown in green.  
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CHAPTER V ANALYSIS & DISCUSSION 
 
5.1 Analysis 
5.1.1 Implications of EMG data 
5.1.1.1 Tibialis Anterior 
There are two ways to compare the data collected: a comparison of each 
locomotion method across one level of gravity, or a comparison of one locomotion 
method across all three gravity levels. Both styles have been presented here, as they 
contain fascinating insights into the movement in these conditions.  
5.1.1.1.1 Gravity Trends 
These data mirror the setup of the ANOVA and T-Test for the tibialis anterior: 
significant differences between walking, running, and skipping were observed between 
1g and Martian and lunar gravities in the ANOVA, prompting the T-Test. In the T-Test, 
significant differences were seen between 1g and Martian skipping conditions, where 
there was less activation energy to skip in most Martian conditions than in 1g (at 2, 3, 4, 
and 6MPH for the left leg, 3-6 MPH for right leg), and also in one of the running 
conditions at the 4 MPH speed for the left tibialis anterior. Additionally, there were 
significant changes from Lunar g to 1g, with walking at 6 MPH (right) Skipping from 2-5 
and 6 (left) and 4-6MPH (right) and running from 2-5 and 6 MPH (left) and 3-6 MPH 
(right). While the significance of these values is represented in the chart, a graphical view 
of the values makes comparisons to 1g possible, an allows for comparisons to the PTS 
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research to evaluate whether activation energy levels are high or low enough to speak to 
locomotion method selection.  
The collected activation energy data of the tibialis anterior in normal Earth 
conditions are consistent with the frequently demonstrated PTS from current literature. 
There is a point between 4 and 5 MPH where the activation energy of the tibialis anterior 
during walking intersects with running, after which running prompts less activation. This 
value was between 40-50 mV (See Figure 2). There is a difference in activation values 
from left and right legs, with the right leg having higher activation at the same time for 
the same locomotion method. This could be due to the preferred handedness of the 
individuals or the mechanics of novel skipping gaits.  
Tibialis anterior activation in simulated Martian conditions sees a change from 1g, 
with the activation energy of running and skipping staying well below their values for the 
same speed in Earth gravity. Walking has a similar activation curve in Martian gravity 
compared to 1g, though there is a marked decrease in activation between 5 and 6 MPH. 
These values are close to the PTS values seen in 1g, while the 5MPH Martian levels are 
beyond the crossover point seen in 1g.  Skipping and running activation levels start close 
to that of walking but remain low while walking increases. Skipping EMG values also 
remain lower than running throughout the entire range of speeds. 
Lunar gravity activation levels also have walking with higher activation energy 
levels than running and skipping. Activation levels for walking peak at the same level 
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exhibited while walking between 3 and 4 MPH in 1g. Running and skipping have almost 
identical values, peaking under the activation required for both methods at 2 MPH in 1g.  
5.1.1.1.2 Locomotion Trends 
Activation levels start the same for walking across all gravity levels but start to 
differentiate after the 3 MPH mark. The trends continue as would be expected, with 1g 
levels requiring the most activation, Martian levels requiring less and Lunar levels 
requiring the least amount of the three. Similar activation levels are seen between 
walking and running, with the levels of activation energy being the highest at 1g and 
lowest at lunar gravity, with Martian in the middle. The difference here from walking is 
that the values do not start at the same level.  Skipping follows the running trends, but the 
skipping values between lunar and Martian are incredibly similar. The levels of activation 
energy in fractional gravity environments never crosses that seen at the PTS in 1g under 
any of the locomotion methods. From this perspective, it is unlikely that muscle fatigue 
from the tibialis would impact the movement selection on other planets.  
5.1.1.2 Medial Gastrocnemius 
5.1.1.2.1 Gravity Trends:  
Again, these data mirror the ANOVA and T-Test tables. The left medial 
gastrocnemius was wholly different at all speeds and locomotion levels for the left leg, 
and in all conditions except walking at 3 and 4 MPH on the right leg. The T-Test data 
showed that both Martian and Lunar gravity levels were significantly different from 1g 
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levels for the left leg, and that also was the case in the right leg, except for walking in 
Martian gravity levels, which were not statistically different from 1g.  
Activation of the medial gastrocnemius is different between left and right legs in 
1g. There was a crossover event just above 4 PMH for walking with running and skipping 
for the left leg, while this intersection did not occur until 5 PMH on the right leg. Right 
leg activation levels were much higher for running and skipping than in the left leg, 
reaching a plateau around 4 PMH that continues to 6 MPH.  
5.1.1.2.2 Locomotion Trends 
1g activation levels of the medial gastrocnemius are much higher than those of 
Martian and lunar gravity levels for all locomotion methods, with the latter two methods 
being very similar. Medial gastrocnemius activation starts low and reaches a high at 6 
MPH, while lunar and Martian levels have a small slope and barely reach the level of 
activation seen at 2 MPH in 1g. Activation levels start at a medium range for running in 
1g, while Martian and lunar levels remain much lower in Martian and lunar levels, and 
never reach a level exhibited in 1g. Skipping levels are very similar to running, with a 
medium level of activation in 1g and shallow level of activation in Martian and lunar 
levels. Martian and lunar values are indistinguishable from each other and are at the same 
activation as 2 MPH values for walking in 1g. Given these results it is unlikely that 
activation of the medial gastrocnemius impacts locomotion choice in Martian or Lunar 
gravity levels, as there would be no energy advantage for any method.  
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5.1.2 Implications of AAA data 
5.1.2.1 Dorsiflexion 
Dorsiflexion shows less significant changes in ANOVA and T-Tests compared to 
EMG data, but under reduced gravity conditions some practical significance is apparent 
(See Tables 3 and 4).  
5.1.2.1.1 Walking 
Dorsiflexion values for walking are higher in lunar and Martian gravity, respectively, 
though lunar levels are close to those seen on Earth at 6 MPH. This is in contrast to the 
EMG data from this study that show a positive correlation between activation energy at 
specific speeds and gravity levels. This implies a change to the mechanism of movement, 
as opposed to the straight scaling of movement across gravity levels. This should be 
expanded upon in future studies.  
5.1.2.1.2 Running 
Dorsiflexion levels decrease under Martian and lunar gravity levels compared to 1g. 
Dorsiflexion of running increases in both Martian and 1g but decreases in Earth gravity. 
These mirror what is shown in the EMG data, where the difference between Martian and 
1g is less significant, but the difference between lunar and 1g are significant at higher 
speeds.   
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5.1.2.1.3 Skipping 
Dorsiflexion remains consistent on the left leg between 1g and Martian 
conditions, with the average peaks remaining similar across all speeds. In lunar gravity, 
however, dorsiflexion begins and ends at a lower value. This is in contrast with the EMG 
data, which shows that 1g conditions are significantly different from Martian and lunar 
conditions, with Martian and Lunar conditions being very close in value. Again, this 
implies a change in movement across gravity levels, not a straight scaling of movement.  
Unlike the other two locomotion methods, in skipping we see an erratic difference 
between dorsiflexion of the left and right foot, which could be explained by skipping 
being a locomotion method not actively practiced by the participants , leading to 
differences in usage of legs (favoring the dominant leg, as you would handedness, is a 
possibility that comes to mind that is often seen in people who participate in sports, 
though the jury is still out on the effect of leg preference on muscle activation (Vaisman 
et al., 2017, Carpes et al., 2010).  
5.1.2.2 Plantar flexion 
Significant changes to plantar flexion levels are observed during several sets of 
conditions, most notably in walking from 2-5 MPH with the left leg in Martian gravity 
and at 2 MPH in lunar gravity, as well as skipping at 5 MPH in Martian gravity and from 
4-6 MPH in lunar gravity (See Tables 6 and 7). The right leg shows significance in 2 and 
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3 MPH walking between 1g and Martian gravity, as well as 2-3 MPH walking and 5 
MPH skipping in lunar gravity.  
5.1.2.2.1 Walking 
The level of medial gastrocnemius activation is consistent with some of the 
changes seen in plantar flexion during walking, but not at all points. Low activation 
occurred under almost all scenarios, except for walking under lunar conditions. However, 
T-Test show that significantly increased plantarflexion occurred during walking (Martian 
left 2-5MPH and right 2 & 4 MPH, Lunar Left at 2 MPH and right at 2&3 MPH) 
5.1.2.2.2 Running 
There was no significant change in plantar flexion found during T-Tests between 
the gravity environments. However, comparing the graphs of running in the different 
gravity levels shows a higher starting plantarflexion angle for Martian and lunar 
conditions than 1g. These levels even out as the participant approaches 6 MPH.  
5.1.2.2.3 Skipping 
T-Tests show significant increases in plantar flexion for the left leg in Martian 
gravity at 5 MPH, and the left and right legs at 4-6 MPH and 5 MPH, respectively. 
Graphs of the mean peaks demonstrate that Martian and Lunar gravity exhibits higher 
plantarflexion values across the entire speed range.  
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5.1.2.2.4 Gravity Levels 
Plantar flexion remained very similar between all locomotion methods in 1g, with 
each method showing similar levels of plantar flexion in each leg. However, Changes can 
be seen in Martian and Lunar conditions. Under Martian conditions walking levels seem 
might higher than skipping and running at the beginning of the tests for the left leg, but 
skipping starts at a higher level, similar to running on the right leg. These values 
converge near the 5 and 6 MPH mark. The difference in left and right leg plantarflexion 
during skipping again might suggest handedness preferences that reflect on gait 
characteristics. Similarly, we see that walking and running plantar flexion levels remain 
the same between left and right legs in Lunar gravity, with skipping plantar flexion levels 
varying greatly between the two. Walking begins at higher levels but has a negative 
slope, crossing running’s plantar flexion line around the 4 MPH mark. Skipping starts 
high on the left leg and lower on the right leg.  
 
5.2 Discussion 
The data collected support the rejection of all four null hypotheses, as there are p-values 
<.05 present in simulated Martian and lunar gravity conditions. This rejection shines a 
light on areas for exploration, such as the role of the tibialis anterior and medial 
gastrocnemius in fractional gravity environments, potential for injury or pathology 
development, and training regimen development.  
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5.2.1 Plantar Flexion  
Though plantar flexion values increased in these conditions, the medial 
gastrocnemius EMG T-Test data shows that there is reduced activation for all conditions 
except walking in Martian gravity levels. There are two probable reasons for these 
changes. First, that while the gastrocnemius is a major contributor to plantar flexion, this 
study only focused on the medial gastrocnemius activation energy, where the differences 
in activation energy and plantar flexion could be due to participation of lateral 
gastrocnemius or other plantar flexors, such as the soleus. Alternatively, might suggest 
another change in the mechanics of movement on other planets at a variety of speeds.  
The increase in plantar flexion in walking and skipping may increase the chance 
of tripping or injury.  Mistiming of movements of the foot can cause injury, especially if 
muscles are weakened (Baker et al., 2016), such as in an individual who has been living 
in reduced gravity conditions. Plantar flexion also increases the instability of the ankle 
joint (Mansfield and Neumann, 2019), increasing the likelihood of a rolled ankle and 
sprains (Farr et al., 2018) unless mitigated. This could be solved by spacesuit boot design, 
but joints are restricted can also account for mistimed movements (Baker et al., 2016) 
which could cause injury. Mobility and restriction and their effects on the ankle joint and 
gait stability will end up being an important trade study for future suit design. 
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5.2.2 Asymmetrical Gaits 
While bilateral skipping is a symmetric gait, unilateral skipping, as seen in Apollo 
astronaut footage is an asymmetrical gait. Walking and running are inherently symmetric 
gaits, as the human body is symmetric. This ensures that the muscles on either side of the 
body are more or less equal in size and strength. Asymmetrical gaits, on the other hand, 
will use different muscles on either leg, altering the muscle development between the 
two. A study by LaRoche et al. (2012) explored how strength asymmetry (>20% strength 
in one leg verses the other) in the legs affected gait asymmetry and variability in an older 
population. They saw that these variables were positively correlated and noted that all 
three variables are related to fall risks in older adults (LaRoche et al, 2012). If strength 
asymmetry can be caused by unilateral skipping methods, it could increase the likelihood 
of falls in astronauts that are already dealing with the deleterious effects of living in 
micro/fractional gravity environments over long periods of time.  This could be combated 
with an alteration in exercise or countermeasure regimen but could exacerbate the 
problems with muscle and bone degradation unnecessarily.  
As the growth and degradation of muscles would be unknown in a unilateral 
skipping scenario, i.e., which muscles would grow in either leg or which would diminish, 
it is impossible to assess the effects of this change in movement. The human body is 
extremely resilient and develops solutions to return to equilibrium, meaning that it often 
overcompensates in one area to fill a void in another. Jeon et al. discovered that, in the 
event of ankle strengths asymmetry, a counterbalance of knee strength increase is 
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observed in what can be determined as an attempt to maintain the body’s center of mass 
(Jeon et al., 2016). This is just one example of an unknown consequence of astronauts 
developing muscle asymmetry because of a unilateral skipping gait. It is well understood 
that while there are muscles acting on the ankle, knee and hip joints during locomotion, 
other muscle groups are actively engaging during locomotion. One such muscle group is 
the abdominal muscles which provide trunk stability and protection of the spine 
throughout the jarring leg movements necessary to propel yourself forward. Changes 
could affect these muscles, which could result in full-body problems that can be a major 
risk factor for mission success and astronaut health.  
5.2.3 Training Implications 
Astronauts spend two years preparing for their first spaceflight, with many of 
those months spent in simulators acclimatizing them to movement in fractional gravity 
environments. The addition of a skipping gait into these training sessions would be 
effortless, especially considering that the ARGOS was utilized for this study and is 
suspected to be an essential training tool for astronaut training for future missions. The 
success of this study using current ARGOS hardware, as well as a collection of base 
mean and standard deviation data from this study that will allow for the development of 
future testing and follow-on studies, would create a natural starting point for this training 
and subsequent locomotion training development.  
A change in locomotion mechanics can have a negative effect, even if it is 
“better” in the long run. With this in mind we have to focus on the fact that skipping, 
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whether in 1g environments or on other celestial bodies, is a novel gait. As discussed in 
Olin and Gutierrez (2013) transitioning from one style of locomotion to another, in their 
case shoed heel-strike running to barefoot toe-trike running, has an effect on muscle 
activation and forces felt in the body. Their study saw increased EMG values for the 
medial gastrocnemius and peak tibial shock while transitioning to this new method of 
running, even though it has been touted as a healthier way to run given the evolution of 
humans to moving without shoes (Olin & Gutierrez, 2013). The creation of a gradual 
training method was suggested, and the switch from walking or running to skipping in 
non-terrestrial gravity levels should undergo the same amount of attention. Considering 
long-duration missions to the Moon or Mars are (seemly fast) approaching, and that 
current studies focused on days are not minutes or hours of exercise, a more extended 
duration study into the effect of skipping on muscles and joints of the leg and hip should 
be conducted. These studies should focus on suited and shirt-sleeve locomotion, as 
equipment will also affect the running mechanics.  
5.2.4 Suit Design 
Just as changes in foot-strike can impact muscle forces, changes in exterior 
conditions, i.e., shoes, can change the muscle activation and forces exerted on the body. 
In a 2003 study, Tscharner et al. discovered that the tibialis anterior responds to the 
addition of shoes as compared to barefoot running. Shoes act as dampeners to movement 
across a plane (Tscharner et al., 2003), and one of the functions of the tibialis anterior 
96 
 
muscle (and other dorsiflexors) is to prevent the impacts of the foot on the ground. By 
incorporating this into shoe design, foot and leg health is improved. 
 Similarly, designing spacesuits and boots to benefit the wearer instead of counting 
on the already existing mechanics of a suit to determine locomotion methods is 
paramount. While the pressure of the suit might make skipping mechanically less energy, 
that does not mean the suit was designed, so that would be a primary function or benefit. 
Current suits cause mobility restriction (Carr and McGee, 2009) which could aid or 
hinder astronauts depending on the gravity-based predisposition for changes in ankle 
angle. Working leg health and locomotion mechanics into the next iterations of spacesuit 
design will benefit the argument for or against skipping as the suggested movement in 
fractional gravity environments.  
5.3 Limitations 
5.3.1 ARGOS 
As with any gimbal system, the ARGOS has a possible limitation from humans 
“gaming” the system by leaning forward to regain some semblance of a normal gravity 
environment. This may have affected the fidelity of microgravity simulation but would be 
extremely hard to observe and quantify during this study. Also, the gimbal system 
obstructed the view of the reflective markers during some movements, reducing the data 
collected for extrapolating hip movement. While the ankle data were the main focus of 
this study, a workaround for this should be developed for studies looking into knee and 
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hip mechanics. Finally, the speed of the treadmill does not always represent the speed the 
participants  are going during the tests – the force of the participant’s body hitting the 
treadmill may have caused a slowing of the belt, or the high variation of the treadmill 
might mean more precise values may be slightly off.  
5.3.2 Length of Time  
The cost of operating the machine and time to complete the trials was prohibitive, 
as the sample size was forced to remain small, so testing would not last more than three 
days. Additional testing where the participants traversed for more extended periods of 
time to get used to the treadmill, equipment, and gimbal system. Additional replications 
of the experiment tests would have been ideal for the statistical analysis but were 
unrealistic for the time allotted. Long-term testing will be necessary to corroborate 
current mechanical simulations regarding their similarity to muscle degradation during 
long-duration missions to other celestial bodies. 
5.3.3 Sample Size 
Though typical for this type of study, the small relative sample size of this study 
prohibited a higher statistical power that would have been ideal.  
5.3.4 Skipping 
The assumption was made that participants would understand what skipping was 
from previous experience. There was one participant who began the study not knowing 
what skipping was and was trained on it after signing their necessary forms and before 
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their tests began, but the introduction of a novel gait so soon before the study may have 
impacted the trials themselves. Also, both bilateral and unilateral skipping methods were 
demonstrated for all participants, with the suggestion that they practice both and then 
pick the one that seemed more natural before the 10-second data collection periods. Five 
of the six participants proceeded to perform bilateral skipping as their selected 
movement, while one proceeded to use unilateral. How the differences in locomotion 
affected the data acquisition, or how shifting of weight was impacted by the ARGOS 
remains unknown.  
5.3.5 Participants 
One participant was unable to walk at high speeds on the treadmill, so the data 
from their walking conditions were not included in the ANOVA or T-Tests. The 
inclusion of that data may have influenced the p-values gained through that analysis. A 
correlation between leg length and fastest speed that can be achieved through walking 
should be considered before participant selection in future studies. Additionally, data was 
missing from two of the subjects while walking a 6 MPH (one subject under earth 
conditions, one under lunar conditions). The resulting n=5 for walking conditions.  
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CHAPTER VI. FUTURE RESEARCH & CONCLUSIONS 
 
6.1 Future Research  
 
6.1.1 Verification  
These experiments are limited by the fractional gravity simulators and computer 
programs available to terrestrial researchers. These methods and those from other 
biomechanics and locomotion studies should be performed on the Moon and Mars upon 
the first trips to/ back to these bodies. By validating the results, or by showing the 
inconsistencies, a more realistic fractional analog can be created, and a more robust 
training regimen can be devised.  
6.1.2 Other Kinematic and Kinetic Factors 
Further research into the lower leg and ankle muscle moments and force could be 
conducted from these trials, as they were another set of factors that were indicated as the 
main contributor to the run-walk transition is the muscle moment of the ankle in a study 
by Hreljac et al., in 2008.  
6.1.3 Gaits & Gerontology 
Continuing to apply gerontology to spaceflight situations (and vice versa) can 
expand upon both fields of study. A study comparing the step length of astronauts under 
different levels of gravity and locomotion styles could be compared to gerontology data 
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about the incidents of falls and gait stability explored in papers such as Pavol et al. 
(1999). 
6.1.4 Suited Applications 
The next logical step forward is suited testing with the same testing procedure. 
While this study focused on general locomotion as would be exhibited in a habitat, such 
as in exercise capacity, EVA research will require the same tests be reproduced with a 
suited participant to further assess the impact of skipping in fractional gravity 
environments.  
6.1.5 Spacesuit Design  
After suited trials are performed, suit and boot design iterations can include data 
from those trials as a branching off point for future designs. Continued design and testing 
will ensure that the restriction of the suit does not negatively impact astronaut movement 
or health, and actively supports them instead.  
6.1.6 Training Design 
A synthesis of past locomotion research should be conducted to determine 
whether unilateral or bilateral skipping is better for movement in fractional gravity 
environments, or if there is a preference. Once this is conducted, additional information 
from gerontological and spacesuit design should be included in a trade study that 
ultimately suggests the type of locomotion best suited for fractional gravity exploration. 
This should be used to create a training regimen for Astronaut Candidates. It may be too 
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risky to do this as a study, as not properly training or improperly training Astronaut 
Candidates could result in injury in those environments. The usage of bed rest studies and 
continued utilization of the ARGOS or other simulators could inform this decision.  
 6.2 Conclusion 
 
Human locomotion on other planets will be a major issue requiring preventative 
training due to the changes in mechanics and muscle usage. The change in dorsiflexion 
and plantar flexion values indicates an increased rate of trips and falls, especially with 
exacerbation of muscle degradation exhibited in micro and reduced gravity. The reduced 
muscle activation between Earth, Martian and Lunar gravity levels indicates that 
locomotion method selection will not rely on energy expenditure but will instead depend 
on training and suit design. Skipping does not show an obvious benefit in unsuited 
methods above walking and running considering the similar values of all locomotion 
methods in those environments. Secondly, unilateral skipping offers the possibility of 
additional harm, resulting in asymmetrical strength which can lead to further injury. 
Astronauts will need to be properly trained, but this training will need to be developed 
with the deleterious effects of asymmetrical movement in mind. Without this training, 
astronauts could suffer injuries that endanger their mission success and put them at risk 
for long-lasting pathologies. 
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INTRODUCTION/PURPOSE 
This report is the Integrated Hazard Analysis for using the BIOPACK MP150 system and 
EMG100C amplifiers in the Gen 2b Active Response Gravity Offload System (ARGOS) 
for testing.  The use of the system includes, but is not limited to, characterization of the 
system, characterization of humans, and test specific objectives.  This hazard analysis is 
specific to the testing to be performed and approved by the test specific Test Readiness 
Review.  
All hazards that have the potential for harming test personnel (test team and test 
participant) are compiled into this integrated hazard analysis.  
 The purpose of this document is to identify potential hazards involved in operating the 
Gen 2b ARGOS assembly, control system, support hardware, and human interaction with 
the system and support hardware, as well as the integrated use of the BIOPACK MP150 
system and EMG100C amplifiers with these systems.  This includes all mockups, tools, 
and equipment that the test participant will interact with.  The document analyzes the use 
of the hardware provided by the Software, Robotics and Simulation Division 
(SR&SD/ER).  A “hazard” is defined as any condition that has the potential for harming 
personnel or equipment.  
The process for approving ARGOS for Human in the Loop testing is documented in the 
ARGOS Project Management Plan, SRSD-14-004.  This process includes a System 
Acceptance Review and oversight by an Independent Review Team.  
The hardware, mockups and risk will be evaluated before the TRR using the ARGOS 
Pre-TRR process as defined in SRSD-16-002.  The Pre-TRR Risk Review Board will 
make a recommendation and present any dissenting opinions at the TRR.  
 
 
BIOPAC MP150 and EMG100C Hardware 
The subjects will be connected to the BIOPAC MP150 data acquisition and analysis 
system with the EMG100C Electromyogram Amplifier attachment. The EMG100C 
amplifies general and skeletal muscle electrical activity. The connection points will be 
electrodes that effectively senses muscle activation and send the signal to the EMG100C, 
which then integrates with the main MP150 unit. These electrodes only receive signals, 
they do not emit signals to the subject. The operating voltage of the unit is 10 V. 
Placement of these electrodes will be on the leg on the skin above the tibialis anterior and 
medial gastrocnemius medialis. The electrodes have a sticker built into them, and 
conductive gel will also be used to ensure signal strength. These are surface electrodes 
and do not penetrate the skin in any way. Specialized tape will be used to ensure 
electrodes do not move during movement during testing. This data will later be analyzed 
with the BIOPAC AcqKnowledge software to compare the activation energy the tibialis 
anterior and gastrocnemius medialis muscles exhibited during the tests. The BIOPAC 
system is currently used by UND and other universities as a research tool, and is not 
intended to be used as a medical device.  
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Motion Capture System 
In addition to the BIOPAC system, the Vicon infrared motion capture analysis system will be employed 
during testing. This consists of 10 motion capture cameras that will map the movement of the subjects by 
receiving light shining off of reflective markers placed on key points of the subject’s body (these points are 
standardized). This allows for a comparison between joint angles and overall movement of the subject’s 
body. Each test will be recorded and then the data will be recorded using the Vicon Nexus software, which 
will allow for analysis of gait changes between tests. Subjects will not be involved in the placement or 
operation of the cameras.  
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Hexoskin Smart Shirt 
These will allow the study staff to monitor the subjects’ heart rate (via an ECG channel) 
and breathing rate. This device is comprised of a shirt and data collection device which 
can connect to a computer or cellular device to show real time data. This data will be 
monitored to ensure that subjects have not overexerted themselves. The power is 
provided by a 3.7V battery pack. 
  
 
 
Figure 4. 10 Vicon infrared cameras 
will be set up around the testing area.  
Figure 3. Data from the Vicon motion 
capture camera system will be 
represented in 3D form and used for 
analysis. 
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2.0  SCOPE 
This Hazard Analysis covers the specific tasks of using BIOPAC Electromyography 
equipment in the Gen 2b Active Response Gravity Offload System (ARGOS) for human 
in the loop testing.  The analysis covers custom horizontal system, the custom z-axis 
system, system operations with a human participant or robotic system, Gen 2b ARGOS 
provided support hardware, and Gen 2b ARGOS control rack.  A human test subject 
provides an input into the ARGOS (through attachment to system via harness and/or by 
providing an external force to system).  Each test will require a test specific integrated 
hazard analysis.  A detailed description of the ARGOS is available in SRSD-15-014 
ARGOS System Description Document.  
 
The equipment assessed in this integrated HA is as follows:  
  
ARGOS System (Vertical, Horizontal, and Structure)  
Emergency Extraction Equipment (Ladders, Sky Genie)  
Horizontal gimbal and harness  
Vertical gimbal and harness 
BIOPAC MP 150 and BIOPAC EMG100C hardware 
Hexoskin Smart Shirt and hardware 
Donning table (no hazards) 
Vicon Motion Capture Cameras, stands and flashlights (no hazards) 
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3.0  HAZARD IDENTIFICATION CRITERIA 
This Report is prepared in accordance with JPR1700.1 Rev J JSC Safety and Health 
Handbooks.  
The “hazards” or “potential hazards” identified in this analysis came from the following 
sources:  
Facility “walk-through” inspections  
Hardware inspections  
System Design Drawings  
Vendor Manuals  
Discussion with Facility, Safety, and Project Engineers  
Lessons Learned from ARGOS Generation 1 and 2a testing  
 
The hardware, mockups and risk will be evaluated before the TRR using the ARGOS 
Pre-TRR process as defined in SRSD-16-002.  The Pre-TRR Risk Review Board will 
make a recommendation and present any dissenting opinions at the TRR.  
Each of the potential hazards identified from these criteria are documented on the 
attached Hazard Analysis Worksheets.  Each worksheet identifies a potential hazard, lists 
what causes that hazard to exist and states what measures have been taken to control or 
minimize that hazard.  It gives a numerical representation of what level or degree of 
severity the hazard is rated by the analyzer and also lists the probability of the 
occurrence.  
Signatures on the Signature Sheet of this document indicate that all hazard worksheets 
listed in Appendix A – Hazard Analysis Worksheets have been reviewed and that the risk 
is accepted by the appropriate authority for the level of risk.  Any hazard with a RAC of 3 
after controls requires a division chief signature for acceptance.  Any hazard with a RAC 
of 4, 5, or 6 after controls requires a branch chief signature for acceptance.  
 
3.01. Hazard Definitions  
 
The following definitions are vital to an understanding of the requirements contained in this 
document:  
  
a. Hazard – An unsafe or unhealthy condition that could lead to a mishap if it is not corrected.  
 
b. Consequence – The subjective estimate of worst credible outcome in terms of potential 
personnel injury, equipment/facility damage and monetary losses.  Consequence is further defined 
by severity classifications.  Consequence severity classes are defined as follows:  
 
 
1. Class I – Catastrophic. A condition that may cause death or permanently disabling injury, 
facility destruction on the ground.  
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2. Class II – Critical. A condition that may cause severe injury or occupational illness, or 
major property damage to facilities, systems, equipment, or flight hardware.  
 
  
3. Class III – Moderate. A condition that may cause minor injury or occupational illness, or 
minor property damage to facilities, systems, equipment, or flight hardware.  
 
  
4. Class IV – Negligible. A condition that could cause the need for minor first-aid treatment 
but would not adversely affect personal safety or health; damage to facilities, equipment, 
or flight hardware more than normal wear and tear level.  
 
  
c. Likelihood – The relative likelihood a hazard may occur.  The complete probability range 
is separated into intervals for additional classification.  It is important to note that even though 
quantitative probability intervals are listed in this document they are only for numeric comparison 
and that the actual probability is derived by subjective estimation of a qualitative nature.  The 
hazard probability categories are defined as follows:  
1. Likelihood A. Likely to occur.  
  
2. Likelihood B. Probably will occur.  
 
  
3. Likelihood C. May occur.  
 
  
4. Likelihood D. Unlikely to occur.  
 
  
5. Likelihood E. Improbable.  
 
d. Risk Assessment Code (RAC) – The Risk Assessment Code is the numerical value that 
represents the hazard risk associated with a given task, project, test, or equipment and is the point 
of intersection of the consequence severity estimate and the probability estimate on the RAC 
matrix.  
e. Risk Assessment Code (RAC) Matrix – A matrix made up of probability estimates, 
severity estimates and risk assessment codes.  The matrix is used to derive the risk assessment code 
once the severity and probability have been determined.  
f. Hazard Disposition – The status of a hazard after controls are in place.  Hazard 
Dispositions are utilized in this analysis, documented at the bottom of each hazard analysis 
worksheet, to supplement the risk assessment codes and to further describe the control or status of 
the hazard.  The disposition criteria are defined as follows:  
 
Open / No action – A hazard exists in the system, and no controlling equipment or procedures 
have been implemented to minimize the hazard  
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Closed/Controlled – A hazard exists in the system, and appropriate mechanical/electrical 
procedural actions have been taken to reduce the hazard to a minimal level  
  
Closed/Eliminated – A hazard that is no longer in the system because it has been eliminated  
  
Closed/Accepted – A hazard of RAC 2 or 3 after controls whose risk has been accepted by NASA 
management.  
g. Hazard Summary – A list of the hazard categories with before and after control RACs.  
h. Verification – The validation method or process that confirms the hazard control.  
Verifications of the hazard controls are identified via review of test procedures, equipment 
operating instructions and checklists, test system drawings and schematics, personnel training 
records, applicable JSC, EA, Division and Branch work instructions and operating procedures, 
inspection of test equipment/area and interviews with facility engineers, technicians, test directors, 
and management.  
i. Hazard Analysis Work Sheet (HAWS) – The Form which documents the system or process 
that is being analyzed, the system location, hazard description, before and after controls RACs, 
causes, controls, verifications and disposition status.  
j. The RAC matrix is defined as follows:  
 
k. The table below specifies the required action(s) for each RAC:  
 
RAC Action 
1 Unacceptable – All operations must cease immediately until the hazard is corrected or 
until temporary controls are in place and permanent controls are in work.  A safety or 
health professional must stay at the scene at least until temporary controls are in place. 
RAC 1 hazards have the highest priority for hazard controls. 
2 Undesirable – All operations must cease immediately until the hazard is corrected or 
until temporary controls are in place and permanent controls are in work. 
RAC2 hazards are next in priority after RAC1 hazards for control. 
Program Manager (Directorate Level), Organizational Director, or equivalent 
3 Acceptable with Controls – Division Chief or equivalent management is authorized to 
accept the risk with adequate justification 
   SRSD-17-002 
Baseline 
Appendix A – Integrated Hazard Analysis for Electromyography and Motion Capture Systems in ARGOS 
 
4-7 Acceptable with Controls – Branch Chief or equivalent management is authorized to 
accept the risk with adequate justification 
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A APPLICABLE DOCUMENTS 
Document  
Number  
Revision  Date  Document Title  
192-120102N15      Compax3S Installation Manual  
88-022337-01G      ACR9000 Series Hardware Installation Guide  
AWI 1.11  Rev. B  Apr. 2016  Active Response Gravity Offload (ARGOS) Training 
Work Instruction 
AWI 1.14  Rev M.4  Oct 2017  Gen2 ARGOS Operating Procedure for Facility  
Operation  
AWI 1.30  C  May 2016  Active Response Gravity Offload System (ARGOS)  
Maintenance Plan  
AWI 1.31  Baseline  May 2016  ARGOS Lockout Tagout Plan  
EA-WI-017  Rev. A  May 2007  Engineering Directorate Control of Hazardous Energy  
(Lockout Tagout) Process  
ESCG-4450-10- 
STAN-DOC-0032  
    ARGOS Eyebolt Assessment  
ESCG-4450-10- 
STAN-DOC-0064  
    Strength Assessment of Heavy Lift Z-Axis Assembly  
ESCG-4450-12- 
STAN-DOC-0067  
    Strength and Fracture Assessment of the Versatile  
Neutral Capability Horizontal Interface (VNCHI) Gimbal 
Assembly of the ARGOS  
ESTA-TH-7B198 Baseline 4/9/2015 EDU Bank Build and Test 
http://irb.nasa.gov/      IRB Web Page  
JETS-JE32-13-SMA-
DOC-0013 
Rev. B  Strength Assessment of the ARGOS EMU Gimbal 
Assembly  
JETS-JE32-14- 
SMA-DOC-0105  
    Strength Assessment of the ARGOS Gen2 Unsuited  
Gimbal (ARGOSGUE500)  
JETS-JE32-14- 
SMA-DOC-0111  
    Strength Assessment of the ARGOS VNCHI Gimbal  
Assembly (ARGOSHGE710)  
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JETS-JE32-15- 
SMA-DOC-0013A  
    Strength Assessment of the ARGOS Top Level Y-Axis  
Assembly (ARGOSYAE552)  
JETS-JE32-15- 
SMA-DOC-0036  
    Strength Assessment of the ARGOS Gen2B Hoist  
Assembly (ARGOSZAE600)  
JPR1700.1   Rev. K  Nov. 2013  JSC Safety and Health Handbook  
SRSD-16-007 Rev. D October 2017 Integrated Hazard Analysis for EMU in ARGOS 
 
B ACRONYMS 
ACFM Actual Cubic Feet per Minute 
ARGOS Active Response Gravity Offload System  
ATP Acceptance Test Procedure 
AWI ARGOS Work Instruction 
BACC Breathing Air Compressor Cart 
COTS  Commercial Off The Shelf  
dB Decibel 
EMU Extravehicular Mobility Unit 
ESTA Energy Systems Test Area 
EVA Extravehicular Activity 
FMEA Failure Modes and Effects Analysis 
FOD Foreign Object Debris 
GSE Ground Support Equipment 
HA Hazard Analysis 
HUT Hard Upper Torso 
IRB Institutional Review Board 
JSC Johnson Space Center 
LTA Lower Torso Assembly 
MAWP Maximum Allowable Working Pressure  
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MLI Multi Layer Insulation 
NASA National Aeronautics and Space Administration 
NBL Neutral Buoyancy Laboratory 
NFPA National Fire Protection Association 
PPE Personal Protective Equipment 
PSID Pounds per square inch, Differential 
PSIG Pounds per Square inch, Gage 
PTC Passive Thermal Control 
QD Quick Disconnect 
RAC Risk Assessment Code 
RITF Receiving Inspection and Test Facility 
SAR System Acceptance Review 
SRSD Software, Robotics, and Simulation Division 
TRR Test Readiness Review 
UND University of North Dakota 
VNCHI Versatile Neutral Capability Horizontal Interface 
WAD Work Authorizing Document 
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6.0  HAZARD SUMMARY 
#  Potential Hazard  Subsystem  
Severity/Probability/RAC 
Before Controls After Controls 
1 Test Subject Discomfort/Injury Hexoskin Smart Shirt 1/C/3 I/C/4 
3 Electrical Hazards BIOPAC MP150 System II/D/4 II/E/5 
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Appendix A - HAZARD ANALYSIS WORKSHEETS 
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ARGOS HAZARD ANALYSIS WORKSHEET 
Title 
Test Subject Discomfort/Injury 
No. 
          
1 
Date 
October 2017 
System 
 
 
Subsystem 
Hexoskin Smart Shirt 
Severity/Probability/RAC     Severity/Probability/RAC 
  Before Hazard Controls       After Hazard Controls 
                  II/C/3                               II/D/4 
Hazard Description: 
Testing activities that leads to the test subjects discomfort or injury including, dizziness, nausea, headaches, orthostatic 
intolerance and unconsciousness. 
 
Hazard Causes: 
1. 1 Test subject physical condition 
2. Test subject anxiety or overexertion 
3. Improper thermal regulation 
 
Hazard Control: 
1a. Test subject will be selected based on specific physical characteristics and requirements. 
1b. Subject will be monitored during all testing phases for physical or emotional discomfort by specified team members 
and the project leader. 
1c. The project leader will be directing the test subject during testing and will maintain open communication. 
1d. Medical assistance plan to deal with urgent situations will be taught and discussed with all team members. 
2a, 3a. Subjects are actively monitored by specific team members at all times for physical and emotional discomfort. 
2b. Subjects will be wearing Hexoskin Smart Shirt as a monitoring device for heart and breathing rates.  
2c. Open communication between test subject, project leader, and team are maintained at all times. 
2d. Subject will have time prior to testing to familiarize with ARGOS movement. 
3b. Heart rate will remain below 85% of max while testing procedure are under way. 
 
Additional Hazard Control Constants: 
- Subject can terminate the test at any time as per AWI 1.14 Section 7. 
- Testing will be terminated if any parameters fall below acceptable levels for testing as per AWI 1.14 Section 7 and 
UND 1.1 Section 3.5. 
 
Hazard Control Verifications: 
1a. These requirements are outlined by the NASA IRB guidelines and Test Subject Selection criteria on exercise 
protocol. 
1b. UND 1.1 Test Plan, AWI 1.1 
1c. UND 1.1 Test Plan Section 4.1, 4.2 
1d. UND 1.1, AWI 1.14 Section 9.4 and 9.7 
2a, 3a . UND 1.1 Test Plan Section 3.3 
2b. UND 1.1 Test Plan Sections 1.3, 4.5 
2c. UND 1.1 Test Plan, AWI 1.14 section 7. 
 
2d. UND 1.1 Test Plan Section 4.6 
3b. UND 1.1 Test Plan Section 3.5 
 
Remarks:   
- The Hexoskin Smart Shirt is a wireless COTS telemetric data device that can be worn under the subject’s 
clothing and cooling devices.   
 
 
Hazard Disposition: Closed/Accepted 
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ARGOS HAZARD ANALYSIS WORKSHEET 
 
Title 
Electrical Hazards 
No. 
          
3 
Date 
October 2017 
System 
 
 
Subsystem 
BIOPAC MP150 System and Hexoskin 
Smart Shirt 
Severity/Probability/RAC     Severity/Probability/RAC 
  Before Hazard Controls       After Hazard Controls 
                  II/D/4                               II/E/5 
Hazard Description: 
Exposure to electrical current resulting in personal injury and hardware damage. 
 
Hazard Causes: 
1. Electromyography system component failure 
2. Facility electrical failure 
3. Test support hardware electrical failure 
 
Hazard Control: 
1a. The electromyography system is inspected and tested prior to use per the BIOPAC MP150 System Product Sheet. 
1b. The power supplied to the electromyography unit is in a low voltage application (10V) and conforms to Low Voltage 
Directive 73/23/EEC and 2014/35/EU following EN 60950-1 Standards. 
1c. Electromyography system is created by company that conforms to ISO 9001:2008 standards 
2a. Facility power has a circuit breaker and is grounded. 
2b. Electrical components and terminals are not exposed under normal conditions. 
2c. Electrical systems have been worked on and manipulated by qualified personnel and inspected prior to use and testing 
will be terminated if these standards are not met 
3a. Support hardware will be functionally tested prior to use. 
3b. Systems are powered off during connection and disconnection times. 
 
Additional Hazard Control Constants: 
- Project leader and testing team are trained and practiced in emergency egress scenarios. 
- Subject will be monitored by project leader and testing team at all times during the test. 
- Emergency procedures and safety briefings are provided prior to the commencement of any testing. 
- ARGOS Personnel are trained in emergency procedures AWI 1.14. 
 
Hazard Control Verifications: 
1a.UND 1.1 Section 4.4 
1b. UND 1.1 Section 2.1, BIOPAC MP150 EC Declaration of Conformity, BIOPAC MP150 Hardware specifications sheet 
1c. UND 1.1 Section 2.1, ISO Certification document # 45311-IS2 
2a, b. AWI 1.14, section 3 
2c. AWI 1.14 
3a. UND 1.1, AWI 1.14 
3b. UND 1.1 Section 4 
Remarks:   
BIOPAC MP150 system, Hexoskin units and all related equipment are COTS. 
 
 
Hazard Disposition: Closed/Accepted 
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NASA INSTITUTIONAL REVIEW BOARD (IRB) 
CONSENT TO BE A PART OF A RESEARCH STUDY 
 
NOTE:  Any alterations to this consent document will invalidate the test subjects’ consent 
unless the changes are approved in advance by the IRB. 
 
 
  ABOUT THIS RESEARCH CONSENT FORM 
 
You may be eligible to take part in a research study. 
 
A research study is carefully planned and designed to increase scientific knowledge. 
 
This NASA IRB Consent form describes important information related to participation in a research 
study including the purpose, planned procedures, and potential risks. 
Please take time to review this information carefully.  Talk to the researchers about the study and 
ask any questions you have.  Make sure you fully understand what will be expected of you and 
the risks associated with participating in this study.  You may also wish to talk to others (for 
example, your friends, family, or doctors) about your participation in this study.  If and when you 
decide to be a participant, you will be asked to sign this form and you will be given a copy. 
 
Taking part in this study is completely voluntary.  The decision to participate is yours.  You may 
also leave the study at any time.  If you leave the study before it is finished, there will be no penalty 
to you. 
 
This NASA IRB Consent form provides a detailed description regarding essential information 
including, but not limited to, how, when, where, and by whom a signed informed consent will be 
obtained. 
 
Note: Failure to disclose pre-existing medical conditions may place you at greater risk for 
injury or other adverse events resulting from your participation in this study. 
 
 
1.  GENERAL INFORMATION 
 
1.1 Your study title is: Effects of locomotor gaits under simulated reduced gravity conditions 
on muscles of the leg 
 
    
Appendix B – NASA Informed Consent Form 
 
1.2 Your study team includes a Principal Investigator, Co-Investigator, Key-Personnel (names, 
degrees, affiliations):  
 
 PI: Sophie Orr, University of North Dakota 
  B.S. Anthropology 
  Currently a M.S. Space Studies Student at the University of North Dakota 
 Co-Investigator: Pablo de Leon, University of North Dakota 
  PhD History (Science and Technology) 
  B.S. Aeronautical Engineering 
  
  
 
 
 Key-Personnel: 
 Jesse Rhoades, University of North Dakota 
   PhD Pedagogical Kinesiology,  
  M.S. in Exercise Science (Biomechanics) 
  B.S in Physical Education,  
 Paul Valle, NASA Johnson Space Center  
  ARGOS Project Manager 
  B.S. in Mechanical Engineering 
 
 
1.3 This study is sponsored or funded by: The University of North Dakota Department of 
Space Studies 
 
2.  PURPOSE OF THIS STUDY (History and Background) 
 
2.1 You are being asked to join this study because:  
 
You are invited to be in a research study about the effect of simulated gravity on the locomotion 
patterns of humans, as well as the impact of such locomotion on muscles of the leg. You have 
been chosen because you meet the basic selection criteria needed to fit the equipment associated 
with this study and are available during the testing schedule. 
 
The purpose of this experiment is to suggest a preferred locomotion method to train astronauts in 
for future trips to the moon and Mars. The result of this study will help reduce the possibility of 
harmful training or a misunderstood aspect of living in fractional gravity. This is in line with the 
risk reduction strategy for performance effects put forth in NASA’s Human Research Roadmap. 
This study will serve as a basis for future research.  
 
 
3.  STUDY PARTICIPANTS 
 
3.1 In order to be eligible to participate, you may be asked to undergo the following screening 
tests or procedures: 
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Screening physicians will evaluate subject eligibility for exercise protocols based on age, fitness 
level, and history of pre-existing medical conditions or other pertinent other medical history. 
 
Failure to disclose pre-existing medical conditions may place them at greater risk for injury or 
other adverse events resulting from participation in the study. 
 
This study requires physical exercise on a treadmill with speeds up to 6 miles per hour. To ensure 
the health and safety of the test subjects the following criteria apply: 
- Must be able to complete exercise requirements of this study listed in this 
document. 
- BMI lower than 30 
- BMI higher than 19 
- No recent smoking history 
- No history of lower back pain 
- No history of Achilles tendinitis 
 
3.2 You are one of 6 Subjects. 
 
4.  STUDY PROCEDURES 
 
4.1 The checked boxes below indicate that you will be informed and/or provided the following: 
_x__ Chart or calendar as a possible addition to the explanation of the tests; 
 
_x__ Duration of the study, and when the study is completed; 
 
_x__ Amount of time for each test, frequency of testing, and whether testing is continuous 
or intermittent; 
 
___ Need for follow-up examinations or tests; 
 
_x__ Location of the testing; 
 
___ The amount of blood, urine, saliva, other biological samples and/or tissue to be 
taken and how often; 
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_x_ Detailed explanation of each test, including what data will be collected; 
 
_x_ Whether joining this study limits your chance to join other studies; 
 
_x_ Whether “standard” medical procedures are included in the study; 
 
_x_ How your other activities may be affected by the study (exercise, diet, medications, 
physical activities, etc.). 
 
 
_x__  Check here if Section 4.2 is Not Applicable 
 
4.2 You are being told if the study you are joining includes one of the following categories: 
___  “Randomized” means that you are put into a group by chance (e.g., like flipping a 
coin).  Neither you nor the principal investigator will choose what group you will be 
in.  You will have a chance of being placed in any group. 
 
___  “Blinded” means you (blinded) will not know what group you are in. 
 
___  “Double-Blinded” means that neither you nor the Principal Investigator (double-
blinded) will know what group you are in. 
 
___ “Placebo” means a pill with no medicine.  In a placebo-controlled study, you may 
be given a study medication and it will contain either (name of drug) or placebo 
(pills with no medicine). 
 
___  “Observational” means a chart or record-based study that examines previously 
collected data. 
 
 
 
 
 
 
 
4.3 Study description 
This study will occur at Johnson Space Center in Houston, TX  
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The PI will go over study procedures and all items covered in this document. You will be 
given the chance to ask questions about the procedure, and will be asked to sign this 
informed consent form. Once you have signed the informed consent form, testing will be 
scheduled.  
  
Experiment Test at Johnson Space Center 
This study will take place at Johnson Space Center. You will be connected to the ARGOS 
via a gimbal and harness system, where you will walk, run and skip on a treadmill at 
different speeds. The tests will be repeated for different simulated gravity levels (Lunar and 
Martian gravity), totaling 3 runs per subject. The duration of testing is 1 minute per speed 
with the last 10 seconds of each speed for analysis. This will allow you to get used to the 
speed with the system setup to reduce noise in the data. This will be repeated several times 
to reduce noise in the data. Total time for testing is approximately 90 minutes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
During testing: 
Figure 3. BIOPAC MP150 System. This is hardware used 
to collect data about the human body for research 
purposes. It can have different types of attachments, with 
this experiment utilizing the EMG100C unit that collects 
electromyography data. 
Figure 4. EMG Electrode Placement.  The 
electrodes will be placed on the front and back 
of the lower leg to collect data about your 
muscle activity. 
 
Figure 1. ARGOS (Active Response Gravity Offload 
System).  The ARGOS is designed to simulate 
reduced gravity environments, such as on the Moon 
or Mars, and can even simulates microgravity (free 
floating) conditions. 
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You will be connected to the BIOPAC MP150 data acquisition and analysis system [See 
Figure 3] with the EMG100C Electromyogram Amplifier attachment. The EMG100C 
amplifies general and skeletal muscle electrical activity, a process known as 
“electromyography” or EMG. The connection points will be electrodes that effectively 
senses muscle activation and send the signal to the EMG100C amplifiers, which then 
integrates with the main MP150 unit. These electrodes only receive signals; they do not 
emit signals to you. Placement of these electrodes will be on the shin and the calf of both 
legs [See Figure 4]. The electrodes have a sticker build into them, and conductive gel will 
also be used to ensure signal strength. You will be asked to remove hair from the areas of 
skin that will have the electrodes attached to them. You can do this yourself or the PI will 
shave the areas for you. Specialized tape will be used to ensure electrodes do not move 
during movement during testing.  
 
In addition to the BIOPAC system, the motion capture camera system will be employed 
during testing. This consists of several motion capture cameras that will map your 
movement by receiving light reflected from reflective markers placed on key points of your 
body. Each test will be recorded and then the data will be uploaded to the Ariel 
Performance Analysis System (APAS) which will allow for analysis of gait alterations 
between tests.  
 
The electrodes will remain on you between testing runs, as electrode movement would be 
possible. You are expected to be available for your allotted testing time, but are not 
required to be present for tests of the other subjects if your schedule does not allow for it 
The data collected, including electromyography and 3d motion capture data, will be used in 
Sophie Orr’s master’s thesis. This experiment will involve videotaping, photography and 
interviews in order to allow a full picture of the experiment process be available to 
interested parties and available for use in the written thesis document. Finally, experiments 
and activities that occur at UND and/or at NASA facilities are used for UND/NASA public 
relation stories. This includes, but is not limited to, UND/NASA websites, news sources 
and social media accounts. The sharing of your video, photos and quotes helps spread the 
work about this research and the institutions that help make it possible. 
 
 
5.  DRUGS, BIOLOGICS, and MEDICAL DEVICES 
 
_x_  Check here if Section 5.1 is Not Applicable 
 
5.1 You will be told if the study uses drugs, blood or blood components, allergenic substances, 
vaccines, medical devices or other similar products used to investigate human anatomy or 
physiology, or to prevent or treat disease or injury. 
 
Is a study drug or biologic used? 
 
___ No 
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___ Yes, the study drug or biologic is _________________________________. 
 
___ This drug or biologic is FDA approved. 
 
___ This is an investigational drug or biologic, with the FDA IND number: 
___________________________________. 
 
Is a study medical device used? 
 
___ No 
 
___ Yes, the study medical device is ___________________. 
 
___ This medical device is FDA approved. 
 
___ This is an investigational medical device, with the FDA IDE number 
____________________________________. 
 
___ This is an investigational non-significant risk device, with IRB approval 
for use. A document providing full and informed disclosure is provided 
for your review. 
 
6.  INFORMATION ABOUT RISKS AND HAZARDS 
 
6.1 You are joining a study that is: 
___  “Minimal risk” means that the probability and magnitude of harm or discomfort 
anticipated in the research is not greater in and of themselves than those ordinarily 
encountered in daily life or during the performance of routine physical or 
psychological examinations or tests. 
 
_x_  “Greater than minimal risk” means that the probability and magnitude of harm or 
discomfort anticipated in the research is greater in and of themselves than those 
ordinarily encountered in daily life or during the performance of routine physical or 
psychological examinations or tests, but that the risks of harm or discomfort are 
considered to be acceptable when weighed against the anticipated benefits and the 
importance of the knowledge to be gained from the research. 
 
6.2 You are told that the risks of joining the study and the steps taken to protect against harm 
include:  
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• The ARGOS system and test winch system will suspend you from the ground. While the 
suspension is minimal (these tests are focused on the individuals being able to physically 
touch the ground), a fall is possible. To mitigate the risk of this occurring, you will be 
closely monitored for the entire time you are secured into any system related to the study 
in case unforeseen circumstances arise.  
• You will be running on a treadmill, where you could trip and fall off of the treadmill. 
You will, however, be suspended, which could mitigate the chance of falling off the 
treadmill. To further mitigate chances of this occurring, treadmill speeds will be within 
normal walking and running speeds. You will also be closely monitored for the entire 
time you are secured into any system related to the study in case unforeseen 
circumstances arise.  
• The EMG equipment in use is a non-invasive research grade biological sensing device. It 
is possible that the gel or stickers used to attach the device to the skin might cause mild 
discomfort (similar to putting a piece of tape or sticker on the skin). To mitigate the risk 
of this occurring shaving the areas where the adhesives will contact the skin.  
• As with any physical exercise, you may experience some physical injuries. These are 
expected to be mild and any severe injury will end the study and immediate medical 
attention will be supplied. Some possible injuries during this study may include minor 
cuts, minor bruising, headaches, nausea, dizziness, fatigue, or other unforeseen minor 
injuries. To mitigate the possibility of any injury, treadmill speeds will be within normal 
walking and running speeds and will not exceed speeds above those associated with 
moderate exercise. You will also be closely monitored for the entire time you are secured 
into any system related to the study in case unforeseen circumstances arise. Subjects must 
also pass certain physical requirements to participate in research, further mitigating the 
chances of this occurring.  
During this study you may be seen by bystanders, causing an unintended breach in 
privacy. JSC is a government facility, and as such the key personnel of this study do not 
have the ability to determine who will be at the facility during testing time, nor will the 
key personnel know who else will be in the facility before, during or after the tests. You 
may contact the PI, Sophie Orr, at any time with concerns and if needed the PI will assist 
and fund the participant in locating counseling service to discuss your concerns. 
• Electric shock from the BIOPAC MP150 system is possible though extremely unlikely. 
To mitigate this hazard the hardware will be tested in compliance with the hardware user 
manual prior to testing.  
 
6.3 You are told that the hazards and the steps used to minimize the hazards include:  
 
• The ARGOS system and test winch system will suspend you from the ground. While the 
suspension is minimal (these tests are focused on the individuals being able to physically 
touch the ground), a fall is possible. To mitigate chances of this occurring, you will not 
be suspended higher than is required to simulate the gravity levels being assessed in this 
study.  
• You will be running on a treadmill, where you could trip and fall off of the treadmill. 
You will, however, be suspended, which could mitigate the chance of falling off the 
treadmill. To mitigate chances of this occurring, treadmill speeds will be within normal 
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walking and running speeds. You will be allowed to familiarize yourself with movement 
while connected to the ARGOS gimbal and harness.  
• The EMG equipment in use is a non-invasive research grade biological sensing device. It 
is possible that the gel or stickers used to attach the device to the skin might cause mild 
discomfort (similar to putting a piece of tape or sticker on the skin). This will be 
mitigated by shaving the areas where the adhesives will contact the skin, reducing 
adhesion points that could cause discomfort.  
• As with any physical exercise, you may experience some physical injuries. These are 
expected to be mild and any severe injury will end the study and immediate medical 
attention will be supplied. Some possible injuries during this study may include minor 
cuts, minor bruising, headaches, nausea, dizziness, fatigue, or other unforeseen minor 
injuries. To mitigate the possibility of any injury, treadmill speeds will be within normal 
walking and running speeds and will not exceed speeds above those associated with 
moderate exercise.  
• During this study you may be seen by bystanders, causing an unintended breach in 
privacy. JSC is a government facility, and as such the key personnel of this study do not 
have the ability to determine who will be at the facility during testing time, nor will the 
key personnel know who else will be in the facility before, during or after the tests. You 
may contact the PI, Sophie Orr, at any time with concerns and if needed the PI will assist 
and fund the participant in locating counseling service to discuss your concerns. 
 
 
_x__  Check here if Section 6.4 is Not Applicable 
 
6.4 You are told if you are flying as part of the Reduced Gravity Parabolic Aircraft and 
informed of the following information:  
___  “Since the Reduced Gravity Parabolic Flight Aircraft and other NASA sponsored 
aircraft are considered to be public aircraft within the meaning of the Federal 
Aviation Act of 1958, as amended, and as such do not hold a current airworthiness 
certificate issued by the Federal Aviation Administration, any individual manifested 
to board the Reduced Gravity Parabolic Flight Aircraft or other NASA sponsored 
aircraft should determine before boarding whether their personal life or accident 
insurance provides coverage under such condition.” 
 
7.  TREATMENT, INJURY AND COMPENSATION INFORMATION 
 
7.1 Even though researchers have taken steps to minimize the risks, you may experience 
problems or side effects.  In the event of physical injury resulting from this study, NASA will 
provide or cause to be provided, the necessary immediate action or treatment.  NASA will pay 
for any claims of injury, loss of life or property damage to the extent required by the Federal 
Employees Compensation Act or the Federal Tort Claims Act.  Your agreement to participate 
shall not be construed as a release of NASA or any third party from any future liability, which 
may arise from, or in connection with, the test procedures. 
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_x_  Check here if Section 7.2 is Not Applicable 
 
7.2 For International Partner subjects:  
___ In the event of injury resulting from this study, I understand that I will receive 
medical attention and available treatment.  I also understand that I will be 
compensated for any injuries to the extent permitted under current     (insert agency 
name)    laws and regulations and the provisions of the contract between me and    
(insert agency name)    .  My agreement to participate shall not be construed as a 
release of  (insert agency name)        or any third party liability which may arise 
from, or in connection with, the above procedures. 
 
___ Include the HRMRB Multinational consent form 
 
 
8.  BENEFITS INFORMATION 
 
8.1 Participation in NASA studies generally result in no direct benefit to you as an 
individual.  It is hoped that the information learned from this research study will help NASA 
learn more about human physiological and psychological changes for future space flight 
missions. 
 
9.  NEW FINDINGS 
 
9.1 If new information is obtained during the study after you have joined, you will be informed.  
You may change your mind about continuing in the study.  You may be asked to sign a new 
consent form that includes the new information. 
 
10.  STUDY WITHDRAWAL and/or TERMINATION 
 
10.1 You may withdraw from the study at any time.  If you decide to leave before the study is 
finished, please tell the investigator or study staff.  Your refusal will be honored, except in 
cases when the responsible physician’s opinion is that study termination could have undesired 
consequences for your health and/or the health of other subjects.  You will be told if there 
could be any harm to you if you decide to leave before the study is finished.  If you tell the 
researchers your reasons for leaving the study, that information will be part of the study 
record. 
 
10.2 Your withdrawal or refusal to participate in the study will not result in any penalty or loss 
of benefits to which you are otherwise entitled. 
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10.3  If you decide not to join the study, you may be eligible to participate in other studies. 
 
10.4 Researchers may need to stop your participation in the study even if you want to continue 
participation.  Some examples of this scenario include: (Check applicable boxes) 
 
_x_ The researcher believes that it is not in your best interest to stay in the study 
 
_x_ There is any problem with following study related instructions 
 
___ There is any problem with following hospital, clinic, or laboratory policies and 
procedures 
 
_x_ There is any serious complication during the study  
 
_x_ There is inappropriate behavior 
 
_x_ The study is suspended or canceled 
 
_x_ The subject’s information is or becomes unusable for any reason 
 
_x_ Events beyond NASA’s control occur, for example: fire, explosion, disease, 
weather, floods, terrorism, wars, insurrection, civil strife, riots, government action, 
or failure of utilities 
 
___ Existing data reveal answers earlier than expected 
 
11.  COST and FINANCIAL INFORMATION 
 
11.1  There are no costs or bills to you for participation in this study. 
 
12.  PAYMENT and REIMBURSEMENT 
 
___  Check here if Section 12.1 is Not Applicable 
 
12.1 You will be paid to participate in the study as follows: 
___ Is the total dollar amount for the study, including pro-rating (if you do not complete 
the study or if there is a bonus payment at the end of the study). 
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_x_ No payment if you are a NASA, non-NASA, federal civil servant employee, 
contractor, or International Partner crewmember participating in ESA, JAXA, CSA, 
or NASA-sponsored studies. 
 
13.  SUBJECT RECORD CONFIDENTIALITY AND AUTHORIZATION TO 
RELEASE PROTECTED HEALTH INFORMATION (PHI) 
 
13.1 Your privacy and the confidentiality of data collected as a part of this research study will be 
protected from unauthorized disclosure according to applicable federal law. 
 
13.2 Your protected health information may be used or shared with others during the research.  
This may include: 
• Existing medical records; 
• Video and photographic materials; 
• New information created from study-related tests, procedures, visits, and/or 
questionnaires. 
 
13.3 Your protected information may be used or shared by NASA offices of research oversight or 
quality assurance, medical monitors, and researchers for the reasons below: 
• To conduct and oversee the research; 
• To make sure the research meets NASA requirements; 
• To conduct monitoring activities (including situations where you or others may be at 
risk of harm or reporting of adverse events); 
• To become part of your medical record, if necessary, for your medical care; 
• To review the safety of the research. 
• To support “NASA Clinical Summit” activities where clinical experts evaluate relevant 
medical and research data to recommend clinical practice guidelines specifically for 
astronauts.  These data will not include names or other information that explicitly link 
the information to you. 
 
13.4 Every effort will be made to maintain the confidentiality of your study records.  There are 
many reasons why information about you may be used or seen by the researchers or others 
during or after this study.  Examples include: 
• The researchers may need the information to make sure you can take part in the study. 
• NASA and other government officials may need the information to make sure that the 
study is done in a safe and proper manner.  These agencies may include the Department 
of Health and Human Services (DHHS), the Food and Drug Administration (FDA), the 
National Institutes of Health (NIH), and/or the Office for Human Research Protections 
(OHRP) or other domestic or foreign government bodies if required by law and/or 
necessary for oversight purposes. 
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• The FDA may need to review the information if the study involves the use of an 
experimental drug or device. 
• Safety monitors, medical personnel, or safety committees may review your research 
data and/or medical records for the purposes of medical safety or for verification of 
research procedures. 
• A data and safety monitoring board (DSMB) may oversee the research, if applicable. 
• The results may be used by the research team and possibly be presented/published at 
scientific conferences and/or in an article, but would not include information that 
would identify you without your consent. 
 
13.5 You have the right to withdraw your consent for the researchers to use or share your protected 
health information.  The researchers will not be able to withdraw all the information that already 
has been used or shared with others to carry out related activities such as oversight, or to ensure 
quality of the study.  To withdraw your consent, you must do so in writing by contacting the 
researcher. 
 
13.6  You have the right to request access to your study records after the study is completed.  To 
request this information, you must do so in writing by contacting the researcher. 
 
13.7  If physiologic data (including but not limited to standard measures, laboratory data, 
psychological, or physiological measurements) are obtained from you for this study, they 
may become the property of NASA’s Life Science Data Archive.  These data may be used in 
this research, may be used in other research, and may be shared with other organizations.  All 
federal regulations concerning the privacy and confidentiality of these data will be followed.  
Records stored in this archive will not include names, registration numbers, or other 
information that explicitly links the information to you. 
 
14.  CONTACT INFORMATION 
 
14.1 You may contact the Principal Investigator to: 
• Obtain more information about the study; 
• Ask a question about the study procedures; 
• Report an illness, injury, or other problem; 
• Leave the study before it is finished; 
• Express a concern about the study. 
 
Principal Investigator and Study Coordinator: Sophie Orr 
Email Address: Sophie.orr@und.edu 
Mailing Address:  
Department of Space Studies 
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Clifford Hall, Room 512 
4149 University Ave Stop 9908 
Grand Forks, ND 58202-9008 
Phone: (65070 799-5638 
 
 
Study Co-Investigator and Faculty Advisor: Pablo de Leòn 
Email Address deleon@space.edu 
Mailing Address: Department of Space Studies 
Clifford Hall, Room 512 
4149 University Ave Stop 9908 
Grand Forks, ND 58202-9008 
 
 
You may express a concern about this study by contacting the NASA JSC Institutional Review 
Board (IRB) listed below: 
 
Office of Research Assurance: Research Integrity & Protection of Human Subjects 
2101 NASA Parkway 
Mail Code SA 
Houston, Texas  77058 
Telephone: (281) 204-1650 
E-mail:  NASA-IRB@nasa.gov 
 
 
 
15.  RECORD of INFORMATION PROVIDED  
 
15.1 Your signature in the next section means that you have received copies of all of the following 
documents: 
___ This NASA IRB “Consent to be Part of a Research Study” document 
 
___ Other (specify): _______________________________ 
 
16.  SIGNATURES 
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___ Check here if the study will NOT utilize video, audio or still photography 
Video, Audio, and Photo: 
I understand that this study will utilize video and/or still photography to analyze study results and I 
consent for the use of these materials. 
 ___ I accept 
 ___ I do not accept  
 
Signature: _____________________________ 
 
I give consent for my quotes to be used for this study; however, I will not be identified. 
 ___ I accept 
 ___ I do not accept  
 
Signature: _____________________________ 
 
 
 
Research Subject: 
I understand the information printed on this form.  I have discussed this study, its risks and potential 
benefits, and my other choices with _________________________.  My questions so far have been 
answered.  I understand that if I have more questions or concerns about the study or my 
participation as a research subject, I may contact the study team.  I understand that I will receive a 
copy of this form at the time I sign it and later upon request. 
Signature of Subject: __________________________________  Date: ________________ 
Name (Print legal name): ___________________________________________________________ 
 
Principal Investigator (or Designee): 
I have given this subject information about this study.  I believe this to be accurate and complete.  
The subject has indicated that he or she understands the nature of the risks and benefits of 
participating in this study. 
Name: Sophie Orr      Title: Principal Investigator  
Signature: _________________________________  Date: ___________________________ 
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Witness (optional): 
I observed the above subject sign this consent document. 
Name: ________________________________ 
Signature: _____________________________  Date: _________________________ 
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EMG Descriptives 
  
N Mean Std. Deviation Std. Error 
95% Confidence Interval for Mean Minimum Maximum 
  Lower Bound Upper Bound 
  
          
CH1W2 1.0 6 0.0119017 0.00240264 0.00098087 0.0093803 0.0144231 0.00827 0.01487 
2.0 6 0.0118967 0.00336430 0.00137347 0.0083661 0.0154273 0.00828 0.01810 
3.0 6 0.0130083 0.00574129 0.00234387 0.0069832 0.0190334 0.00657 0.02321 
Total 18 0.0122689 0.00387442 0.00091321 0.0103422 0.0141956 0.00657 0.02321 
CH1R2 1.0 6 0.0217167 0.00943205 0.00385062 0.0118183 0.0316150 0.01259 0.03743 
2.0 6 0.0151267 0.00524365 0.00214071 0.0096238 0.0206295 0.00790 0.02351 
3.0 6 0.0108933 0.00466404 0.00190409 0.0059987 0.0157879 0.00555 0.01766 
Total 18 0.0159122 0.00785176 0.00185068 0.0120076 0.0198168 0.00555 0.03743 
CH1S2 1.0 6 0.0240483 0.00863427 0.00352493 0.0149872 0.0331094 0.01086 0.03494 
2.0 6 0.0121650 0.00399277 0.00163004 0.0079748 0.0163552 0.00618 0.01841 
3.0 6 0.0093383 0.00658955 0.00269017 0.0024230 0.0162536 0.00441 0.02212 
Total 18 0.0151839 0.00907728 0.00213954 0.0106699 0.0196979 0.00441 0.03494 
CH1W3 1.0 6 0.0152467 0.00400368 0.00163450 0.0110451 0.0194483 0.01057 0.02122 
2.0 6 0.0172117 0.00618400 0.00252461 0.0107220 0.0237014 0.01047 0.02601 
3.0 6 0.0178767 0.00705357 0.00287961 0.0104744 0.0252789 0.00703 0.02712 
Total 18 0.0167783 0.00564937 0.00133157 0.0139690 0.0195877 0.00703 0.02712 
CH1R3 1.0 6 0.0226683 0.00915209 0.00373633 0.0130638 0.0322729 0.01363 0.03803 
2.0 6 0.0161750 0.00541569 0.00221095 0.0104916 0.0218584 0.00834 0.02330 
3.0 6 0.0112100 0.00372102 0.00151910 0.0073050 0.0151150 0.00844 0.01837 
Total 18 0.0166844 0.00778724 0.00183547 0.0128119 0.0205569 0.00834 0.03803 
CH1S3 1.0 6 0.0257067 0.01004610 0.00410130 0.0151639 0.0362494 0.01253 0.04094 
2.0 6 0.0130700 0.00448861 0.00183247 0.0083595 0.0177805 0.00748 0.02004 
3.0 6 0.0097433 0.00287973 0.00117564 0.0067212 0.0127654 0.00480 0.01332 
Total 18 0.0161733 0.00938704 0.00221255 0.0115053 0.0208414 0.00480 0.04094 
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CH1W4 1.0 6 0.0227217 0.00637772 0.00260369 0.0160287 0.0294147 0.01329 0.02877 
2.0 6 0.0252033 0.01252528 0.00511342 0.0120589 0.0383478 0.01210 0.04369 
3.0 6 0.0165033 0.00736964 0.00300864 0.0087694 0.0242373 0.00901 0.02893 
Total 18 0.0214761 0.00939455 0.00221432 0.0168043 0.0261479 0.00901 0.04369 
CH1R4 1.0 6 0.0317917 0.01012375 0.00413300 0.0211674 0.0424159 0.02095 0.04330 
2.0 6 0.0177367 0.00541138 0.00220918 0.0120578 0.0234156 0.00808 0.02204 
3.0 6 0.0118067 0.00390641 0.00159478 0.0077071 0.0159062 0.00789 0.01784 
Total 18 0.0204450 0.01084485 0.00255616 0.0150520 0.0258380 0.00789 0.04330 
CH1S4 1.0 6 0.0295233 0.01143577 0.00466863 0.0175222 0.0415244 0.01610 0.04287 
2.0 6 0.0153100 0.00516194 0.00210735 0.0098929 0.0207271 0.00868 0.02087 
3.0 6 0.0111000 0.00403110 0.00164569 0.0068696 0.0153304 0.00654 0.01727 
Total 18 0.0186444 0.01081036 0.00254803 0.0132686 0.0240203 0.00654 0.04287 
CH1W5 1.0 6 0.0544283 0.04579759 0.01869679 0.0063667 0.1024900 0.02448 0.14518 
2.0 6 0.0444450 0.03821618 0.01560169 0.0043396 0.0845504 0.02096 0.11911 
3.0 6 0.0294717 0.02906874 0.01186726 -0.0010341 0.0599774 0.01058 0.08612 
Total 18 0.0427817 0.03750125 0.00883913 0.0241327 0.0614306 0.01058 0.14518 
CH1R5 1.0 6 0.0487600 0.03633883 0.01483527 0.0106247 0.0868953 0.02343 0.11818 
2.0 6 0.0258433 0.01508373 0.00615791 0.0100139 0.0416727 0.00985 0.05236 
3.0 6 0.0161200 0.00927535 0.00378664 0.0063861 0.0258539 0.00798 0.03140 
Total 18 0.0302411 0.02605479 0.00614117 0.0172844 0.0431979 0.00798 0.11818 
CH1S5 1.0 6 0.0390983 0.02436821 0.00994828 0.0135255 0.0646712 0.02065 0.08666 
2.0 6 0.0205133 0.00926660 0.00378307 0.0107886 0.0302380 0.01087 0.03751 
3.0 6 0.0179983 0.01066976 0.00435591 0.0068011 0.0291956 0.00659 0.03310 
Total 18 0.0258700 0.01808719 0.00426319 0.0168755 0.0348645 0.00659 0.08666 
CH1W6 1.0 5 0.0614740 0.01270649 0.00568252 0.0456968 0.0772512 0.04588 0.08112 
2.0 6 0.0373167 0.01629788 0.00665358 0.0202131 0.0544202 0.02596 0.06470 
3.0 5 0.0260220 0.01401661 0.00626842 0.0086181 0.0434259 0.01309 0.04230 
Total 16 0.0413363 0.02009478 0.00502370 0.0306285 0.0520440 0.01309 0.08112 
CH1R6 1.0 6 0.0425733 0.01878268 0.00766800 0.0228621 0.0622845 0.02511 0.06802 
2.0 6 0.0266333 0.01257081 0.00513201 0.0134411 0.0398256 0.01085 0.04342 
3.0 6 0.0181950 0.00825109 0.00336849 0.0095360 0.0268540 0.00917 0.02787 
Total 18 0.0291339 0.01668684 0.00393313 0.0208357 0.0374321 0.00917 0.06802 
CH1S6 1.0 6 0.0341150 0.00903987 0.00369051 0.0246282 0.0436018 0.02541 0.05035 
2.0 6 0.0190017 0.00612571 0.00250081 0.0125731 0.0254302 0.01363 0.02896 
3.0 6 0.0157183 0.00581206 0.00237276 0.0096189 0.0218177 0.00961 0.02265 
Total 18 0.0229450 0.01062843 0.00250514 0.0176596 0.0282304 0.00961 0.05035 
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CH2W2 1.0 6 0.0169100 0.00861211 0.00351588 0.0078721 0.0259479 0.00976 0.03225 
2.0 6 0.0059117 0.00132557 0.00054116 0.0045206 0.0073028 0.00445 0.00753 
3.0 6 0.0035867 0.00123990 0.00050619 0.0022855 0.0048879 0.00223 0.00522 
Total 18 0.0088028 0.00765074 0.00180330 0.0049982 0.0126074 0.00223 0.03225 
CH2R2 1.0 6 0.0349883 0.01595278 0.00651269 0.0182469 0.0517297 0.02159 0.06059 
2.0 6 0.0087100 0.00152852 0.00062401 0.0071059 0.0103141 0.00681 0.01036 
3.0 6 0.0052500 0.00228443 0.00093262 0.0028526 0.0076474 0.00364 0.00953 
Total 18 0.0163161 0.01624086 0.00382801 0.0082397 0.0243925 0.00364 0.06059 
CH2S2 1.0 6 0.02969000 0.006818853 0.002783785 0.02253405 0.03684595 0.018800 0.036190 
2.0 6 0.00917150 0.005155409 0.002104687 0.00376123 0.01458177 0.000519 0.016260 
3.0 6 0.00620500 0.002468933 0.001007938 0.00361401 0.00879599 0.002810 0.009100 
Total 18 0.01502217 0.011778748 0.002776278 0.00916473 0.02087960 0.000519 0.036190 
CH2W3 1.0 6 0.0249950 0.01289812 0.00526563 0.0114593 0.0385307 0.00956 0.04675 
2.0 6 0.0095083 0.00327642 0.00133759 0.0060699 0.0129467 0.00514 0.01413 
3.0 6 0.0055633 0.00226401 0.00092428 0.0031874 0.0079393 0.00320 0.00883 
Total 18 0.0133556 0.01131654 0.00266733 0.0077280 0.0189831 0.00320 0.04675 
CH2R3 1.0 6 0.0379083 0.01215678 0.00496299 0.0251506 0.0506661 0.02407 0.05339 
2.0 6 0.0096350 0.00263844 0.00107714 0.0068661 0.0124039 0.00630 0.01316 
3.0 6 0.0056550 0.00121136 0.00049454 0.0043838 0.0069262 0.00364 0.00709 
Total 18 0.0177328 0.01625546 0.00383145 0.0096491 0.0258164 0.00364 0.05339 
CH2S3 1.0 6 0.0321400 0.01212124 0.00494848 0.0194195 0.0448605 0.01595 0.04747 
2.0 6 0.0108000 0.00409819 0.00167308 0.0064992 0.0151008 0.00394 0.01549 
3.0 6 0.0068167 0.00300600 0.00122719 0.0036621 0.0099713 0.00376 0.01064 
Total 18 0.0165856 0.01347950 0.00317715 0.0098824 0.0232888 0.00376 0.04747 
CH2W4 1.0 6 0.0378633 0.02511884 0.01025472 0.0115027 0.0642239 0.00867 0.08139 
2.0 6 0.0132667 0.00435421 0.00177760 0.0086972 0.0178361 0.00827 0.01876 
3.0 6 0.0069783 0.00237683 0.00097034 0.0044840 0.0094727 0.00304 0.00882 
Total 18 0.0193694 0.01951571 0.00459990 0.0096645 0.0290744 0.00304 0.08139 
CH2R4 1.0 6 0.0395033 0.01274804 0.00520436 0.0261251 0.0528816 0.02215 0.05609 
2.0 6 0.0119850 0.00309873 0.00126505 0.0087331 0.0152369 0.00883 0.01586 
3.0 6 0.0063083 0.00190781 0.00077886 0.0043062 0.0083105 0.00440 0.00856 
Total 18 0.0192656 0.01655926 0.00390305 0.0110308 0.0275003 0.00440 0.05609 
CH2S4 1.0 6 0.03973667 0.017707723 0.007229148 0.02115355 0.05831978 0.022620 0.067090 
2.0 6 0.01202333 0.004575678 0.001868013 0.00722145 0.01682521 0.005260 0.017070 
3.0 6 0.00729850 0.004064877 0.001659479 0.00303267 0.01156433 0.000621 0.012620 
Total 18 0.01968617 0.017889025 0.004216484 0.01079016 0.02858217 0.000621 0.067090 
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CH2W5 1.0 6 0.0597267 0.03611314 0.01474313 0.0218282 0.0976251 0.01209 0.12269 
2.0 6 0.0158333 0.00903119 0.00368697 0.0063557 0.0253110 0.00881 0.03306 
3.0 6 0.0082017 0.00209020 0.00085332 0.0060081 0.0103952 0.00500 0.01142 
Total 18 0.0279206 0.03089816 0.00728277 0.0125553 0.0432858 0.00500 0.12269 
CH2R5 1.0 6 0.0424983 0.01342356 0.00548014 0.0284112 0.0565855 0.02059 0.05751 
2.0 6 0.0135050 0.00311446 0.00127147 0.0102366 0.0167734 0.00963 0.01856 
3.0 6 0.0078283 0.00211958 0.00086531 0.0056040 0.0100527 0.00474 0.01023 
Total 18 0.0212772 0.01735717 0.00409113 0.0126457 0.0299087 0.00474 0.05751 
CH2S5 1.0 6 0.0377483 0.01258228 0.00513669 0.0245440 0.0509526 0.02426 0.05778 
2.0 6 0.0143433 0.00517374 0.00211217 0.0089138 0.0197728 0.00849 0.02109 
3.0 6 0.0093033 0.00274058 0.00111884 0.0064273 0.0121794 0.00578 0.01206 
Total 18 0.0204650 0.01480776 0.00349022 0.0131013 0.0278287 0.00578 0.05778 
CH2W6 1.0 5 0.0549640 0.02059373 0.00920979 0.0293935 0.0805345 0.03073 0.08539 
2.0 6 0.0180167 0.01235221 0.00504277 0.0050538 0.0309795 0.00947 0.04129 
3.0 5 0.0116980 0.00254203 0.00113683 0.0085417 0.0148543 0.00942 0.01559 
Total 16 0.0275881 0.02315814 0.00578953 0.0152480 0.0399282 0.00942 0.08539 
CH2R6 1.0 6 0.0448583 0.01675253 0.00683919 0.0272776 0.0624390 0.01761 0.06146 
2.0 6 0.0161300 0.00456917 0.00186535 0.0113350 0.0209250 0.01010 0.02393 
3.0 6 0.0106100 0.00261155 0.00106616 0.0078693 0.0133507 0.00596 0.01349 
Total 18 0.0238661 0.01814840 0.00427762 0.0148411 0.0328911 0.00596 0.06146 
CH2S6 1.0 6 0.0394983 0.01141463 0.00466000 0.0275194 0.0514773 0.02509 0.05077 
2.0 6 0.0153983 0.00523497 0.00213717 0.0099046 0.0208921 0.00941 0.02214 
3.0 6 0.0092067 0.00177416 0.00072430 0.0073448 0.0110685 0.00721 0.01202 
Total 18 0.0213678 0.01510297 0.00355980 0.0138572 0.0288783 0.00721 0.05077 
CH3W2 1.0 6 0.0191817 0.00983321 0.00401439 0.0088623 0.0295010 0.00843 0.03083 
2.0 6 0.0097783 0.00549397 0.00224290 0.0040128 0.0155439 0.00457 0.01886 
3.0 6 0.0066617 0.00673814 0.00275083 -0.0004096 0.0137329 0.00322 0.02037 
Total 18 0.0118739 0.00898091 0.00211682 0.0074078 0.0163400 0.00322 0.03083 
CH3R2 1.0 6 0.0335100 0.02406968 0.00982641 0.0082504 0.0587696 0.01853 0.08141 
2.0 6 0.0113350 0.00317499 0.00129618 0.0080031 0.0146669 0.00658 0.01572 
3.0 6 0.0066900 0.00176730 0.00072150 0.0048353 0.0085447 0.00410 0.00876 
Total 18 0.0171783 0.01786881 0.00421172 0.0082924 0.0260643 0.00410 0.08141 
CH3S2 1.0 6 0.0425483 0.01814252 0.00740665 0.0235089 0.0615877 0.02362 0.06598 
2.0 6 0.0147100 0.00447726 0.00182783 0.0100114 0.0194086 0.01035 0.02162 
3.0 6 0.0094433 0.00278104 0.00113536 0.0065248 0.0123619 0.00620 0.01301 
Total 18 0.0222339 0.01812044 0.00427103 0.0132228 0.0312450 0.00620 0.06598 
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CH3W3 1.0 6 0.0254033 0.01373752 0.00560832 0.0109867 0.0398200 0.00999 0.04457 
2.0 6 0.0157967 0.01040549 0.00424802 0.0048768 0.0267166 0.00569 0.03328 
3.0 6 0.0087733 0.00712143 0.00290731 0.0012999 0.0162468 0.00440 0.02314 
Total 18 0.0166578 0.01230707 0.00290080 0.0105376 0.0227779 0.00440 0.04457 
CH3R3 1.0 6 0.0407617 0.02734129 0.01116203 0.0120687 0.0694546 0.01471 0.09236 
2.0 6 0.0140167 0.00387432 0.00158168 0.0099508 0.0180825 0.00704 0.01798 
3.0 6 0.0080533 0.00319674 0.00130506 0.0046986 0.0114081 0.00441 0.01351 
Total 18 0.0209439 0.02101157 0.00495247 0.0104951 0.0313927 0.00441 0.09236 
CH3S3 1.0 6 0.0455517 0.02458431 0.01003650 0.0197520 0.0713513 0.02168 0.08141 
2.0 6 0.0146567 0.00413663 0.00168877 0.0103155 0.0189978 0.00983 0.02196 
3.0 6 0.0095633 0.00329797 0.00134639 0.0061023 0.0130243 0.00523 0.01323 
Total 18 0.0232572 0.02130050 0.00502057 0.0126647 0.0338497 0.00523 0.08141 
CH3W4 1.0 6 0.0370567 0.02301728 0.00939676 0.0129015 0.0612118 0.01121 0.06314 
2.0 6 0.0210950 0.01337373 0.00545980 0.0070601 0.0351299 0.00874 0.04443 
3.0 6 0.0123167 0.00949316 0.00387557 0.0023542 0.0222791 0.00466 0.03049 
Total 18 0.0234894 0.01860054 0.00438419 0.0142396 0.0327393 0.00466 0.06314 
CH3R4 1.0 6 0.0524233 0.03100360 0.01265717 0.0198870 0.0849596 0.01979 0.09549 
2.0 6 0.0162983 0.00564168 0.00230321 0.0103778 0.0222189 0.00758 0.02248 
3.0 6 0.0105033 0.00401509 0.00163916 0.0062897 0.0147169 0.00642 0.01639 
Total 18 0.0264083 0.02571064 0.00606006 0.0136227 0.0391939 0.00642 0.09549 
CH3S4 1.0 6 0.0563617 0.03019181 0.01232575 0.0246773 0.0880460 0.02708 0.09387 
2.0 6 0.0170917 0.00546475 0.00223097 0.0113568 0.0228266 0.00924 0.02362 
3.0 6 0.0112017 0.00378170 0.00154387 0.0072330 0.0151703 0.00632 0.01480 
Total 18 0.0282183 0.02658068 0.00626513 0.0150001 0.0414366 0.00632 0.09387 
CH3W5 1.0 6 0.0531133 0.03211754 0.01311193 0.0194080 0.0868186 0.01978 0.09431 
2.0 6 0.0233450 0.01269391 0.00518227 0.0100236 0.0366664 0.00929 0.04073 
3.0 6 0.0129100 0.00597364 0.00243873 0.0066410 0.0191790 0.00456 0.02108 
Total 18 0.0297894 0.02585535 0.00609416 0.0169319 0.0426470 0.00456 0.09431 
CH3R5 1.0 6 0.0559283 0.03422347 0.01397167 0.0200130 0.0918437 0.02045 0.10163 
2.0 6 0.0181983 0.00666818 0.00272227 0.0112005 0.0251962 0.00912 0.02655 
3.0 6 0.0118233 0.00472586 0.00192932 0.0068638 0.0167828 0.00709 0.01956 
Total 18 0.0286500 0.02766300 0.00652023 0.0148935 0.0424065 0.00709 0.10163 
CH3S5 1.0 6 0.0554533 0.02636162 0.01076208 0.0277885 0.0831182 0.03214 0.09236 
2.0 6 0.0211617 0.00860432 0.00351270 0.0121320 0.0301914 0.01253 0.03580 
3.0 6 0.0118533 0.00423154 0.00172752 0.0074126 0.0162941 0.00721 0.01710 
Total 18 0.0294894 0.02456854 0.00579086 0.0172718 0.0417071 0.00721 0.09236 
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CH3W6 1.0 5 0.0569360 0.02784887 0.01245439 0.0223571 0.0915149 0.03814 0.10394 
2.0 6 0.0270767 0.01712097 0.00698960 0.0091093 0.0450440 0.01235 0.05294 
3.0 5 0.0166960 0.00896187 0.00400787 0.0055684 0.0278236 0.00940 0.03133 
Total 16 0.0331638 0.02489041 0.00622260 0.0199006 0.0464269 0.00940 0.10394 
CH3R6 1.0 6 0.0617317 0.04144189 0.01691858 0.0182411 0.1052223 0.02463 0.13471 
2.0 6 0.0203800 0.00677882 0.00276744 0.0132661 0.0274939 0.01351 0.03040 
3.0 6 0.0161933 0.00453841 0.00185280 0.0114306 0.0209561 0.00868 0.02086 
Total 18 0.0327683 0.03117536 0.00734810 0.0172652 0.0482715 0.00868 0.13471 
CH3S6 1.0 6 0.0617617 0.02472691 0.01009472 0.0358124 0.0877110 0.03322 0.08642 
2.0 6 0.0231267 0.00880946 0.00359645 0.0138817 0.0323716 0.01441 0.03741 
3.0 6 0.0128517 0.00474788 0.00193831 0.0078691 0.0178343 0.00661 0.02072 
Total 18 0.0325800 0.02605277 0.00614070 0.0196243 0.0455357 0.00661 0.08642 
CH4W2 1.0 6 0.0122367 0.00720036 0.00293953 0.0046804 0.0197930 0.00666 0.02642 
2.0 6 0.0152983 0.00839111 0.00342566 0.0064924 0.0241043 0.00543 0.02756 
3.0 6 0.0164450 0.01018123 0.00415647 0.0057605 0.0271295 0.00669 0.03288 
Total 18 0.0146600 0.00835381 0.00196901 0.0105057 0.0188143 0.00543 0.03288 
CH4R2 1.0 6 0.0310150 0.01988062 0.00811623 0.0101516 0.0518784 0.01190 0.06682 
2.0 6 0.0209717 0.01230355 0.00502290 0.0080599 0.0338835 0.00621 0.03978 
3.0 6 0.0121383 0.00769154 0.00314006 0.0040666 0.0202101 0.00453 0.02263 
Total 18 0.0213750 0.01552859 0.00366012 0.0136528 0.0290972 0.00453 0.06682 
CH4S2 1.0 6 0.0286433 0.01778412 0.00726034 0.0099800 0.0473066 0.01300 0.05682 
2.0 6 0.0133967 0.00821812 0.00335503 0.0047723 0.0220211 0.00519 0.02462 
3.0 6 0.0112017 0.00798053 0.00325804 0.0028266 0.0195767 0.00369 0.02225 
Total 18 0.0177472 0.01397579 0.00329413 0.0107972 0.0246972 0.00369 0.05682 
CH4W3 1.0 6 0.0215400 0.01301658 0.00531400 0.0078799 0.0352001 0.01063 0.03855 
2.0 6 0.0246600 0.01725161 0.00704294 0.0065555 0.0427645 0.01068 0.05600 
3.0 6 0.0239950 0.01559583 0.00636697 0.0076282 0.0403618 0.00623 0.05034 
Total 18 0.0233983 0.01451937 0.00342225 0.0161780 0.0306186 0.00623 0.05600 
CH4R3 1.0 6 0.0422050 0.03920230 0.01600427 0.0010647 0.0833453 0.01296 0.11522 
2.0 6 0.0210867 0.01045148 0.00426680 0.0101185 0.0320548 0.01155 0.03730 
3.0 6 0.0150050 0.00767901 0.00313494 0.0069464 0.0230636 0.00786 0.02566 
Total 18 0.0260989 0.02540348 0.00598766 0.0134660 0.0387317 0.00786 0.11522 
CH4S3 1.0 6 0.0344300 0.01859180 0.00759007 0.0149191 0.0539409 0.01796 0.06860 
2.0 6 0.0153633 0.00733107 0.00299290 0.0076699 0.0230568 0.00610 0.02517 
3.0 6 0.0129200 0.00547585 0.00223550 0.0071735 0.0186665 0.00601 0.02271 
Total 18 0.0209044 0.01497311 0.00352920 0.0134585 0.0283504 0.00601 0.06860 
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CH4W4 1.0 6 0.0310333 0.01875409 0.00765633 0.0113521 0.0507145 0.01568 0.06126 
2.0 6 0.0363983 0.03055505 0.01247405 0.0043328 0.0684639 0.01277 0.09250 
3.0 6 0.0255233 0.02521689 0.01029475 -0.0009402 0.0519868 0.00753 0.07301 
Total 18 0.0309850 0.02420611 0.00570544 0.0189476 0.0430224 0.00753 0.09250 
CH4R4 1.0 6 0.0465400 0.03234190 0.01320353 0.0125993 0.0804807 0.01748 0.09359 
2.0 6 0.0223700 0.00941049 0.00384182 0.0124943 0.0322457 0.01094 0.03501 
3.0 6 0.0156550 0.00686893 0.00280423 0.0084465 0.0228635 0.00897 0.02575 
Total 18 0.0281883 0.02310464 0.00544582 0.0166987 0.0396780 0.00897 0.09359 
CH4S4 1.0 6 0.0374200 0.01812442 0.00739926 0.0183996 0.0564404 0.02203 0.06776 
2.0 6 0.0184450 0.00939651 0.00383611 0.0085840 0.0283060 0.00999 0.03513 
3.0 6 0.0157033 0.01093972 0.00446612 0.0042228 0.0271839 0.00637 0.03678 
Total 18 0.0238561 0.01601597 0.00377500 0.0158916 0.0318207 0.00637 0.06776 
CH4W5 1.0 6 0.0559100 0.04521317 0.01845820 0.0084617 0.1033583 0.02453 0.14518 
2.0 6 0.0489667 0.03801742 0.01552055 0.0090698 0.0888635 0.02116 0.11911 
3.0 6 0.0293050 0.02926544 0.01194757 -0.0014072 0.0600172 0.00889 0.08612 
Total 18 0.0447272 0.03758546 0.00885898 0.0260364 0.0634180 0.00889 0.14518 
CH4R5 1.0 6 0.0525967 0.03521746 0.01437747 0.0156382 0.0895551 0.01946 0.11818 
2.0 6 0.0292133 0.01628332 0.00664764 0.0121250 0.0463016 0.01425 0.05236 
3.0 6 0.0176767 0.00934522 0.00381517 0.0078695 0.0274839 0.00970 0.03140 
Total 18 0.0331622 0.02630400 0.00619991 0.0200816 0.0462429 0.00970 0.11818 
CH4S5 1.0 6 0.0441483 0.02255671 0.00920874 0.0204765 0.0678202 0.02665 0.08666 
2.0 6 0.0197817 0.01033607 0.00421968 0.0089346 0.0306287 0.00955 0.03751 
3.0 6 0.0163117 0.00895930 0.00365762 0.0069095 0.0257139 0.00790 0.03310 
Total 18 0.0267472 0.01916009 0.00451608 0.0172191 0.0362753 0.00790 0.08666 
CH4W6 1.0 5 0.0721760 0.02991433 0.01337809 0.0350325 0.1093195 0.03929 0.11032 
2.0 6 0.0558433 0.04221636 0.01723476 0.0115400 0.1001467 0.02491 0.12474 
3.0 5 0.0373800 0.03622528 0.01620044 -0.0075996 0.0823596 0.01105 0.09772 
Total 16 0.0551775 0.03721184 0.00930296 0.0353487 0.0750063 0.01105 0.12474 
CH4R6 1.0 6 0.0627183 0.03991823 0.01629655 0.0208267 0.1046099 0.02348 0.13174 
2.0 6 0.0362050 0.02618271 0.01068905 0.0087279 0.0636821 0.01211 0.08010 
3.0 6 0.0228600 0.01352586 0.00552191 0.0086655 0.0370545 0.01080 0.04552 
Total 18 0.0405944 0.03185372 0.00750799 0.0247540 0.0564349 0.01080 0.13174 
CH4S6 1.0 6 0.0444350 0.01648853 0.00673141 0.0271314 0.0617386 0.02958 0.07517 
2.0 6 0.0246700 0.01257591 0.00513409 0.0114724 0.0378676 0.01409 0.04790 
3.0 6 0.0185683 0.01175775 0.00480008 0.0062293 0.0309073 0.00767 0.04046 
Total 18 0.0292244 0.01721027 0.00405650 0.0206660 0.0377829 0.00767 0.07517 
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EMG ANOVA 
  Sum of Squares df Mean Square F Sig. 
CH1W2 Between Groups 0.000 2 0.000 0.147 0.864 
Within Groups 0.000 15 0.000     
Total 0.000 17       
CH1R2 Between Groups 0.000 2 0.000 3.874 0.044 
Within Groups 0.001 15 0.000     
Total 0.001 17       
CH1S2 Between Groups 0.001 2 0.000 8.190 0.004 
Within Groups 0.001 15 0.000     
Total 0.001 17       
CH1W3 Between Groups 0.000 2 0.000 0.324 0.728 
Within Groups 0.001 15 0.000     
Total 0.001 17       
CH1R3 Between Groups 0.000 2 0.000 4.682 0.026 
Within Groups 0.001 15 0.000     
Total 0.001 17       
CH1S3 Between Groups 0.001 2 0.000 9.869 0.002 
Within Groups 0.001 15 0.000     
Total 0.001 17       
CH1W4 Between Groups 0.000 2 0.000 1.435 0.269 
Within Groups 0.001 15 0.000     
Total 0.002 17       
CH1R4 Between Groups 0.001 2 0.001 12.897 0.001 
Within Groups 0.001 15 0.000     
Total 0.002 17       
CH1S4 Between Groups 0.001 2 0.001 9.659 0.002 
Within Groups 0.001 15 0.000     
Total 0.002 17       
CH1W5 Between Groups 0.002 2 0.001 0.645 0.539 
Within Groups 0.022 15 0.001     
Total 0.024 17       
CH1R5 Between Groups 0.003 2 0.002 3.094 0.075 
Within Groups 0.008 15 0.001     
Total 0.012 17       
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CH1S5 Between Groups 0.002 2 0.001 3.013 0.079 
Within Groups 0.004 15 0.000     
Total 0.006 17       
CH1W6 Between Groups 0.003 2 0.002 7.766 0.006 
Within Groups 0.003 13 0.000     
Total 0.006 15       
CH1R6 Between Groups 0.002 2 0.001 4.766 0.025 
Within Groups 0.003 15 0.000     
Total 0.005 17       
CH1S6 Between Groups 0.001 2 0.001 11.324 0.001 
Within Groups 0.001 15 0.000     
Total 0.002 17       
CH2W2 Between Groups 0.001 2 0.000 11.769 0.001 
Within Groups 0.000 15 0.000     
Total 0.001 17       
CH2R2 Between Groups 0.003 2 0.002 18.167 0.000 
Within Groups 0.001 15 0.000     
Total 0.004 17       
CH2S2 Between Groups 0.002 2 0.001 37.186 0.000 
Within Groups 0.000 15 0.000     
Total 0.002 17       
CH2W3 Between Groups 0.001 2 0.001 10.421 0.001 
Within Groups 0.001 15 0.000     
Total 0.002 17       
CH2R3 Between Groups 0.004 2 0.002 35.633 0.000 
Within Groups 0.001 15 0.000     
Total 0.004 17       
CH2S3 Between Groups 0.002 2 0.001 19.320 0.000 
Within Groups 0.001 15 0.000     
Total 0.003 17       
CH2W4 Between Groups 0.003 2 0.002 7.315 0.006 
Within Groups 0.003 15 0.000     
Total 0.006 17       
CH2R4 Between Groups 0.004 2 0.002 32.285 0.000 
Within Groups 0.001 15 0.000     
Total 0.005 17       
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CH2S4 Between Groups 0.004 2 0.002 15.748 0.000 
Within Groups 0.002 15 0.000     
Total 0.005 17       
CH2W5 Between Groups 0.009 2 0.005 10.013 0.002 
Within Groups 0.007 15 0.000     
Total 0.016 17       
CH2R5 Between Groups 0.004 2 0.002 32.022 0.000 
Within Groups 0.001 15 0.000     
Total 0.005 17       
CH2S5 Between Groups 0.003 2 0.001 21.532 0.000 
Within Groups 0.001 15 0.000     
Total 0.004 17       
CH2W6 Between Groups 0.006 2 0.003 14.541 0.000 
Within Groups 0.002 13 0.000     
Total 0.008 15       
CH2R6 Between Groups 0.004 2 0.002 19.738 0.000 
Within Groups 0.002 15 0.000     
Total 0.006 17       
CH2S6 Between Groups 0.003 2 0.002 28.662 0.000 
Within Groups 0.001 15 0.000     
Total 0.004 17       
CH3W2 Between Groups 0.001 2 0.000 4.439 0.031 
Within Groups 0.001 15 0.000     
Total 0.001 17       
CH3R2 Between Groups 0.002 2 0.001 6.241 0.011 
Within Groups 0.003 15 0.000     
Total 0.005 17       
CH3S2 Between Groups 0.004 2 0.002 15.958 0.000 
Within Groups 0.002 15 0.000     
Total 0.006 17       
CH3W3 Between Groups 0.001 2 0.000 3.608 0.053 
Within Groups 0.002 15 0.000     
Total 0.003 17       
CH3R3 Between Groups 0.004 2 0.002 7.068 0.007 
Within Groups 0.004 15 0.000     
Total 0.008 17       
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CH3S3 Between Groups 0.005 2 0.002 10.795 0.001 
Within Groups 0.003 15 0.000     
Total 0.008 17       
CH3W4 Between Groups 0.002 2 0.001 3.545 0.055 
Within Groups 0.004 15 0.000     
Total 0.006 17       
CH3R4 Between Groups 0.006 2 0.003 9.203 0.002 
Within Groups 0.005 15 0.000     
Total 0.011 17       
CH3S4 Between Groups 0.007 2 0.004 11.352 0.001 
Within Groups 0.005 15 0.000     
Total 0.012 17       
CH3W5 Between Groups 0.005 2 0.003 6.378 0.010 
Within Groups 0.006 15 0.000     
Total 0.011 17       
CH3R5 Between Groups 0.007 2 0.003 8.262 0.004 
Within Groups 0.006 15 0.000     
Total 0.013 17       
CH3S5 Between Groups 0.006 2 0.003 12.061 0.001 
Within Groups 0.004 15 0.000     
Total 0.010 17       
CH3W6 Between Groups 0.004 2 0.002 5.855 0.015 
Within Groups 0.005 13 0.000     
Total 0.009 15       
CH3R6 Between Groups 0.008 2 0.004 6.392 0.010 
Within Groups 0.009 15 0.001     
Total 0.017 17       
CH3S6 Between Groups 0.008 2 0.004 16.824 0.000 
Within Groups 0.004 15 0.000     
Total 0.012 17       
CH4W2 Between Groups 0.000 2 0.000 0.377 0.692 
Within Groups 0.001 15 0.000     
Total 0.001 17       
CH4R2 Between Groups 0.001 2 0.001 2.651 0.103 
Within Groups 0.003 15 0.000     
Total 0.004 17       
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CH4S2 Between Groups 0.001 2 0.001 3.630 0.052 
Within Groups 0.002 15 0.000     
Total 0.003 17       
CH4W3 Between Groups 0.000 2 0.000 0.068 0.934 
Within Groups 0.004 15 0.000     
Total 0.004 17       
CH4R3 Between Groups 0.002 2 0.001 2.152 0.151 
Within Groups 0.009 15 0.001     
Total 0.011 17       
CH4S3 Between Groups 0.002 2 0.001 5.814 0.014 
Within Groups 0.002 15 0.000     
Total 0.004 17       
CH4W4 Between Groups 0.000 2 0.000 0.277 0.762 
Within Groups 0.010 15 0.001     
Total 0.010 17       
CH4R4 Between Groups 0.003 2 0.002 4.019 0.040 
Within Groups 0.006 15 0.000     
Total 0.009 17       
CH4S4 Between Groups 0.002 2 0.001 4.693 0.026 
Within Groups 0.003 15 0.000     
Total 0.004 17       
CH4W5 Between Groups 0.002 2 0.001 0.789 0.472 
Within Groups 0.022 15 0.001     
Total 0.024 17       
CH4R5 Between Groups 0.004 2 0.002 3.577 0.054 
Within Groups 0.008 15 0.001     
Total 0.012 17       
CH4S5 Between Groups 0.003 2 0.001 5.952 0.013 
Within Groups 0.003 15 0.000     
Total 0.006 17       
CH4W6 Between Groups 0.003 2 0.002 1.111 0.359 
Within Groups 0.018 13 0.001     
Total 0.021 15       
CH4R6 Between Groups 0.005 2 0.002 3.009 0.080 
Within Groups 0.012 15 0.001     
Total 0.017 17       
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CH4S6 Between Groups 0.002 2 0.001 5.791 0.014 
Within Groups 0.003 15 0.000     
Total 0.005 17       
 
 
 
 
 
 
EMG ANOVA Post Hoc - Bonferroni 
 
       
Dependent Variable (I) V1 (J) V1 
Mean Difference (I-J) Std. Error Sig. 
97.5% Confidence Interval 
      Lower Bound Upper Bound 
CH1W2 1.0 2.0 0.00000500 0.00235829 1.000 -0.0071554 0.0071654 
3.0 -0.00110667 0.00235829 1.000 -0.0082671 0.0060538 
2.0 1.0 -0.00000500 0.00235829 1.000 -0.0071654 0.0071554 
3.0 -0.00111167 0.00235829 1.000 -0.0082721 0.0060488 
3.0 1.0 0.00110667 0.00235829 1.000 -0.0060538 0.0082671 
2.0 0.00111167 0.00235829 1.000 -0.0060488 0.0082721 
CH1R2 1.0 2.0 0.00659000 0.00391880 0.340 -0.0053086 0.0184886 
3.0 0.01082333 0.00391880 0.044 -0.0010752 0.0227219 
2.0 1.0 -0.00659000 0.00391880 0.340 -0.0184886 0.0053086 
3.0 0.00423333 0.00391880 0.891 -0.0076652 0.0161319 
3.0 1.0 -0.01082333 0.00391880 0.044 -0.0227219 0.0010752 
2.0 -0.00423333 0.00391880 0.891 -0.0161319 0.0076652 
CH1S2 1.0 2.0 .01188333* 0.00385739 0.023 0.0001712 0.0235955 
3.0 .01471000* 0.00385739 0.005 0.0029979 0.0264221 
2.0 1.0 -.01188333* 0.00385739 0.023 -0.0235955 -0.0001712 
3.0 0.00282667 0.00385739 1.000 -0.0088855 0.0145388 
3.0 1.0 -.01471000* 0.00385739 0.005 -0.0264221 -0.0029979 
2.0 -0.00282667 0.00385739 1.000 -0.0145388 0.0088855 
CH1W3 1.0 2.0 -0.00196500 0.00339974 1.000 -0.0122876 0.0083576 
3.0 -0.00263000 0.00339974 1.000 -0.0129526 0.0076926 
2.0 1.0 0.00196500 0.00339974 1.000 -0.0083576 0.0122876 
3.0 -0.00066500 0.00339974 1.000 -0.0109876 0.0096576 
3.0 1.0 0.00263000 0.00339974 1.000 -0.0076926 0.0129526 
2.0 0.00066500 0.00339974 1.000 -0.0096576 0.0109876 
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CH1R3 1.0 2.0 0.00649333 0.00375554 0.313 -0.0049095 0.0178962 
3.0 .01145833* 0.00375554 0.024 0.0000555 0.0228612 
2.0 1.0 -0.00649333 0.00375554 0.313 -0.0178962 0.0049095 
3.0 0.00496500 0.00375554 0.618 -0.0064379 0.0163679 
3.0 1.0 -.01145833* 0.00375554 0.024 -0.0228612 -0.0000555 
2.0 -0.00496500 0.00375554 0.618 -0.0163679 0.0064379 
CH1S3 1.0 2.0 .01263667* 0.00379128 0.014 0.0011253 0.0241481 
3.0 .01596333* 0.00379128 0.002 0.0044519 0.0274747 
2.0 1.0 -.01263667* 0.00379128 0.014 -0.0241481 -0.0011253 
3.0 0.00332667 0.00379128 1.000 -0.0081847 0.0148381 
3.0 1.0 -.01596333* 0.00379128 0.002 -0.0274747 -0.0044519 
2.0 -0.00332667 0.00379128 1.000 -0.0148381 0.0081847 
CH1W4 1.0 2.0 -0.00248167 0.00529013 1.000 -0.0185440 0.0135807 
3.0 0.00621833 0.00529013 0.774 -0.0098440 0.0222807 
2.0 1.0 0.00248167 0.00529013 1.000 -0.0135807 0.0185440 
3.0 0.00870000 0.00529013 0.363 -0.0073623 0.0247623 
3.0 1.0 -0.00621833 0.00529013 0.774 -0.0222807 0.0098440 
2.0 -0.00870000 0.00529013 0.363 -0.0247623 0.0073623 
CH1R4 1.0 2.0 .01405500* 0.00404191 0.010 0.0017826 0.0263274 
3.0 .01998500* 0.00404191 0.001 0.0077126 0.0322574 
2.0 1.0 -.01405500* 0.00404191 0.010 -0.0263274 -0.0017826 
3.0 0.00593000 0.00404191 0.489 -0.0063424 0.0182024 
3.0 1.0 -.01998500* 0.00404191 0.001 -0.0322574 -0.0077126 
2.0 -0.00593000 0.00404191 0.489 -0.0182024 0.0063424 
CH1S4 1.0 2.0 .01421333* 0.00439282 0.017 0.0008755 0.0275512 
3.0 .01842333* 0.00439282 0.002 0.0050855 0.0317612 
2.0 1.0 -.01421333* 0.00439282 0.017 -0.0275512 -0.0008755 
3.0 0.00421000 0.00439282 1.000 -0.0091279 0.0175479 
3.0 1.0 -.01842333* 0.00439282 0.002 -0.0317612 -0.0050855 
2.0 -0.00421000 0.00439282 1.000 -0.0175479 0.0091279 
CH1W5 1.0 2.0 0.00998333 0.02211809 1.000 -0.0571734 0.0771401 
3.0 0.02495667 0.02211809 0.831 -0.0422001 0.0921134 
2.0 1.0 -0.00998333 0.02211809 1.000 -0.0771401 0.0571734 
3.0 0.01497333 0.02211809 1.000 -0.0521834 0.0821301 
3.0 1.0 -0.02495667 0.02211809 0.831 -0.0921134 0.0422001 
2.0 -0.01497333 0.02211809 1.000 -0.0821301 0.0521834 
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CH1R5 1.0 2.0 0.02291667 0.01347451 0.329 -0.0179958 0.0638291 
3.0 0.03264000 0.01347451 0.086 -0.0082724 0.0735524 
2.0 1.0 -0.02291667 0.01347451 0.329 -0.0638291 0.0179958 
3.0 0.00972333 0.01347451 1.000 -0.0311891 0.0506358 
3.0 1.0 -0.03264000 0.01347451 0.086 -0.0735524 0.0082724 
2.0 -0.00972333 0.01347451 1.000 -0.0506358 0.0311891 
CH1S5 1.0 2.0 0.01858500 0.00938985 0.199 -0.0099252 0.0470952 
3.0 0.02110000 0.00938985 0.120 -0.0074102 0.0496102 
2.0 1.0 -0.01858500 0.00938985 0.199 -0.0470952 0.0099252 
3.0 0.00251500 0.00938985 1.000 -0.0259952 0.0310252 
3.0 1.0 -0.02110000 0.00938985 0.120 -0.0496102 0.0074102 
2.0 -0.00251500 0.00938985 1.000 -0.0310252 0.0259952 
CH1W6 1.0 2.0 0.02415733 0.00882270 0.051 -0.0032550 0.0515697 
3.0 .03545200* 0.00921501 0.006 0.0068207 0.0640833 
2.0 1.0 -0.02415733 0.00882270 0.051 -0.0515697 0.0032550 
3.0 0.01129467 0.00882270 0.669 -0.0161177 0.0387070 
3.0 1.0 -.03545200* 0.00921501 0.006 -0.0640833 -0.0068207 
2.0 -0.01129467 0.00882270 0.669 -0.0387070 0.0161177 
CH1R6 1.0 2.0 0.01594000 0.00802008 0.196 -0.0084112 0.0402912 
3.0 .02437833* 0.00802008 0.025 0.0000271 0.0487296 
2.0 1.0 -0.01594000 0.00802008 0.196 -0.0402912 0.0084112 
3.0 0.00843833 0.00802008 0.928 -0.0159129 0.0327896 
3.0 1.0 -.02437833* 0.00802008 0.025 -0.0487296 -0.0000271 
2.0 -0.00843833 0.00802008 0.928 -0.0327896 0.0159129 
CH1S6 1.0 2.0 .01511333* 0.00412342 0.007 0.0025935 0.0276332 
3.0 .01839667* 0.00412342 0.001 0.0058768 0.0309165 
2.0 1.0 -.01511333* 0.00412342 0.007 -0.0276332 -0.0025935 
3.0 0.00328333 0.00412342 1.000 -0.0092365 0.0158032 
3.0 1.0 -.01839667* 0.00412342 0.001 -0.0309165 -0.0058768 
2.0 -0.00328333 0.00412342 1.000 -0.0158032 0.0092365 
CH2W2 1.0 2.0 .01099833* 0.00293377 0.006 0.0020906 0.0199061 
3.0 .01332333* 0.00293377 0.001 0.0044156 0.0222311 
2.0 1.0 -.01099833* 0.00293377 0.006 -0.0199061 -0.0020906 
3.0 0.00232500 0.00293377 1.000 -0.0065827 0.0112327 
3.0 1.0 -.01332333* 0.00293377 0.001 -0.0222311 -0.0044156 
2.0 -0.00232500 0.00293377 1.000 -0.0112327 0.0065827 
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CH2R2 1.0 2.0 .02627833* 0.00539595 0.001 0.0098947 0.0426620 
3.0 .02973833* 0.00539595 0.000 0.0133547 0.0461220 
2.0 1.0 -.02627833* 0.00539595 0.001 -0.0426620 -0.0098947 
3.0 0.00346000 0.00539595 1.000 -0.0129236 0.0198436 
3.0 1.0 -.02973833* 0.00539595 0.000 -0.0461220 -0.0133547 
2.0 -0.00346000 0.00539595 1.000 -0.0198436 0.0129236 
CH2S2 1.0 2.0 .020518500* 0.002965929 0.000 0.01151310 0.02952390 
3.0 .023485000* 0.002965929 0.000 0.01447960 0.03249040 
2.0 1.0 -.020518500* 0.002965929 0.000 -0.02952390 -0.01151310 
3.0 0.002966500 0.002965929 0.999 -0.00603890 0.01197190 
3.0 1.0 -.023485000* 0.002965929 0.000 -0.03249040 -0.01447960 
2.0 -0.002966500 0.002965929 0.999 -0.01197190 0.00603890 
CH2W3 1.0 2.0 .01548667* 0.00449966 0.011 0.0018244 0.0291489 
3.0 .01943167* 0.00449966 0.002 0.0057694 0.0330939 
2.0 1.0 -.01548667* 0.00449966 0.011 -0.0291489 -0.0018244 
3.0 0.00394500 0.00449966 1.000 -0.0097172 0.0176072 
3.0 1.0 -.01943167* 0.00449966 0.002 -0.0330939 -0.0057694 
2.0 -0.00394500 0.00449966 1.000 -0.0176072 0.0097172 
CH2R3 1.0 2.0 .02827333* 0.00416621 0.000 0.0156235 0.0409231 
3.0 .03225333* 0.00416621 0.000 0.0196035 0.0449031 
2.0 1.0 -.02827333* 0.00416621 0.000 -0.0409231 -0.0156235 
3.0 0.00398000 0.00416621 1.000 -0.0086698 0.0166298 
3.0 1.0 -.03225333* 0.00416621 0.000 -0.0449031 -0.0196035 
2.0 -0.00398000 0.00416621 1.000 -0.0166298 0.0086698 
CH2S3 1.0 2.0 .02134000* 0.00438122 0.001 0.0080374 0.0346426 
3.0 .02532333* 0.00438122 0.000 0.0120207 0.0386260 
2.0 1.0 -.02134000* 0.00438122 0.001 -0.0346426 -0.0080374 
3.0 0.00398333 0.00438122 1.000 -0.0093193 0.0172860 
3.0 1.0 -.02532333* 0.00438122 0.000 -0.0386260 -0.0120207 
2.0 -0.00398333 0.00438122 1.000 -0.0172860 0.0093193 
CH2W4 1.0 2.0 0.02459667 0.00853466 0.034 -0.0013170 0.0505103 
3.0 .03088500* 0.00853466 0.008 0.0049713 0.0567987 
2.0 1.0 -0.02459667 0.00853466 0.034 -0.0505103 0.0013170 
3.0 0.00628833 0.00853466 1.000 -0.0196253 0.0322020 
3.0 1.0 -.03088500* 0.00853466 0.008 -0.0567987 -0.0049713 
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2.0 -0.00628833 0.00853466 1.000 -0.0322020 0.0196253 
CH2R4 1.0 2.0 .02751833* 0.00441908 0.000 0.0141008 0.0409359 
3.0 .03319500* 0.00441908 0.000 0.0197774 0.0466126 
2.0 1.0 -.02751833* 0.00441908 0.000 -0.0409359 -0.0141008 
3.0 0.00567667 0.00441908 0.655 -0.0077409 0.0190942 
3.0 1.0 -.03319500* 0.00441908 0.000 -0.0466126 -0.0197774 
2.0 -0.00567667 0.00441908 0.655 -0.0190942 0.0077409 
CH2S4 1.0 2.0 .027713333* 0.006245207 0.001 0.00875112 0.04667555 
3.0 .032438167* 0.006245207 0.000 0.01347595 0.05140038 
2.0 1.0 -.027713333* 0.006245207 0.001 -0.04667555 -0.00875112 
3.0 0.004724833 0.006245207 1.000 -0.01423738 0.02368705 
3.0 1.0 -.032438167* 0.006245207 0.000 -0.05140038 -0.01347595 
2.0 -0.004724833 0.006245207 1.000 -0.02368705 0.01423738 
CH2W5 1.0 2.0 .04389333* 0.01242797 0.009 0.0061585 0.0816282 
3.0 .05152500* 0.01242797 0.003 0.0137902 0.0892598 
2.0 1.0 -.04389333* 0.01242797 0.009 -0.0816282 -0.0061585 
3.0 0.00763167 0.01242797 1.000 -0.0301032 0.0453665 
3.0 1.0 -.05152500* 0.01242797 0.003 -0.0892598 -0.0137902 
2.0 -0.00763167 0.01242797 1.000 -0.0453665 0.0301032 
CH2R5 1.0 2.0 .02899333* 0.00464739 0.000 0.0148825 0.0431041 
3.0 .03467000* 0.00464739 0.000 0.0205592 0.0487808 
2.0 1.0 -.02899333* 0.00464739 0.000 -0.0431041 -0.0148825 
3.0 0.00567667 0.00464739 0.722 -0.0084341 0.0197875 
3.0 1.0 -.03467000* 0.00464739 0.000 -0.0487808 -0.0205592 
2.0 -0.00567667 0.00464739 0.722 -0.0197875 0.0084341 
CH2S5 1.0 2.0 .02340500* 0.00462592 0.000 0.0093594 0.0374506 
3.0 .02844500* 0.00462592 0.000 0.0143994 0.0424906 
2.0 1.0 -.02340500* 0.00462592 0.000 -0.0374506 -0.0093594 
3.0 0.00504000 0.00462592 0.879 -0.0090056 0.0190856 
3.0 1.0 -.02844500* 0.00462592 0.000 -0.0424906 -0.0143994 
2.0 -0.00504000 0.00462592 0.879 -0.0190856 0.0090056 
CH2W6 1.0 2.0 .03694733* 0.00837220 0.002 0.0109347 0.0629599 
3.0 .04326600* 0.00874447 0.001 0.0160967 0.0704353 
2.0 1.0 -.03694733* 0.00837220 0.002 -0.0629599 -0.0109347 
3.0 0.00631867 0.00837220 1.000 -0.0196939 0.0323313 
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3.0 1.0 -.04326600* 0.00874447 0.001 -0.0704353 -0.0160967 
2.0 -0.00631867 0.00837220 1.000 -0.0323313 0.0196939 
CH2R6 1.0 2.0 .02872833* 0.00585325 0.001 0.0109562 0.0465005 
3.0 .03424833* 0.00585325 0.000 0.0164762 0.0520205 
2.0 1.0 -.02872833* 0.00585325 0.001 -0.0465005 -0.0109562 
3.0 0.00552000 0.00585325 1.000 -0.0122521 0.0232921 
3.0 1.0 -.03424833* 0.00585325 0.000 -0.0520205 -0.0164762 
2.0 -0.00552000 0.00585325 1.000 -0.0232921 0.0122521 
CH2S6 1.0 2.0 .02410000* 0.00422751 0.000 0.0112641 0.0369359 
3.0 .03029167* 0.00422751 0.000 0.0174558 0.0431276 
2.0 1.0 -.02410000* 0.00422751 0.000 -0.0369359 -0.0112641 
3.0 0.00619167 0.00422751 0.491 -0.0066442 0.0190276 
3.0 1.0 -.03029167* 0.00422751 0.000 -0.0431276 -0.0174558 
2.0 -0.00619167 0.00422751 0.491 -0.0190276 0.0066442 
CH3W2 1.0 2.0 0.00940333 0.00437516 0.145 -0.0038809 0.0226876 
3.0 0.01252000 0.00437516 0.036 -0.0007642 0.0258042 
2.0 1.0 -0.00940333 0.00437516 0.145 -0.0226876 0.0038809 
3.0 0.00311667 0.00437516 1.000 -0.0101676 0.0164009 
3.0 1.0 -0.01252000 0.00437516 0.036 -0.0258042 0.0007642 
2.0 -0.00311667 0.00437516 1.000 -0.0164009 0.0101676 
CH3R2 1.0 2.0 0.02217500 0.00811414 0.046 -0.0024618 0.0468118 
3.0 .02682000* 0.00811414 0.014 0.0021832 0.0514568 
2.0 1.0 -0.02217500 0.00811414 0.046 -0.0468118 0.0024618 
3.0 0.00464500 0.00811414 1.000 -0.0199918 0.0292818 
3.0 1.0 -.02682000* 0.00811414 0.014 -0.0514568 -0.0021832 
2.0 -0.00464500 0.00811414 1.000 -0.0292818 0.0199918 
CH3S2 1.0 2.0 .02783833* 0.00629754 0.001 0.0087172 0.0469594 
3.0 .03310500* 0.00629754 0.000 0.0139839 0.0522261 
2.0 1.0 -.02783833* 0.00629754 0.001 -0.0469594 -0.0087172 
3.0 0.00526667 0.00629754 1.000 -0.0138544 0.0243878 
3.0 1.0 -.03310500* 0.00629754 0.000 -0.0522261 -0.0139839 
2.0 -0.00526667 0.00629754 1.000 -0.0243878 0.0138544 
CH3W3 1.0 2.0 0.00960667 0.00621565 0.429 -0.0092658 0.0284791 
3.0 0.01663000 0.00621565 0.052 -0.0022425 0.0355025 
2.0 1.0 -0.00960667 0.00621565 0.429 -0.0284791 0.0092658 
3.0 0.00702333 0.00621565 0.829 -0.0118491 0.0258958 
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3.0 1.0 -0.01663000 0.00621565 0.052 -0.0355025 0.0022425 
2.0 -0.00702333 0.00621565 0.829 -0.0258958 0.0118491 
CH3R3 1.0 2.0 0.02674500 0.00926628 0.034 -0.0013900 0.0548800 
3.0 .03270833* 0.00926628 0.009 0.0045733 0.0608434 
2.0 1.0 -0.02674500 0.00926628 0.034 -0.0548800 0.0013900 
3.0 0.00596333 0.00926628 1.000 -0.0221717 0.0340984 
3.0 1.0 -.03270833* 0.00926628 0.009 -0.0608434 -0.0045733 
2.0 -0.00596333 0.00926628 1.000 -0.0340984 0.0221717 
CH3S3 1.0 2.0 .03089500* 0.00838237 0.007 0.0054438 0.0563462 
3.0 .03598833* 0.00838237 0.002 0.0105371 0.0614396 
2.0 1.0 -.03089500* 0.00838237 0.007 -0.0563462 -0.0054438 
3.0 0.00509333 0.00838237 1.000 -0.0203579 0.0305446 
3.0 1.0 -.03598833* 0.00838237 0.002 -0.0614396 -0.0105371 
2.0 -0.00509333 0.00838237 1.000 -0.0305446 0.0203579 
CH3W4 1.0 2.0 0.01596167 0.00942085 0.333 -0.0126427 0.0445660 
3.0 0.02474000 0.00942085 0.057 -0.0038644 0.0533444 
2.0 1.0 -0.01596167 0.00942085 0.333 -0.0445660 0.0126427 
3.0 0.00877833 0.00942085 1.000 -0.0198260 0.0373827 
3.0 1.0 -0.02474000 0.00942085 0.057 -0.0533444 0.0038644 
2.0 -0.00877833 0.00942085 1.000 -0.0373827 0.0198260 
CH3R4 1.0 2.0 .03612500* 0.01058916 0.012 0.0039733 0.0682767 
3.0 .04192000* 0.01058916 0.004 0.0097683 0.0740717 
2.0 1.0 -.03612500* 0.01058916 0.012 -0.0682767 -0.0039733 
3.0 0.00579500 0.01058916 1.000 -0.0263567 0.0379467 
3.0 1.0 -.04192000* 0.01058916 0.004 -0.0740717 -0.0097683 
2.0 -0.00579500 0.01058916 1.000 -0.0379467 0.0263567 
CH3S4 1.0 2.0 .03927000* 0.01030485 0.005 0.0079815 0.0705585 
3.0 .04516000* 0.01030485 0.002 0.0138715 0.0764485 
2.0 1.0 -.03927000* 0.01030485 0.005 -0.0705585 -0.0079815 
3.0 0.00589000 0.01030485 1.000 -0.0253985 0.0371785 
3.0 1.0 -.04516000* 0.01030485 0.002 -0.0764485 -0.0138715 
2.0 -0.00589000 0.01030485 1.000 -0.0371785 0.0253985 
CH3W5 1.0 2.0 0.02976833 0.01168264 0.067 -0.0057035 0.0652401 
3.0 .04020333* 0.01168264 0.011 0.0047315 0.0756751 
2.0 1.0 -0.02976833 0.01168264 0.067 -0.0652401 0.0057035 
3.0 0.01043500 0.01168264 1.000 -0.0250368 0.0459068 
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3.0 1.0 -.04020333* 0.01168264 0.011 -0.0756751 -0.0047315 
2.0 -0.01043500 0.01168264 1.000 -0.0459068 0.0250368 
CH3R5 1.0 2.0 .03773000* 0.01172862 0.017 0.0021186 0.0733414 
3.0 .04410500* 0.01172862 0.006 0.0084936 0.0797164 
2.0 1.0 -.03773000* 0.01172862 0.017 -0.0733414 -0.0021186 
3.0 0.00637500 0.01172862 1.000 -0.0292364 0.0419864 
3.0 1.0 -.04410500* 0.01172862 0.006 -0.0797164 -0.0084936 
2.0 -0.00637500 0.01172862 1.000 -0.0419864 0.0292364 
CH3S5 1.0 2.0 .03429167* 0.00935043 0.007 0.0059011 0.0626822 
3.0 .04360000* 0.00935043 0.001 0.0152094 0.0719906 
2.0 1.0 -.03429167* 0.00935043 0.007 -0.0626822 -0.0059011 
3.0 0.00930833 0.00935043 1.000 -0.0190822 0.0376989 
3.0 1.0 -.04360000* 0.00935043 0.001 -0.0719906 -0.0152094 
2.0 -0.00930833 0.00935043 1.000 -0.0376989 0.0190822 
CH3W6 1.0 2.0 0.02985933 0.01174303 0.074 -0.0066265 0.0663452 
3.0 .04024000* 0.01226519 0.018 0.0021318 0.0783482 
2.0 1.0 -0.02985933 0.01174303 0.074 -0.0663452 0.0066265 
3.0 0.01038067 0.01174303 1.000 -0.0261052 0.0468665 
3.0 1.0 -.04024000* 0.01226519 0.018 -0.0783482 -0.0021318 
2.0 -0.01038067 0.01174303 1.000 -0.0468665 0.0261052 
CH3R6 1.0 2.0 0.04135167 0.01407906 0.031 -0.0013964 0.0840997 
3.0 .04553833* 0.01407906 0.017 0.0027903 0.0882864 
2.0 1.0 -0.04135167 0.01407906 0.031 -0.0840997 0.0013964 
3.0 0.00418667 0.01407906 1.000 -0.0385614 0.0469347 
3.0 1.0 -.04553833* 0.01407906 0.017 -0.0882864 -0.0027903 
2.0 -0.00418667 0.01407906 1.000 -0.0469347 0.0385614 
CH3S6 1.0 2.0 .03863500* 0.00889175 0.002 0.0116371 0.0656329 
3.0 .04891000* 0.00889175 0.000 0.0219121 0.0759079 
2.0 1.0 -.03863500* 0.00889175 0.002 -0.0656329 -0.0116371 
3.0 0.01027500 0.00889175 0.798 -0.0167229 0.0372729 
3.0 1.0 -.04891000* 0.00889175 0.000 -0.0759079 -0.0219121 
2.0 -0.01027500 0.00889175 0.798 -0.0372729 0.0167229 
CH4W2 1.0 2.0 -0.00306167 0.00501014 1.000 -0.0182739 0.0121505 
3.0 -0.00420833 0.00501014 1.000 -0.0194205 0.0110039 
2.0 1.0 0.00306167 0.00501014 1.000 -0.0121505 0.0182739 
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3.0 -0.00114667 0.00501014 1.000 -0.0163589 0.0140655 
3.0 1.0 0.00420833 0.00501014 1.000 -0.0110039 0.0194205 
2.0 0.00114667 0.00501014 1.000 -0.0140655 0.0163589 
CH4R2 1.0 2.0 0.01004333 0.00820417 0.719 -0.0148669 0.0349535 
3.0 0.01887667 0.00820417 0.108 -0.0060335 0.0437869 
2.0 1.0 -0.01004333 0.00820417 0.719 -0.0349535 0.0148669 
3.0 0.00883333 0.00820417 0.896 -0.0160769 0.0337435 
3.0 1.0 -0.01887667 0.00820417 0.108 -0.0437869 0.0060335 
2.0 -0.00883333 0.00820417 0.896 -0.0337435 0.0160769 
CH4S2 1.0 2.0 0.01524667 0.00705141 0.142 -0.0061634 0.0366567 
3.0 0.01744167 0.00705141 0.077 -0.0039684 0.0388517 
2.0 1.0 -0.01524667 0.00705141 0.142 -0.0366567 0.0061634 
3.0 0.00219500 0.00705141 1.000 -0.0192151 0.0236051 
3.0 1.0 -0.01744167 0.00705141 0.077 -0.0388517 0.0039684 
2.0 -0.00219500 0.00705141 1.000 -0.0236051 0.0192151 
CH4W3 1.0 2.0 -0.00312000 0.00888369 1.000 -0.0300934 0.0238534 
3.0 -0.00245500 0.00888369 1.000 -0.0294284 0.0245184 
2.0 1.0 0.00312000 0.00888369 1.000 -0.0238534 0.0300934 
3.0 0.00066500 0.00888369 1.000 -0.0263084 0.0276384 
3.0 1.0 0.00245500 0.00888369 1.000 -0.0245184 0.0294284 
2.0 -0.00066500 0.00888369 1.000 -0.0276384 0.0263084 
CH4R3 1.0 2.0 0.02111833 0.01376397 0.437 -0.0206730 0.0629096 
3.0 0.02720000 0.01376397 0.200 -0.0145913 0.0689913 
2.0 1.0 -0.02111833 0.01376397 0.437 -0.0629096 0.0206730 
3.0 0.00608167 0.01376397 1.000 -0.0357096 0.0478730 
3.0 1.0 -0.02720000 0.01376397 0.200 -0.0689913 0.0145913 
2.0 -0.00608167 0.01376397 1.000 -0.0478730 0.0357096 
CH4S3 1.0 2.0 0.01906667 0.00690720 0.044 -0.0019055 0.0400389 
3.0 .02151000* 0.00690720 0.021 0.0005378 0.0424822 
2.0 1.0 -0.01906667 0.00690720 0.044 -0.0400389 0.0019055 
3.0 0.00244333 0.00690720 1.000 -0.0185289 0.0234155 
3.0 1.0 -.02151000* 0.00690720 0.021 -0.0424822 -0.0005378 
2.0 -0.00244333 0.00690720 1.000 -0.0234155 0.0185289 
CH4W4 1.0 2.0 -0.00536500 0.01461057 1.000 -0.0497268 0.0389968 
3.0 0.00551000 0.01461057 1.000 -0.0388518 0.0498718 
2.0 1.0 0.00536500 0.01461057 1.000 -0.0389968 0.0497268 
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3.0 0.01087500 0.01461057 1.000 -0.0334868 0.0552368 
3.0 1.0 -0.00551000 0.01461057 1.000 -0.0498718 0.0388518 
2.0 -0.01087500 0.01461057 1.000 -0.0552368 0.0334868 
CH4R4 1.0 2.0 0.02417000 0.01145881 0.156 -0.0106222 0.0589622 
3.0 0.03088500 0.01145881 0.050 -0.0039072 0.0656772 
2.0 1.0 -0.02417000 0.01145881 0.156 -0.0589622 0.0106222 
3.0 0.00671500 0.01145881 1.000 -0.0280772 0.0415072 
3.0 1.0 -0.03088500 0.01145881 0.050 -0.0656772 0.0039072 
2.0 -0.00671500 0.01145881 1.000 -0.0415072 0.0280772 
CH4S4 1.0 2.0 0.01897500 0.00772058 0.080 -0.0044669 0.0424169 
3.0 0.02171667 0.00772058 0.039 -0.0017252 0.0451585 
2.0 1.0 -0.01897500 0.00772058 0.080 -0.0424169 0.0044669 
3.0 0.00274167 0.00772058 1.000 -0.0207002 0.0261835 
3.0 1.0 -0.02171667 0.00772058 0.039 -0.0451585 0.0017252 
2.0 -0.00274167 0.00772058 1.000 -0.0261835 0.0207002 
CH4W5 1.0 2.0 0.00694333 0.02197478 1.000 -0.0597783 0.0736650 
3.0 0.02660500 0.02197478 0.734 -0.0401167 0.0933267 
2.0 1.0 -0.00694333 0.02197478 1.000 -0.0736650 0.0597783 
3.0 0.01966167 0.02197478 1.000 -0.0470600 0.0863833 
3.0 1.0 -0.02660500 0.02197478 0.734 -0.0933267 0.0401167 
2.0 -0.01966167 0.02197478 1.000 -0.0863833 0.0470600 
CH4R5 1.0 2.0 0.02338333 0.01330309 0.298 -0.0170086 0.0637753 
3.0 0.03492000 0.01330309 0.057 -0.0054719 0.0753119 
2.0 1.0 -0.02338333 0.01330309 0.298 -0.0637753 0.0170086 
3.0 0.01153667 0.01330309 1.000 -0.0288553 0.0519286 
3.0 1.0 -0.03492000 0.01330309 0.057 -0.0753119 0.0054719 
2.0 -0.01153667 0.01330309 1.000 -0.0519286 0.0288553 
CH4S5 1.0 2.0 0.02436667 0.00879336 0.043 -0.0023325 0.0510658 
3.0 .02783667* 0.00879336 0.019 0.0011375 0.0545358 
2.0 1.0 -0.02436667 0.00879336 0.043 -0.0510658 0.0023325 
3.0 0.00347000 0.00879336 1.000 -0.0232291 0.0301691 
3.0 1.0 -.02783667* 0.00879336 0.019 -0.0545358 -0.0011375 
2.0 -0.00347000 0.00879336 1.000 -0.0301691 0.0232291 
CH4W6 1.0 2.0 0.01633267 0.02236849 1.000 -0.0531668 0.0858321 
3.0 0.03479600 0.02336313 0.481 -0.0377938 0.1073858 
2.0 1.0 -0.01633267 0.02236849 1.000 -0.0858321 0.0531668 
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3.0 0.01846333 0.02236849 1.000 -0.0510361 0.0879628 
3.0 1.0 -0.03479600 0.02336313 0.481 -0.1073858 0.0377938 
2.0 -0.01846333 0.02236849 1.000 -0.0879628 0.0510361 
CH4R6 1.0 2.0 0.02651333 0.01653934 0.389 -0.0237048 0.0767315 
3.0 0.03985833 0.01653934 0.088 -0.0103598 0.0900765 
2.0 1.0 -0.02651333 0.01653934 0.389 -0.0767315 0.0237048 
3.0 0.01334500 0.01653934 1.000 -0.0368731 0.0635631 
3.0 1.0 -0.03985833 0.01653934 0.088 -0.0900765 0.0103598 
2.0 -0.01334500 0.01653934 1.000 -0.0635631 0.0368731 
CH4S6 1.0 2.0 0.01976500 0.00794614 0.075 -0.0043617 0.0438917 
3.0 .02586667* 0.00794614 0.016 0.0017399 0.0499934 
2.0 1.0 -0.01976500 0.00794614 0.075 -0.0438917 0.0043617 
3.0 0.00610167 0.00794614 1.000 -0.0180251 0.0302284 
3.0 1.0 -.02586667* 0.00794614 0.016 -0.0499934 -0.0017399 
2.0 -0.00610167 0.00794614 1.000 -0.0302284 0.0180251 
*. The mean difference is significant at the 0.025 level. 
 
 
 
Ankle Angle - Descriptives 
  
N Mean Std. Deviation Std. Error 
95% Confidence Interval for Mean 
Minimum Maximum   Lower Bound Upper Bound 
PLeftW2 1.0 6 11.05152 3.70931 1.51432 7.15883 14.94421 6.96000 17.16730 
2.0 6 9.20886 2.73791 1.11775 6.33560 12.08212 4.90257 13.24900 
3.0 6 9.24317 4.66878 1.90602 4.34359 14.14275 3.84100 14.99433 
Total 18 9.83452 3.66700 0.86432 8.01096 11.65807 3.84100 17.16730 
PLeftR2 1.0 6 15.51959 4.22964 1.72674 11.08086 19.95833 11.12830 21.07730 
2.0 6 15.23052 4.91284 2.00566 10.07481 20.38623 9.81785 21.18570 
3.0 6 12.20160 7.13667 2.91353 4.71213 19.69108 2.63420 22.79930 
Total 18 14.31724 5.45206 1.28506 11.60599 17.02848 2.63420 22.79930 
PLeftS2 1.0 6 15.29254 5.79193 2.36454 9.21428 21.37079 7.34918 21.70317 
2.0 6 14.13723 5.47962 2.23705 8.38672 19.88774 7.28150 20.95520 
3.0 6 12.25487 5.89542 2.40679 6.06801 18.44173 4.54830 22.78400 
Total 18 13.89488 5.52989 1.30341 11.14493 16.64483 4.54830 22.78400 
PLeftW3 1.0 6 10.11462 3.48326 1.42204 6.45915 13.77008 6.86867 16.49163 
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2.0 6 11.63894 5.17127 2.11116 6.21203 17.06585 4.20429 17.59500 
3.0 6 10.43645 3.78951 1.54706 6.45961 14.41330 5.48990 16.37350 
Total 18 10.73000 4.01412 0.94614 8.73383 12.72618 4.20429 17.59500 
PLeftR3 1.0 6 16.63269 4.47132 1.82541 11.94032 21.32505 11.41755 22.22518 
2.0 6 14.76509 5.00222 2.04215 9.51558 20.01460 10.18455 21.38457 
3.0 6 12.69458 5.16226 2.10748 7.27712 18.11203 8.10567 21.32756 
Total 18 14.69745 4.88025 1.15029 12.27056 17.12434 8.10567 22.22518 
PLeftS3 1.0 6 12.65761 4.42524 1.80660 8.01361 17.30162 6.53643 19.04886 
2.0 6 13.04446 6.09128 2.48676 6.65205 19.43688 4.74600 19.10970 
3.0 6 8.66513 6.88760 2.81185 1.43703 15.89322 1.02880 21.14150 
Total 18 11.45573 5.89698 1.38993 8.52323 14.38823 1.02880 21.14150 
PLeftW4 1.0 6 9.09632 2.95136 1.20489 5.99906 12.19359 5.13210 14.08775 
2.0 6 13.60528 7.03060 2.87023 6.22712 20.98345 5.96167 24.28000 
3.0 6 10.84460 4.28868 1.75084 6.34391 15.34529 4.95450 18.35540 
Total 18 11.18207 5.11446 1.20549 8.63871 13.72543 4.95450 24.28000 
PLeftR4 1.0 6 18.07534 4.21609 1.72121 13.65083 22.49986 14.10617 23.51942 
2.0 6 15.85320 3.44754 1.40745 12.23522 19.47117 12.87044 20.65400 
3.0 6 11.05943 6.32605 2.58260 4.42065 17.69821 4.05857 22.40288 
Total 18 14.99599 5.43778 1.28170 12.29184 17.70014 4.05857 23.51942 
PLeftS4 1.0 6 14.08296 4.84087 1.97628 9.00278 19.16314 8.75856 20.98213 
2.0 6 14.60302 6.18608 2.52546 8.11113 21.09492 6.68583 22.07730 
3.0 6 10.25396 6.63139 2.70725 3.29475 17.21318 -0.68730 19.45271 
Total 18 12.97998 5.92143 1.39569 10.03532 15.92464 -0.68730 22.07730 
PLeftW5 1.0 6 7.90302 3.92625 1.60288 3.78267 12.02337 4.49650 14.90764 
2.0 6 15.73296 6.19965 2.53100 9.22683 22.23910 9.63992 24.14070 
3.0 6 12.41604 5.02672 2.05215 7.14082 17.69125 7.17170 21.89150 
Total 18 12.01734 5.84581 1.37787 9.11029 14.92439 4.49650 24.14070 
PLeftR5 1.0 6 19.46479 4.27151 1.74384 14.98211 23.94747 14.05242 25.00892 
2.0 6 14.61629 4.33943 1.77157 10.06233 19.17024 6.20140 18.46060 
3.0 6 9.87043 6.61212 2.69939 2.93144 16.80942 2.80625 21.49657 
Total 18 14.65050 6.32525 1.49087 11.50503 17.79597 2.80625 25.00892 
PLeftS5 1.0 6 16.10789 5.48848 2.24066 10.34809 21.86770 9.57013 22.43788 
2.0 6 14.05030 9.41073 3.84191 4.17434 23.92625 -0.04840 27.44444 
3.0 6 9.37471 7.59117 3.09908 1.40827 17.34116 1.56750 23.53840 
Total 18 13.17763 7.76272 1.82969 9.31732 17.03794 -0.04840 27.44444 
PLeftW6 1.0 5 11.33548 8.79304 3.93237 0.41748 22.25349 1.29440 25.31300 
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2.0 6 17.31744 6.92286 2.82624 10.05234 24.58253 9.96742 28.56200 
3.0 6 12.75807 5.37857 2.19579 7.11361 18.40253 8.54580 23.38536 
Total 17 13.94885 7.08998 1.71957 10.30352 17.59418 1.29440 28.56200 
PLeftR6 1.0 6 19.84979 4.66102 1.90285 14.95835 24.74124 13.49533 26.19800 
2.0 6 16.40053 3.31374 1.35283 12.92298 19.87809 12.29000 21.99200 
3.0 6 10.43093 4.82936 1.97158 5.36283 15.49903 5.69360 19.08900 
Total 18 15.56042 5.70160 1.34388 12.72508 18.39576 5.69360 26.19800 
PLeftS6 1.0 6 16.31538 7.33345 2.99387 8.61940 24.01136 8.70713 27.94313 
2.0 6 14.21610 7.68716 3.13827 6.14891 22.28328 3.45925 24.65000 
3.0 6 10.20204 6.18092 2.52335 3.71557 16.68851 5.35850 22.50471 
Total 18 13.57784 7.15855 1.68729 10.01797 17.13771 3.45925 27.94313 
PRightW2 1.0 6 9.44898 4.61483 1.88400 4.60601 14.29195 1.97900 16.30929 
2.0 6 9.97336 3.20582 1.30877 6.60906 13.33766 6.58183 13.95533 
3.0 6 9.70521 5.59629 2.28468 3.83226 15.57816 1.82483 18.35457 
Total 18 9.70918 4.30654 1.01506 7.56759 11.85078 1.82483 18.35457 
PRightR2 1.0 6 15.79248 3.08903 1.26109 12.55074 19.03422 11.08782 19.37964 
2.0 6 16.54885 3.50645 1.43150 12.86906 20.22865 10.76811 21.18670 
3.0 6 13.24290 4.91689 2.00731 8.08295 18.40286 8.74200 22.26350 
Total 18 15.19475 3.95615 0.93247 13.22740 17.16209 8.74200 22.26350 
PRightS2 1.0 6 20.00245 9.99560 4.08069 9.51271 30.49219 10.33486 38.57300 
2.0 6 10.43370 4.76800 1.94653 5.42998 15.43741 1.00583 14.22525 
3.0 6 14.17140 3.11170 1.27035 10.90587 17.43694 10.21040 19.07970 
Total 18 14.86918 7.43880 1.75334 11.16995 18.56841 1.00583 38.57300 
PRightW3 1.0 6 10.15139 3.56142 1.45394 6.41391 13.88887 5.85644 14.42813 
2.0 6 11.38978 5.71352 2.33254 5.39380 17.38575 2.67933 18.03800 
3.0 6 10.11674 5.36192 2.18899 4.48975 15.74373 1.05883 15.57057 
Total 18 10.55264 4.70733 1.10953 8.21174 12.89354 1.05883 18.03800 
PRightR3 1.0 6 16.86211 3.33903 1.36315 13.35801 20.36620 13.80850 21.78464 
2.0 6 16.08958 3.72594 1.52111 12.17945 19.99972 10.02527 20.04600 
3.0 6 13.79127 5.47474 2.23505 8.04589 19.53666 7.91130 23.03350 
Total 18 15.58099 4.24015 0.99941 13.47241 17.68956 7.91130 23.03350 
PRightS3 1.0 6 15.03391 3.74642 1.52947 11.10228 18.96554 8.44340 20.08763 
2.0 6 11.30431 5.99561 2.44770 5.01230 17.59632 2.71155 18.68780 
3.0 6 7.60749 6.70891 2.73890 0.56692 14.64806 -1.83611 17.65567 
Total 18 11.31524 6.13773 1.44668 8.26302 14.36746 -1.83611 20.08763 
PRightW4 1.0 6 8.51549 3.56349 1.45479 4.77584 12.25514 3.82010 14.09410 
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2.0 6 12.85428 5.73877 2.34284 6.83181 18.87675 6.20764 18.77867 
3.0 6 12.29804 2.94853 1.20373 9.20374 15.39233 8.81064 16.14740 
Total 18 11.22260 4.46235 1.05179 9.00353 13.44168 3.82010 18.77867 
PRightR4 1.0 6 18.71592 4.67099 1.90693 13.81401 23.61783 15.11131 25.85940 
2.0 6 16.45988 3.82925 1.56329 12.44132 20.47843 9.41700 19.93088 
3.0 6 13.36237 2.94042 1.20042 10.27659 16.44815 9.44873 17.68480 
Total 18 16.17939 4.28628 1.01028 14.04787 18.31090 9.41700 25.85940 
PRightS4 1.0 6 14.88738 3.85736 1.57476 10.83933 18.93543 9.84070 21.54913 
2.0 6 11.65394 5.32782 2.17508 6.06273 17.24515 4.57582 17.61613 
3.0 6 10.05684 4.54457 1.85531 5.28761 14.82607 3.91620 15.03029 
Total 18 12.19939 4.80361 1.13222 9.81061 14.58817 3.91620 21.54913 
PRightW5 1.0 6 7.95261 6.02580 2.46002 1.62892 14.27631 1.76800 18.21238 
2.0 6 15.67765 4.42470 1.80638 11.03421 20.32109 8.17469 20.72730 
3.0 6 11.75103 1.94357 0.79346 9.71137 13.79068 9.34754 13.80256 
Total 18 11.79376 5.29913 1.24902 9.15857 14.42896 1.76800 20.72730 
PRightR5 1.0 6 20.21627 3.39852 1.38744 16.64974 23.78280 15.92850 24.63400 
2.0 6 14.11733 4.63718 1.89312 9.25090 18.98375 8.32300 19.11189 
3.0 6 11.54551 2.73121 1.11501 8.67928 14.41174 7.60650 15.91533 
Total 18 15.29304 5.09066 1.19988 12.76151 17.82456 7.60650 24.63400 
PRightS5 1.0 6 17.18942 2.02343 0.82606 15.06596 19.31289 15.10163 20.18430 
2.0 6 14.01910 5.12032 2.09036 8.64566 19.39255 9.53290 23.13920 
3.0 6 6.60667 5.55447 2.26760 0.77761 12.43572 -0.97138 13.72840 
Total 18 12.60506 6.22991 1.46840 9.50700 15.70313 -0.97138 23.13920 
PRightW6 1.0 5 12.35313 7.10723 3.17845 3.52834 21.17792 4.37500 20.27415 
2.0 6 17.46136 5.08716 2.07683 12.12271 22.80001 8.96700 22.95236 
3.0 6 13.19485 2.37049 0.96775 10.70718 15.68253 10.11890 16.04518 
Total 17 14.45312 5.27606 1.27963 11.74041 17.16582 4.37500 22.95236 
PRightR6 1.0 6 20.88636 4.14420 1.69186 16.53729 25.23543 15.49650 25.99717 
2.0 6 18.06311 4.21968 1.72268 13.63482 22.49139 10.47725 21.83225 
3.0 6 10.96609 2.61972 1.06950 8.21686 13.71532 7.88400 13.63457 
Total 18 16.63852 5.54508 1.30699 13.88101 19.39603 7.88400 25.99717 
PRightS6 1.0 6 15.66869 3.28031 1.33918 12.22622 19.11116 10.98033 19.28800 
2.0 6 17.65290 15.36810 6.27400 1.52507 33.78073 2.94267 46.21980 
3.0 6 12.63688 4.79172 1.95621 7.60827 17.66548 9.20443 20.37750 
Total 18 15.31949 9.15898 2.15879 10.76484 19.87414 2.94267 46.21980 
PPLeftW2 1.0 6 12.62139 5.72428 2.33693 6.61412 18.62866 5.59717 21.59313 
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2.0 6 25.50624 10.35211 4.22623 14.64237 36.37011 11.81125 42.17433 
3.0 6 25.38397 6.54491 2.67195 18.51551 32.25243 17.70588 35.60343 
Total 18 21.17053 9.61519 2.26632 16.38901 25.95206 5.59717 42.17433 
PPLeftR2 1.0 6 11.28356 3.72196 1.51948 7.37760 15.18952 6.83200 15.60600 
2.0 6 18.43170 10.19472 4.16198 7.73299 29.13040 11.59820 38.56100 
3.0 6 17.45492 9.18619 3.75025 7.81461 27.09524 7.82933 34.36583 
Total 18 15.72339 8.37057 1.97296 11.56081 19.88598 6.83200 38.56100 
PPLeftS2 1.0 6 15.71176 5.55209 2.26663 9.88520 21.53832 8.43700 22.54800 
2.0 6 19.58562 12.05919 4.92314 6.93028 32.24097 4.91670 35.24600 
3.0 6 21.80541 9.68886 3.95546 11.63757 31.97324 8.80825 37.97900 
Total 18 19.03426 9.28234 2.18787 14.41826 23.65026 4.91670 37.97900 
PPLeftW3 1.0 6 19.50165 8.92988 3.64561 10.13031 28.87299 11.39175 33.82144 
2.0 6 30.49681 7.02170 2.86660 23.12799 37.86563 22.06922 43.14663 
3.0 6 27.02536 5.87496 2.39844 20.85997 33.19075 20.06080 34.47213 
Total 18 25.67461 8.39087 1.97775 21.50193 29.84729 11.39175 43.14663 
PPLeftR3 1.0 6 17.75864 4.95381 2.02238 12.55993 22.95734 10.44486 25.11867 
2.0 6 21.54113 9.37662 3.82799 11.70097 31.38129 12.19210 38.58725 
3.0 6 23.05066 9.91713 4.04865 12.64327 33.45805 10.98670 37.90840 
Total 18 20.78348 8.20056 1.93289 16.70543 24.86152 10.44486 38.58725 
PPLeftS3 1.0 6 18.11349 3.75934 1.53474 14.16831 22.05868 12.35760 23.27350 
2.0 6 21.88695 10.18909 4.15968 11.19416 32.57974 6.06320 35.06680 
3.0 6 22.97707 8.23533 3.36206 14.33462 31.61952 9.67300 34.14660 
Total 18 20.99251 7.69651 1.81409 17.16512 24.81989 6.06320 35.06680 
PPLeftR4 1.0 6 20.12113 3.55764 1.45240 16.38762 23.85464 15.58425 25.50640 
2.0 6 23.26329 9.38836 3.83278 13.41081 33.11578 12.57690 38.60100 
3.0 6 25.10757 9.32044 3.80505 15.32637 34.88877 11.77800 39.37325 
Total 18 22.83066 7.72552 1.82092 18.98885 26.67247 11.77800 39.37325 
PPLeftS4 1.0 6 18.31498 2.81799 1.15044 15.35768 21.27227 15.10160 23.53529 
2.0 6 24.97033 10.06549 4.10922 14.40725 35.53341 11.87890 38.15840 
3.0 6 24.35260 5.08355 2.07535 19.01774 29.68746 19.46040 32.63660 
Total 18 22.54597 7.01990 1.65461 19.05505 26.03688 11.87890 38.15840 
PPLeftW5 1.0 6 22.32072 4.46963 1.82472 17.63013 27.01130 15.73890 29.15643 
2.0 6 29.24637 4.70283 1.91992 24.31104 34.18169 21.35520 35.90760 
3.0 6 22.36263 10.73648 4.38315 11.09538 33.62987 6.77310 33.99800 
Total 18 24.64324 7.58301 1.78733 20.87229 28.41418 6.77310 35.90760 
PPLeftR5 1.0 6 23.02842 5.06906 2.06943 17.70877 28.34807 17.06440 29.39030 
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2.0 6 24.80820 8.31370 3.39406 16.08350 33.53290 15.34533 36.31611 
3.0 6 25.29902 8.52387 3.47986 16.35377 34.24427 15.02889 38.27067 
Total 18 24.37855 7.08966 1.67105 20.85294 27.90415 15.02889 38.27067 
PPLeftS5 1.0 6 18.11655 3.35068 1.36791 14.60023 21.63287 13.40275 23.74914 
2.0 6 26.88167 7.72301 3.15290 18.77687 34.98647 16.25120 38.12520 
3.0 6 30.40066 7.66291 3.12837 22.35893 38.44240 22.98014 40.99400 
Total 18 25.13296 8.14638 1.92012 21.08186 29.18406 13.40275 40.99400 
PPLeftW6 1.0 5 22.67948 2.86736 1.28232 19.11918 26.23978 19.12020 26.54430 
2.0 6 25.50107 4.19314 1.71184 21.10064 29.90149 20.21180 32.32067 
3.0 6 23.18958 10.40526 4.24793 12.26994 34.10923 7.49140 34.56467 
Total 17 23.85537 6.55729 1.59038 20.48392 27.22682 7.49140 34.56467 
PPLeftR6 1.0 6 24.82014 5.43825 2.22016 19.11304 30.52724 18.42080 30.78833 
2.0 6 24.42313 9.17383 3.74520 14.79579 34.05046 12.51588 37.32556 
3.0 6 25.34853 10.06165 4.10765 14.78947 35.90758 15.11830 38.68767 
Total 18 24.86393 7.96108 1.87644 20.90498 28.82288 12.51588 38.68767 
PPLeftS6 1.0 6 20.94338 4.01804 1.64036 16.72670 25.16006 15.82863 27.55589 
2.0 6 26.91977 7.41142 3.02570 19.14195 34.69758 17.70950 37.12140 
3.0 6 29.29316 6.13312 2.50383 22.85684 35.72947 22.99600 40.35580 
Total 18 25.71877 6.71076 1.58174 22.38159 29.05595 15.82863 40.35580 
PPRightW2 1.0 6 13.93791 4.99905 2.04085 8.69173 19.18409 6.67633 20.91871 
2.0 6 24.07637 9.84502 4.01921 13.74465 34.40808 13.54943 38.16986 
3.0 6 24.16601 6.13777 2.50573 17.72482 30.60721 14.57700 31.92875 
Total 18 20.72676 8.44622 1.99079 16.52656 24.92697 6.67633 38.16986 
PPRightR2 1.0 6 10.95678 6.85280 2.79765 3.76520 18.14836 3.02390 19.85444 
2.0 6 17.43725 11.51905 4.70263 5.34875 29.52575 3.96522 35.88471 
3.0 6 17.86174 11.26811 4.60019 6.03658 29.68689 2.93983 34.76280 
Total 18 15.41859 10.03760 2.36589 10.42701 20.41017 2.93983 35.88471 
PPRightS2 1.0 6 16.37339 6.75605 2.75815 9.28334 23.46343 8.74488 28.29214 
2.0 6 24.46286 8.83601 3.60728 15.19004 33.73568 11.90840 37.02000 
3.0 6 22.92578 13.25145 5.40988 9.01924 36.83233 8.18200 37.43089 
Total 18 21.25401 10.05302 2.36952 16.25476 26.25326 8.18200 37.43089 
PPRightW3 1.0 6 18.87688 5.31393 2.16940 13.30025 24.45350 12.97367 26.57222 
2.0 6 27.75891 8.46384 3.45535 18.87665 36.64116 19.22350 40.45763 
3.0 6 26.08448 5.44103 2.22129 20.37447 31.79449 16.82411 31.75511 
Total 18 24.24009 7.33518 1.72892 20.59239 27.88779 12.97367 40.45763 
PPRightR3 1.0 6 15.77299 5.87098 2.39682 9.61178 21.93420 11.06769 25.38280 
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2.0 6 19.75496 8.07563 3.29686 11.28011 28.22982 9.57044 32.87863 
3.0 6 21.21740 12.33100 5.03411 8.27681 34.15799 5.21983 37.94800 
Total 18 18.91512 8.92439 2.10350 14.47712 23.35311 5.21983 37.94800 
PPRightS3 1.0 6 17.33686 6.88080 2.80907 10.11591 24.55781 9.78371 28.94400 
2.0 6 26.43148 7.66374 3.12871 18.38888 34.47408 17.51283 35.99880 
3.0 6 26.45500 10.44826 4.26548 15.49023 37.41977 14.48000 37.13144 
Total 18 23.40778 9.10051 2.14501 18.88220 27.93336 9.78371 37.13144 
PPRightW4 1.0 6 20.88828 4.46046 1.82098 16.20731 25.56925 14.77811 26.12833 
2.0 6 28.44946 5.94872 2.42855 22.20666 34.69226 20.43978 35.79678 
3.0 6 22.19507 9.26267 3.78147 12.47450 31.91565 6.18400 33.61100 
Total 18 23.84427 7.28170 1.71631 20.22317 27.46537 6.18400 35.79678 
PPRightR4 1.0 6 19.57989 4.86439 1.98588 14.47503 24.68475 14.37200 26.86767 
2.0 6 21.58962 9.31972 3.80476 11.80917 31.37007 7.91067 33.63878 
3.0 6 23.16565 11.47116 4.68308 11.12740 35.20390 11.44729 38.02520 
Total 18 21.44505 8.57252 2.02056 17.18204 25.70806 7.91067 38.02520 
PPRightS4 1.0 6 19.38132 5.33522 2.17809 13.78235 24.98029 13.02150 28.53650 
2.0 6 26.18431 9.62124 3.92785 16.08744 36.28118 16.32200 39.84980 
3.0 6 29.14500 9.43036 3.84993 19.24844 39.04156 15.20644 40.69320 
Total 18 24.90354 8.91322 2.10087 20.47110 29.33599 13.02150 40.69320 
PPRightW5 1.0 6 21.91091 5.42536 2.21490 16.21734 27.60447 13.16264 27.61427 
2.0 6 26.72955 5.90943 2.41251 20.52799 32.93111 18.42042 34.11109 
3.0 6 24.45752 9.29677 3.79539 14.70116 34.21388 10.81500 34.62989 
Total 18 24.36599 6.96065 1.64064 20.90454 27.82744 10.81500 34.62989 
PPRightR5 1.0 6 21.41908 5.96707 2.43604 15.15703 27.68113 15.97931 29.07764 
2.0 6 26.88875 14.61271 5.96561 11.55365 42.22384 9.05233 49.29775 
3.0 6 24.96083 12.21162 4.98537 12.14551 37.77614 7.81450 40.42120 
Total 18 24.42288 11.07105 2.60947 18.91738 29.92839 7.81450 49.29775 
PPRightS5 1.0 6 18.89695 6.09293 2.48743 12.50281 25.29109 12.45625 29.33711 
2.0 6 28.11337 8.48340 3.46333 19.21060 37.01615 17.77127 40.11650 
3.0 6 29.60328 6.40661 2.61549 22.87996 36.32661 22.23380 38.93325 
Total 18 25.53787 8.24000 1.94219 21.44022 29.63552 12.45625 40.11650 
PPRightW6 1.0 5 22.47317 3.99582 1.78699 17.51170 27.43464 16.81469 26.82620 
2.0 6 27.98879 8.58850 3.50624 18.97572 37.00187 16.37369 41.67443 
3.0 6 21.89339 12.77769 5.21647 8.48403 35.30275 4.62727 35.16756 
Total 17 24.21523 9.29376 2.25407 19.43683 28.99364 4.62727 41.67443 
PPRightR6 1.0 6 23.26861 6.40104 2.61321 16.55113 29.98609 17.50033 31.20208 
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2.0 6 26.08964 6.47757 2.64446 19.29185 32.88743 16.93520 36.03522 
3.0 6 25.09318 12.90277 5.26753 11.55255 38.63381 6.42600 40.91800 
Total 18 24.81714 8.64880 2.03854 20.51620 29.11809 6.42600 40.91800 
PPRightS6 1.0 6 21.31962 6.74474 2.75353 14.24145 28.39779 11.42878 31.51988 
2.0 6 30.75088 8.03567 3.28055 22.31797 39.18380 21.03800 40.91800 
3.0 6 30.73097 8.54060 3.48669 21.76816 39.69379 18.14650 42.20200 
Total 18 27.60049 8.64350 2.03729 23.30218 31.89881 11.42878 42.20200 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ankle Angles - ANOVA 
  Sum of Squares df Mean Square F Sig. 
PLeftW2 Between Groups 13.333 2 6.667 0.465 0.637 
Within Groups 215.263 15 14.351     
Total 228.597 17       
PLeftR2 Between Groups 40.534 2 20.267 0.654 0.534 
Within Groups 464.790 15 30.986     
Total 505.324 17       
PLeftS2 Between Groups 28.211 2 14.105 0.430 0.658 
Within Groups 491.643 15 32.776     
Total 519.854 17       
PLeftW3 Between Groups 7.746 2 3.873 0.218 0.806 
Within Groups 266.177 15 17.745     
Total 273.924 17       
PLeftR3 Between Groups 46.567 2 23.284 0.975 0.400 
Within Groups 358.319 15 23.888     
Total 404.887 17       
PLeftS3 Between Groups 70.536 2 35.268 1.016 0.386 
Within Groups 520.628 15 34.709     
Total 591.165 17       
PLeftW4 Between Groups 62.017 2 31.009 1.216 0.324 
Within Groups 382.663 15 25.511     
Total 444.680 17       
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PLeftR4 Between Groups 154.282 2 77.141 3.321 0.064 
Within Groups 348.399 15 23.227     
Total 502.681 17       
PLeftS4 Between Groups 67.692 2 33.846 0.961 0.405 
Within Groups 528.385 15 35.226     
Total 596.077 17       
PLeftW5 Between Groups 185.355 2 92.677 3.514 0.056 
Within Groups 395.595 15 26.373     
Total 580.949 17       
PLeftR5 Between Groups 276.166 2 138.083 5.127 0.020 
Within Groups 403.983 15 26.932     
Total 680.149 17       
PLeftS5 Between Groups 142.861 2 71.430 1.215 0.324 
Within Groups 881.555 15 58.770     
Total 1024.416 17       
PLeftW6 Between Groups 110.740 2 55.370 1.118 0.355 
Within Groups 693.545 14 49.539     
Total 804.286 16       
PLeftR6 Between Groups 272.497 2 136.249 7.295 0.006 
Within Groups 280.144 15 18.676     
Total 552.641 17       
PLeftS6 Between Groups 115.785 2 57.893 1.150 0.343 
Within Groups 755.378 15 50.359     
Total 871.163 17       
PRightW2 Between Groups 0.825 2 0.413 0.020 0.981 
Within Groups 314.462 15 20.964     
Total 315.288 17       
PRightR2 Between Groups 36.004 2 18.002 1.174 0.336 
Within Groups 230.065 15 15.338     
Total 266.069 17       
PRightS2 Between Groups 279.065 2 139.532 3.163 0.071 
Within Groups 661.643 15 44.110     
Total 940.708 17       
PRightW3 Between Groups 6.311 2 3.155 0.128 0.881 
Within Groups 370.391 15 24.693     
Total 376.702 17       
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PRightR3 Between Groups 30.618 2 15.309 0.835 0.453 
Within Groups 275.023 15 18.335     
Total 305.641 17       
PRightS3 Between Groups 165.456 2 82.728 2.613 0.106 
Within Groups 474.963 15 31.664     
Total 640.419 17       
PRightW4 Between Groups 66.884 2 33.442 1.847 0.192 
Within Groups 271.629 15 18.109     
Total 338.513 17       
PRightR4 Between Groups 86.690 2 43.345 2.881 0.087 
Within Groups 225.637 15 15.042     
Total 312.327 17       
PRightS4 Between Groups 72.680 2 36.340 1.706 0.215 
Within Groups 319.590 15 21.306     
Total 392.270 17       
PRightW5 Between Groups 179.045 2 89.523 4.501 0.029 
Within Groups 298.329 15 19.889     
Total 477.374 17       
PRightR5 Between Groups 237.987 2 118.993 8.812 0.003 
Within Groups 202.565 15 13.504     
Total 440.551 17       
PRightS5 Between Groups 353.980 2 176.990 8.681 0.003 
Within Groups 305.820 15 20.388     
Total 659.800 17       
PRightW6 Between Groups 85.846 2 42.923 1.671 0.223 
Within Groups 359.543 14 25.682     
Total 445.389 16       
PRightR6 Between Groups 313.500 2 156.750 11.238 0.001 
Within Groups 209.215 15 13.948     
Total 522.715 17       
PRightS6 Between Groups 76.579 2 38.290 0.426 0.661 
Within Groups 1349.497 15 89.966     
Total 1426.076 17       
PPLeftW2 Between Groups 657.835 2 328.918 5.399 0.017 
Within Groups 913.847 15 60.923     
Total 1571.683 17       
    
Appendix D – ANOVA Descriptives & Charts 
 
PPLeftR2 Between Groups 180.271 2 90.136 1.338 0.292 
Within Groups 1010.857 15 67.390     
Total 1191.129 17       
PPLeftS2 Between Groups 114.134 2 57.067 0.634 0.544 
Within Groups 1350.619 15 90.041     
Total 1464.752 17       
PPLeftW3 Between Groups 379.102 2 189.551 3.477 0.057 
Within Groups 817.811 15 54.521     
Total 1196.913 17       
PPLeftR3 Between Groups 89.183 2 44.592 0.635 0.544 
Within Groups 1054.054 15 70.270     
Total 1143.237 17       
PPLeftS3 Between Groups 78.163 2 39.082 0.631 0.546 
Within Groups 928.854 15 61.924     
Total 1007.017 17       
PPLeftR4 Between Groups 76.278 2 38.139 0.610 0.556 
Within Groups 938.344 15 62.556     
Total 1014.622 17       
PPLeftS4 Between Groups 162.256 2 81.128 1.802 0.199 
Within Groups 675.488 15 45.033     
Total 837.744 17       
PPLeftW5 Between Groups 190.705 2 95.352 1.818 0.196 
Within Groups 786.831 15 52.455     
Total 977.536 17       
PPLeftR5 Between Groups 17.128 2 8.564 0.153 0.859 
Within Groups 837.347 15 55.823     
Total 854.475 17       
PPLeftS5 Between Groups 480.220 2 240.110 5.558 0.016 
Within Groups 647.960 15 43.197     
Total 1128.181 17       
PPLeftW6 Between Groups 25.823 2 12.912 0.273 0.765 
Within Groups 662.146 14 47.296     
Total 687.969 16       
PPLeftR6 Between Groups 2.586 2 1.293 0.018 0.982 
Within Groups 1074.852 15 71.657     
Total 1077.439 17       
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PPLeftS6 Between Groups 222.138 2 111.069 3.066 0.077 
Within Groups 543.445 15 36.230     
Total 765.583 17       
PPRightW2 Between Groups 414.821 2 207.410 3.899 0.043 
Within Groups 797.936 15 53.196     
Total 1212.756 17       
PPRightR2 Between Groups 179.710 2 89.855 0.879 0.435 
Within Groups 1533.099 15 102.207     
Total 1712.809 17       
PPRightS2 Between Groups 221.472 2 110.736 1.110 0.355 
Within Groups 1496.601 15 99.773     
Total 1718.073 17       
PPRightW3 Between Groups 267.288 2 133.644 3.096 0.075 
Within Groups 647.396 15 43.160     
Total 914.684 17       
PPRightR3 Between Groups 95.273 2 47.636 0.568 0.579 
Within Groups 1258.689 15 83.913     
Total 1353.962 17       
PPRightS3 Between Groups 331.706 2 165.853 2.312 0.133 
Within Groups 1076.221 15 71.748     
Total 1407.928 17       
PPRightW4 Between Groups 195.993 2 97.997 2.084 0.159 
Within Groups 705.400 15 47.027     
Total 901.393 17       
PPRightR4 Between Groups 38.761 2 19.381 0.240 0.789 
Within Groups 1210.535 15 80.702     
Total 1249.296 17       
PPRightS4 Between Groups 300.752 2 150.376 2.149 0.151 
Within Groups 1049.823 15 69.988     
Total 1350.575 17       
PPRightW5 Between Groups 69.733 2 34.867 0.694 0.515 
Within Groups 753.929 15 50.262     
Total 823.662 17       
PPRightR5 Between Groups 92.356 2 46.178 0.348 0.712 
Within Groups 1991.304 15 132.754     
Total 2083.660 17       
    
Appendix D – ANOVA Descriptives & Charts 
 
PPRightS5 Between Groups 403.576 2 201.788 4.032 0.040 
Within Groups 750.682 15 50.045     
Total 1154.258 17       
PPRightW6 Between Groups 132.958 2 66.479 0.745 0.493 
Within Groups 1249.024 14 89.216     
Total 1381.982 16       
PPRightR6 Between Groups 24.560 2 12.280 0.148 0.864 
Within Groups 1247.068 15 83.138     
Total 1271.629 17       
PPRightS6 Between Groups 355.045 2 177.523 2.910 0.086 
Within Groups 915.027 15 61.002     
Total 1270.072 17       
 
 
 
Ankle Angle ANOVA Post Hoc - Bonferroni 
 
       
Dependent 
Variable (I) ^ (J) ^ 
Mean Difference (I-J) Std. Error Sig. 
97.5% Confidence Interval 
      Lower Bound Upper Bound 
PLeftW2 1.0 2.0 1.842660470085470 2.187150343175110 1.000 -4.798147422683180 8.483468362854120 
3.0 1.808351190476190 2.187150343175110 1.000 -4.832456702292460 8.449159083244840 
2.0 1.0 -1.842660470085470 2.187150343175110 1.000 -8.483468362854120 4.798147422683180 
3.0 -0.034309279609275 2.187150343175110 1.000 -6.675117172377920 6.606498613159380 
3.0 1.0 -1.808351190476190 2.187150343175110 1.000 -8.449159083244840 4.832456702292460 
2.0 0.034309279609275 2.187150343175110 1.000 -6.606498613159380 6.675117172377920 
PLeftR2 1.0 2.0 0.289074462574458 3.213822865142870 1.000 -9.469001983975720 10.047150909124600 
3.0 3.317991414141420 3.213822865142870 0.955 -6.440085032408760 13.076067860691600 
2.0 1.0 -0.289074462574458 3.213822865142870 1.000 -10.047150909124600 9.469001983975720 
3.0 3.028916951566960 3.213822865142870 1.000 -6.729159494983210 12.786993398117100 
3.0 1.0 -3.317991414141420 3.213822865142870 0.955 -13.076067860691600 6.440085032408760 
2.0 -3.028916951566960 3.213822865142870 1.000 -12.786993398117100 6.729159494983210 
PLeftS2 1.0 2.0 1.155308080808090 3.305359463932540 1.000 -8.880699404921200 11.191315566537400 
3.0 3.037671969696970 3.305359463932540 1.000 -6.998335516032320 13.073679455426300 
2.0 1.0 -1.155308080808090 3.305359463932540 1.000 -11.191315566537400 8.880699404921200 
3.0 1.882363888888880 3.305359463932540 1.000 -8.153643596840410 11.918371374618200 
3.0 1.0 -3.037671969696970 3.305359463932540 1.000 -13.073679455426300 6.998335516032320 
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2.0 -1.882363888888880 3.305359463932540 1.000 -11.918371374618200 8.153643596840410 
PLeftW3 1.0 2.0 -1.524322156084660 2.432088588119280 1.000 -8.908831932604400 5.860187620435070 
3.0 -0.321836243386251 2.432088588119280 1.000 -7.706346019905990 7.062673533133480 
2.0 1.0 1.524322156084660 2.432088588119280 1.000 -5.860187620435070 8.908831932604400 
3.0 1.202485912698410 2.432088588119280 1.000 -6.182023863821320 8.586995689218150 
3.0 1.0 0.321836243386251 2.432088588119280 1.000 -7.062673533133480 7.706346019905990 
2.0 -1.202485912698410 2.432088588119280 1.000 -8.586995689218150 6.182023863821320 
PLeftR3 1.0 2.0 1.867601731601730 2.821817146135990 1.000 -6.700234327078170 10.435437790281600 
3.0 3.938112746512740 2.821817146135990 0.549 -4.629723312167170 12.505948805192600 
2.0 1.0 -1.867601731601730 2.821817146135990 1.000 -10.435437790281600 6.700234327078170 
3.0 2.070511014911010 2.821817146135990 1.000 -6.497325043768900 10.638347073590900 
3.0 1.0 -3.938112746512740 2.821817146135990 0.549 -12.505948805192600 4.629723312167170 
2.0 -2.070511014911010 2.821817146135990 1.000 -10.638347073590900 6.497325043768900 
PLeftS3 1.0 2.0 -0.386849353886879 3.401398807720800 1.000 -10.714459487891100 9.940760780117380 
3.0 3.992489748677230 3.401398807720800 0.776 -6.335120385327030 14.320099882681500 
2.0 1.0 0.386849353886879 3.401398807720800 1.000 -9.940760780117380 10.714459487891100 
3.0 4.379339102564110 3.401398807720800 0.652 -5.948271031440150 14.706949236568400 
3.0 1.0 -3.992489748677230 3.401398807720800 0.776 -14.320099882681500 6.335120385327030 
2.0 -4.379339102564110 3.401398807720800 0.652 -14.706949236568400 5.948271031440150 
PLeftW4 1.0 2.0 -4.508961574074080 2.916097320878670 0.429 -13.363058945569800 4.345135797421600 
3.0 -1.748280723905730 2.916097320878670 1.000 -10.602378095401400 7.105816647589950 
2.0 1.0 4.508961574074080 2.916097320878670 0.429 -4.345135797421600 13.363058945569800 
3.0 2.760680850168350 2.916097320878670 1.000 -6.093416521327340 11.614778221664000 
3.0 1.0 1.748280723905730 2.916097320878670 1.000 -7.105816647589950 10.602378095401400 
2.0 -2.760680850168350 2.916097320878670 1.000 -11.614778221664000 6.093416521327340 
PLeftR4 1.0 2.0 2.222144360269380 2.782481154848550 1.000 -6.226256488011440 10.670545208550200 
3.0 7.015913474025990 2.782481154848550 0.070 -1.432487374254830 15.464314322306800 
2.0 1.0 -2.222144360269380 2.782481154848550 1.000 -10.670545208550200 6.226256488011440 
3.0 4.793769113756610 2.782481154848550 0.316 -3.654631734524210 13.242169962037400 
3.0 1.0 -7.015913474025990 2.782481154848550 0.070 -15.464314322306800 1.432487374254830 
2.0 -4.793769113756610 2.782481154848550 0.316 -13.242169962037400 3.654631734524210 
PLeftS4 1.0 2.0 -0.520064760702253 3.426643505127520 1.000 -10.924324945907700 9.884195424503220 
3.0 3.828998677248680 3.426643505127520 0.844 -6.575261507956800 14.233258862454100 
2.0 1.0 0.520064760702253 3.426643505127520 1.000 -9.884195424503220 10.924324945907700 
3.0 4.349063437950930 3.426643505127520 0.671 -6.055196747254540 14.753323623156400 
3.0 1.0 -3.828998677248680 3.426643505127520 0.844 -14.233258862454100 6.575261507956800 
    
Appendix D – ANOVA Descriptives & Charts 
 
2.0 -4.349063437950930 3.426643505127520 0.671 -14.753323623156400 6.055196747254540 
PLeftW5 1.0 2.0 -7.829942195767190 2.964961395501670 0.056 -16.832404737239300 1.172520345704950 
3.0 -4.513016498316490 2.964961395501670 0.446 -13.515479039788600 4.489446043155660 
2.0 1.0 7.829942195767190 2.964961395501670 0.056 -1.172520345704950 16.832404737239300 
3.0 3.316925697450710 2.964961395501670 0.843 -5.685536844021440 12.319388238922900 
3.0 1.0 4.513016498316490 2.964961395501670 0.446 -4.489446043155660 13.515479039788600 
2.0 -3.316925697450710 2.964961395501670 0.843 -12.319388238922900 5.685536844021440 
PLeftR5 1.0 2.0 4.848503793428800 2.996230244316920 0.379 -4.248899829097980 13.945907415955600 
3.0 9.594361257353775* 2.996230244316920 0.018 0.496957634826988 18.691764879880600 
2.0 1.0 -4.848503793428800 2.996230244316920 0.379 -13.945907415955600 4.248899829097980 
3.0 4.745857463924970 2.996230244316920 0.402 -4.351546158601820 13.843261086451800 
3.0 1.0 -9.594361257353775* 2.996230244316920 0.018 -18.691764879880600 -0.496957634826988 
2.0 -4.745857463924970 2.996230244316920 0.402 -13.843261086451800 4.351546158601820 
PLeftS5 1.0 2.0 2.057597619047630 4.426072454633920 1.000 -11.381211917945300 15.496407156040500 
3.0 6.733180357142850 4.426072454633920 0.447 -6.705629179850030 20.171989894135700 
2.0 1.0 -2.057597619047630 4.426072454633920 1.000 -15.496407156040500 11.381211917945300 
3.0 4.675582738095230 4.426072454633920 0.923 -8.763226798897650 18.114392275088100 
3.0 1.0 -6.733180357142850 4.426072454633920 0.447 -20.171989894135700 6.705629179850030 
2.0 -4.675582738095230 4.426072454633920 0.923 -18.114392275088100 8.763226798897650 
PLeftW6 1.0 2.0 -5.981954292929300 4.261956958186840 0.547 -19.060959351313000 7.097050765454360 
3.0 -1.422586175861170 4.261956958186840 1.000 -14.501591234244800 11.656418882522500 
2.0 1.0 5.981954292929300 4.261956958186840 0.547 -7.097050765454360 19.060959351313000 
3.0 4.559368117068130 4.063616516606090 0.842 -7.910973910654550 17.029710144790800 
3.0 1.0 1.422586175861170 4.261956958186840 1.000 -11.656418882522500 14.501591234244800 
2.0 -4.559368117068130 4.063616516606090 0.842 -17.029710144790800 7.910973910654550 
PLeftR6 1.0 2.0 3.449260398860380 2.495078087776950 0.561 -4.126503338683800 11.025024136404600 
3.0 9.418866727716724* 2.495078087776950 0.006 1.843102990172540 16.994630465260900 
2.0 1.0 -3.449260398860380 2.495078087776950 0.561 -11.025024136404600 4.126503338683800 
3.0 5.969606328856340 2.495078087776950 0.091 -1.606157408687840 13.545370066400500 
3.0 1.0 -9.418866727716724* 2.495078087776950 0.006 -16.994630465260900 -1.843102990172540 
2.0 -5.969606328856340 2.495078087776950 0.091 -13.545370066400500 1.606157408687840 
PLeftS6 1.0 2.0 2.099288065175560 4.097094073662540 1.000 -10.340649933003300 14.539226063354400 
3.0 6.113342261904760 4.097094073662540 0.469 -6.326595736274070 18.553280260083600 
2.0 1.0 -2.099288065175560 4.097094073662540 1.000 -14.539226063354400 10.340649933003300 
3.0 4.014054196729200 4.097094073662540 1.000 -8.425883801449630 16.453992194908000 
3.0 1.0 -6.113342261904760 4.097094073662540 0.469 -18.553280260083600 6.326595736274070 
    
Appendix D – ANOVA Descriptives & Charts 
 
2.0 -4.014054196729200 4.097094073662540 1.000 -16.453992194908000 8.425883801449630 
PRightW2 1.0 2.0 -0.524377380952378 2.643492962986420 1.000 -8.550770714112050 7.502015952207300 
3.0 -0.256227436507935 2.643492962986420 1.000 -8.282620769667610 7.770165896651740 
2.0 1.0 0.524377380952378 2.643492962986420 1.000 -7.502015952207300 8.550770714112050 
3.0 0.268149944444444 2.643492962986420 1.000 -7.758243388715230 8.294543277604120 
3.0 1.0 0.256227436507935 2.643492962986420 1.000 -7.770165896651740 8.282620769667610 
2.0 -0.268149944444444 2.643492962986420 1.000 -8.294543277604120 7.758243388715230 
PRightR2 1.0 2.0 -0.756372575757569 2.261098007126420 1.000 -7.621706519948360 6.108961368433220 
3.0 2.549579461279460 2.261098007126420 0.832 -4.315754482911330 9.414913405470250 
2.0 1.0 0.756372575757569 2.261098007126420 1.000 -6.108961368433220 7.621706519948360 
3.0 3.305952037037030 2.261098007126420 0.493 -3.559381907153770 10.171285981227800 
3.0 1.0 -2.549579461279460 2.261098007126420 0.832 -9.414913405470250 4.315754482911330 
2.0 -3.305952037037030 2.261098007126420 0.493 -10.171285981227800 3.559381907153770 
PRightS2 1.0 2.0 9.568749867724860 3.834472087845850 0.074 -2.073793400974950 21.211293136424700 
3.0 5.831040608465600 3.834472087845850 0.447 -5.811502660234210 17.473583877165400 
2.0 1.0 -9.568749867724860 3.834472087845850 0.074 -21.211293136424700 2.073793400974950 
3.0 -3.737709259259260 3.834472087845850 1.000 -15.380252527959100 7.904834009440540 
3.0 1.0 -5.831040608465600 3.834472087845850 0.447 -17.473583877165400 5.811502660234210 
2.0 3.737709259259260 3.834472087845850 1.000 -7.904834009440540 15.380252527959100 
PRightW3 1.0 2.0 -1.238384259259260 2.868956891777590 1.000 -9.949349936758770 7.472581418240240 
3.0 0.034652447089941 2.868956891777590 1.000 -8.676313230409560 8.745618124589440 
2.0 1.0 1.238384259259260 2.868956891777590 1.000 -7.472581418240240 9.949349936758770 
3.0 1.273036706349200 2.868956891777590 1.000 -7.437928971150300 9.984002383848710 
3.0 1.0 -0.034652447089941 2.868956891777590 1.000 -8.745618124589440 8.676313230409560 
2.0 -1.273036706349200 2.868956891777590 1.000 -9.984002383848710 7.437928971150300 
PRightR3 1.0 2.0 0.772524851074870 2.472167460605890 1.000 -6.733675733565530 8.278725435715270 
3.0 3.070835120435130 2.472167460605890 0.700 -4.435365464205270 10.577035705075500 
2.0 1.0 -0.772524851074870 2.472167460605890 1.000 -8.278725435715270 6.733675733565530 
3.0 2.298310269360260 2.472167460605890 1.000 -5.207890315280140 9.804510854000660 
3.0 1.0 -3.070835120435130 2.472167460605890 0.700 -10.577035705075500 4.435365464205270 
2.0 -2.298310269360260 2.472167460605890 1.000 -9.804510854000660 5.207890315280140 
PRightS3 1.0 2.0 3.729597979797980 3.248804912595000 0.807 -6.134693870530990 13.593889830127000 
3.0 7.426421759259250 3.248804912595000 0.112 -2.437870091069720 17.290713609588200 
2.0 1.0 -3.729597979797980 3.248804912595000 0.807 -13.593889830127000 6.134693870530990 
3.0 3.696823779461270 3.248804912595000 0.819 -6.167468070867700 13.561115629790200 
3.0 1.0 -7.426421759259250 3.248804912595000 0.112 -17.290713609588200 2.437870091069720 
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2.0 -3.696823779461270 3.248804912595000 0.819 -13.561115629790200 6.167468070867700 
PRightW4 1.0 2.0 -4.338793602693600 2.456867376289370 0.293 -11.798538798016000 3.120951592628790 
3.0 -3.782547979797980 2.456867376289370 0.433 -11.242293175120400 3.677197215524410 
2.0 1.0 4.338793602693600 2.456867376289370 0.293 -3.120951592628790 11.798538798016000 
3.0 0.556245622895622 2.456867376289370 1.000 -6.903499572426770 8.015990818218010 
3.0 1.0 3.782547979797980 2.456867376289370 0.433 -3.677197215524410 11.242293175120400 
2.0 -0.556245622895622 2.456867376289370 1.000 -8.015990818218010 6.903499572426770 
PRightR4 1.0 2.0 2.256044447681930 2.239231631834970 0.989 -4.542896988067520 9.054985883431390 
3.0 5.353548698523690 2.239231631834970 0.091 -1.445392737225770 12.152490134273100 
2.0 1.0 -2.256044447681930 2.239231631834970 0.989 -9.054985883431390 4.542896988067520 
3.0 3.097504250841760 2.239231631834970 0.560 -3.701437184907700 9.896445686591210 
3.0 1.0 -5.353548698523690 2.239231631834970 0.091 -12.152490134273100 1.445392737225770 
2.0 -3.097504250841760 2.239231631834970 0.560 -9.896445686591210 3.701437184907700 
PRightS4 1.0 2.0 3.233442340067340 2.664958036847800 0.731 -4.858125036734250 11.325009716868900 
3.0 4.830535714285720 2.664958036847800 0.270 -3.261031662515870 12.922103091087300 
2.0 1.0 -3.233442340067340 2.664958036847800 0.731 -11.325009716868900 4.858125036734250 
3.0 1.597093374218380 2.664958036847800 1.000 -6.494474002583210 9.688660751019960 
3.0 1.0 -4.830535714285720 2.664958036847800 0.270 -12.922103091087300 3.261031662515870 
2.0 -1.597093374218380 2.664958036847800 1.000 -9.688660751019960 6.494474002583210 
PRightW5 1.0 2.0 -7.725038461538470 2.574786568480690 0.027 -15.542819721759900 0.092742798682983 
3.0 -3.798412678062690 2.574786568480690 0.482 -11.616193938284100 4.019368582158760 
2.0 1.0 7.725038461538470 2.574786568480690 0.027 -0.092742798682983 15.542819721759900 
3.0 3.926625783475770 2.574786568480690 0.444 -3.891155476745680 11.744407043697200 
3.0 1.0 3.798412678062690 2.574786568480690 0.482 -4.019368582158760 11.616193938284100 
2.0 -3.926625783475770 2.574786568480690 0.444 -11.744407043697200 3.891155476745680 
PRightR5 1.0 2.0 6.098942180504650 2.121658438811300 0.035 -0.343013741813605 12.540898102822900 
3.0 8.670756410256402* 2.121658438811300 0.003 2.228800487938140 15.112712332574700 
2.0 1.0 -6.098942180504650 2.121658438811300 0.035 -12.540898102822900 0.343013741813605 
3.0 2.571814229751750 2.121658438811300 0.733 -3.870141692566510 9.013770152070010 
3.0 1.0 -8.670756410256402* 2.121658438811300 0.003 -15.112712332574700 -2.228800487938140 
2.0 -2.571814229751750 2.121658438811300 0.733 -9.013770152070010 3.870141692566510 
PRightS5 1.0 2.0 3.170322107984610 2.606915417315400 0.728 -4.745011436922220 11.085655652891400 
3.0 10.582758134920638* 2.606915417315400 0.003 2.667424590013810 18.498091679827500 
2.0 1.0 -3.170322107984610 2.606915417315400 0.728 -11.085655652891400 4.745011436922220 
3.0 7.412436026936030 2.606915417315400 0.037 -0.502897517970795 15.327769571842900 
3.0 1.0 -
10.582758134920638* 
2.606915417315400 0.003 -18.498091679827500 -2.667424590013810 
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2.0 -7.412436026936030 2.606915417315400 0.037 -15.327769571842900 0.502897517970795 
PRightW6 1.0 2.0 -5.108227359307370 3.068648615949610 0.355 -14.525232543583400 4.308777824968700 
3.0 -0.841720867650888 3.068648615949610 1.000 -10.258726051927000 8.575284316625180 
2.0 1.0 5.108227359307370 3.068648615949610 0.355 -4.308777824968700 14.525232543583400 
3.0 4.266506491656480 2.925841654848210 0.501 -4.712255654282540 13.245268637595500 
3.0 1.0 0.841720867650888 3.068648615949610 1.000 -8.575284316625180 10.258726051927000 
2.0 -4.266506491656480 2.925841654848210 0.501 -13.245268637595500 4.712255654282540 
PRightR6 1.0 2.0 2.823257300569780 2.156207296774960 0.630 -3.723598739551160 9.370113340690720 
3.0 9.920267710622700* 2.156207296774960 0.001 3.373411670501760 16.467123750743600 
2.0 1.0 -2.823257300569780 2.156207296774960 0.630 -9.370113340690720 3.723598739551160 
3.0 7.097010410052917* 2.156207296774960 0.015 0.550154369931977 13.643866450173900 
3.0 1.0 -9.920267710622700* 2.156207296774960 0.001 -16.467123750743600 -3.373411670501760 
2.0 -7.097010410052917* 2.156207296774960 0.015 -13.643866450173900 -0.550154369931977 
PRightS6 1.0 2.0 -1.984215079365080 5.476205820080670 1.000 -18.611526935587900 14.643096776857800 
3.0 3.031813293650790 5.476205820080670 1.000 -13.595498562572000 19.659125149873600 
2.0 1.0 1.984215079365080 5.476205820080670 1.000 -14.643096776857800 18.611526935587900 
3.0 5.016028373015870 5.476205820080670 1.000 -11.611283483207000 21.643340229238700 
3.0 1.0 -3.031813293650790 5.476205820080670 1.000 -19.659125149873600 13.595498562572000 
2.0 -5.016028373015870 5.476205820080670 1.000 -21.643340229238700 11.611283483207000 
PPLeftW2 1.0 2.0 -
12.884850000000000 
4.506408538901910 0.036 -26.567582641842800 0.797882641842858 
3.0 -
12.762579563492100 
4.506408538901910 0.038 -26.445312205334900 0.920153078350772 
2.0 1.0 12.884850000000000 4.506408538901910 0.036 -0.797882641842858 26.567582641842800 
3.0 0.122270436507915 4.506408538901910 1.000 -13.560462205334900 13.805003078350800 
3.0 1.0 12.762579563492100 4.506408538901910 0.038 -0.920153078350772 26.445312205334900 
2.0 -0.122270436507915 4.506408538901910 1.000 -13.805003078350800 13.560462205334900 
PPLeftR2 1.0 2.0 -7.148138095238120 4.739567408018980 0.457 -21.538807099632900 7.242530909156700 
3.0 -6.171366111111100 4.739567408018980 0.638 -20.562035115505900 8.219302893283730 
2.0 1.0 7.148138095238120 4.739567408018980 0.457 -7.242530909156700 21.538807099632900 
3.0 0.976771984127023 4.739567408018980 1.000 -13.413897020267800 15.367440988521800 
3.0 1.0 6.171366111111100 4.739567408018980 0.638 -8.219302893283730 20.562035115505900 
2.0 -0.976771984127023 4.739567408018980 1.000 -15.367440988521800 13.413897020267800 
PPLeftS2 1.0 2.0 -3.873862698412700 5.478480391989690 1.000 -20.508080799162000 12.760355402336600 
3.0 -6.093646031746030 5.478480391989690 0.851 -22.727864132495300 10.540572069003300 
2.0 1.0 3.873862698412700 5.478480391989690 1.000 -12.760355402336600 20.508080799162000 
3.0 -2.219783333333340 5.478480391989690 1.000 -18.854001434082600 14.414434767416000 
3.0 1.0 6.093646031746030 5.478480391989690 0.851 -10.540572069003300 22.727864132495300 
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2.0 2.219783333333340 5.478480391989690 1.000 -14.414434767416000 18.854001434082600 
PPLeftW3 1.0 2.0 -
10.995163425925900 
4.263047508607940 0.063 -23.938983054398900 1.948656202547030 
3.0 -7.523714417989410 4.263047508607940 0.294 -20.467534046462400 5.420105210483550 
2.0 1.0 10.995163425925900 4.263047508607940 0.063 -1.948656202547030 23.938983054398900 
3.0 3.471449007936520 4.263047508607940 1.000 -9.472370620536440 16.415268636409500 
3.0 1.0 7.523714417989410 4.263047508607940 0.294 -5.420105210483550 20.467534046462400 
2.0 -3.471449007936520 4.263047508607940 1.000 -16.415268636409500 9.472370620536440 
PPLeftR3 1.0 2.0 -3.782494642857150 4.839774020892890 1.000 -18.477419304736700 10.912430019022400 
3.0 -5.292026984126980 4.839774020892890 0.874 -19.986951646006500 9.402897677752550 
2.0 1.0 3.782494642857150 4.839774020892890 1.000 -10.912430019022400 18.477419304736700 
3.0 -1.509532341269840 4.839774020892890 1.000 -16.204457003149400 13.185392320609700 
3.0 1.0 5.292026984126980 4.839774020892890 0.874 -9.402897677752550 19.986951646006500 
2.0 1.509532341269840 4.839774020892890 1.000 -13.185392320609700 16.204457003149400 
PPLeftS3 1.0 2.0 -3.773459126984130 4.543258089848480 1.000 -17.568077442134500 10.021159188166300 
3.0 -4.863575529100530 4.543258089848480 0.904 -18.658193844250900 8.931042786049860 
2.0 1.0 3.773459126984130 4.543258089848480 1.000 -10.021159188166300 17.568077442134500 
3.0 -1.090116402116400 4.543258089848480 1.000 -14.884734717266800 12.704501913034000 
3.0 1.0 4.863575529100530 4.543258089848480 0.904 -8.931042786049860 18.658193844250900 
2.0 1.090116402116400 4.543258089848480 1.000 -12.704501913034000 14.884734717266800 
PPLeftR4 1.0 2.0 -3.142161111111120 4.566407978522370 1.000 -17.007069044852200 10.722746822630000 
3.0 -4.986438888888900 4.566407978522370 0.876 -18.851346822630000 8.878469044852180 
2.0 1.0 3.142161111111120 4.566407978522370 1.000 -10.722746822630000 17.007069044852200 
3.0 -1.844277777777780 4.566407978522370 1.000 -15.709185711518900 12.020630155963300 
3.0 1.0 4.986438888888900 4.566407978522370 0.876 -8.878469044852180 18.851346822630000 
2.0 1.844277777777780 4.566407978522370 1.000 -12.020630155963300 15.709185711518900 
PPLeftS4 1.0 2.0 -6.655349801587280 3.874382666157000 0.319 -18.419072889626300 5.108373286451730 
3.0 -6.037619907407400 3.874382666157000 0.420 -17.801342995446400 5.726103180631610 
2.0 1.0 6.655349801587280 3.874382666157000 0.319 -5.108373286451730 18.419072889626300 
3.0 0.617729894179885 3.874382666157000 1.000 -11.145993193859100 12.381452982218900 
3.0 1.0 6.037619907407400 3.874382666157000 0.420 -5.726103180631610 17.801342995446400 
2.0 -0.617729894179885 3.874382666157000 1.000 -12.381452982218900 11.145993193859100 
PPLeftW5 1.0 2.0 -6.925650793650780 4.181523022188350 0.355 -19.621938991758900 5.770637404457340 
3.0 -0.041912367724848 4.181523022188350 1.000 -12.738200565833000 12.654375830383300 
2.0 1.0 6.925650793650780 4.181523022188350 0.355 -5.770637404457340 19.621938991758900 
3.0 6.883738425925930 4.181523022188350 0.362 -5.812549772182190 19.580026624034000 
3.0 1.0 0.041912367724848 4.181523022188350 1.000 -12.654375830383300 12.738200565833000 
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2.0 -6.883738425925930 4.181523022188350 0.362 -19.580026624034000 5.812549772182190 
PPLeftR5 1.0 2.0 -1.779777777777780 4.313665105745950 1.000 -14.877286767220400 11.317731211664800 
3.0 -2.270595767195780 4.313665105745950 1.000 -15.368104756638400 10.826913222246800 
2.0 1.0 1.779777777777780 4.313665105745950 1.000 -11.317731211664800 14.877286767220400 
3.0 -0.490817989418002 4.313665105745950 1.000 -13.588326978860600 12.606691000024600 
3.0 1.0 2.270595767195780 4.313665105745950 1.000 -10.826913222246800 15.368104756638400 
2.0 0.490817989418002 4.313665105745950 1.000 -12.606691000024600 13.588326978860600 
PPLeftS5 1.0 2.0 -8.765123412698400 3.794617045173620 0.107 -20.286655483987700 2.756408658590900 
3.0 -
12.284113095238101* 
3.794617045173620 0.017 -23.805645166527400 -0.762581023948805 
2.0 1.0 8.765123412698400 3.794617045173620 0.107 -2.756408658590900 20.286655483987700 
3.0 -3.518989682539700 3.794617045173620 1.000 -15.040521753829000 8.002542388749600 
3.0 1.0 12.284113095238101* 3.794617045173620 0.017 0.762581023948805 23.805645166527400 
2.0 3.518989682539700 3.794617045173620 1.000 -8.002542388749600 15.040521753829000 
PPLeftW6 1.0 2.0 -2.821585873015880 4.164362174787290 1.000 -15.601094085636600 9.957922339604810 
3.0 -0.510101944444450 4.164362174787290 1.000 -13.289610157065100 12.269406268176200 
2.0 1.0 2.821585873015880 4.164362174787290 1.000 -9.957922339604810 15.601094085636600 
3.0 2.311483928571430 3.970563541729100 1.000 -9.873299061119200 14.496266918262100 
3.0 1.0 0.510101944444450 4.164362174787290 1.000 -12.269406268176200 13.289610157065100 
2.0 -2.311483928571430 3.970563541729100 1.000 -14.496266918262100 9.873299061119200 
PPLeftR6 1.0 2.0 0.397012962962947 4.887290693972360 1.000 -14.442185776192000 15.236211702117900 
3.0 -0.528388888888905 4.887290693972360 1.000 -15.367587628043900 14.310809850266100 
2.0 1.0 -0.397012962962947 4.887290693972360 1.000 -15.236211702117900 14.442185776192000 
3.0 -0.925401851851852 4.887290693972360 1.000 -15.764600591006800 13.913796887303100 
3.0 1.0 0.528388888888905 4.887290693972360 1.000 -14.310809850266100 15.367587628043900 
2.0 0.925401851851852 4.887290693972360 1.000 -13.913796887303100 15.764600591006800 
PPLeftS6 1.0 2.0 -5.976386574074060 3.475134104916350 0.318 -16.527877953882900 4.575104805734740 
3.0 -8.349775859788350 3.475134104916350 0.089 -18.901267239597200 2.201715520020450 
2.0 1.0 5.976386574074060 3.475134104916350 0.318 -4.575104805734740 16.527877953882900 
3.0 -2.373389285714290 3.475134104916350 1.000 -12.924880665523100 8.178102094094510 
3.0 1.0 8.349775859788350 3.475134104916350 0.089 -2.201715520020450 18.901267239597200 
2.0 2.373389285714290 3.475134104916350 1.000 -8.178102094094510 12.924880665523100 
PPRightW2 1.0 2.0 -
10.138453042328000 
4.210926472651170 0.088 -22.924018443769500 2.647112359113360 
3.0 -
10.228099867724900 
4.210926472651170 0.085 -23.013665269166300 2.557465533716550 
2.0 1.0 10.138453042328000 4.210926472651170 0.088 -2.647112359113360 22.924018443769500 
3.0 -0.089646825396816 4.210926472651170 1.000 -12.875212226838200 12.695918576044600 
3.0 1.0 10.228099867724900 4.210926472651170 0.085 -2.557465533716550 23.013665269166300 
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2.0 0.089646825396816 4.210926472651170 1.000 -12.695918576044600 12.875212226838200 
PPRightR2 1.0 2.0 -6.480471554834060 5.836853653422110 0.853 -24.202812376778100 11.241869267110000 
3.0 -6.904957996633000 5.836853653422110 0.766 -24.627298818577000 10.817382825311000 
2.0 1.0 6.480471554834060 5.836853653422110 0.853 -11.241869267110000 24.202812376778100 
3.0 -0.424486441798937 5.836853653422110 1.000 -18.146827263743000 17.297854380145100 
3.0 1.0 6.904957996633000 5.836853653422110 0.766 -10.817382825311000 24.627298818577000 
2.0 0.424486441798937 5.836853653422110 1.000 -17.297854380145100 18.146827263743000 
PPRightS2 1.0 2.0 -8.089471266233770 5.766957670324850 0.543 -25.599588087357000 9.420645554889490 
3.0 -6.552395171957670 5.766957670324850 0.821 -24.062511993080900 10.957721649165600 
2.0 1.0 8.089471266233770 5.766957670324850 0.543 -9.420645554889490 25.599588087357000 
3.0 1.537076094276100 5.766957670324850 1.000 -15.973040726847200 19.047192915399400 
3.0 1.0 6.552395171957670 5.766957670324850 0.821 -10.957721649165600 24.062511993080900 
2.0 -1.537076094276100 5.766957670324850 1.000 -19.047192915399400 15.973040726847200 
PPRightW3 1.0 2.0 -8.882031944444450 3.792964826306930 0.100 -20.398547411308400 2.634483522419500 
3.0 -7.207605026455020 3.792964826306930 0.230 -18.724120493319000 4.308910440408930 
2.0 1.0 8.882031944444450 3.792964826306930 0.100 -2.634483522419500 20.398547411308400 
3.0 1.674426917989430 3.792964826306930 1.000 -9.842088548874520 13.190942384853400 
3.0 1.0 7.207605026455020 3.792964826306930 0.230 -4.308910440408930 18.724120493319000 
2.0 -1.674426917989430 3.792964826306930 1.000 -13.190942384853400 9.842088548874520 
PPRightR3 1.0 2.0 -3.981976579901570 5.288748792497920 1.000 -20.040115808275100 12.076162648472000 
3.0 -5.444412354312360 5.288748792497920 0.959 -21.502551582685900 10.613726874061200 
2.0 1.0 3.981976579901570 5.288748792497920 1.000 -12.076162648472000 20.040115808275100 
3.0 -1.462435774410790 5.288748792497920 1.000 -17.520575002784300 14.595703453962700 
3.0 1.0 5.444412354312360 5.288748792497920 0.959 -10.613726874061200 21.502551582685900 
2.0 1.462435774410790 5.288748792497920 1.000 -14.595703453962700 17.520575002784300 
PPRightS3 1.0 2.0 -9.094623095238090 4.890401954232770 0.248 -23.943268501723600 5.754022311247400 
3.0 -9.118139761904770 4.890401954232770 0.246 -23.966785168390300 5.730505644580720 
2.0 1.0 9.094623095238090 4.890401954232770 0.248 -5.754022311247400 23.943268501723600 
3.0 -0.023516666666680 4.890401954232770 1.000 -14.872162073152200 14.825128739818800 
3.0 1.0 9.118139761904770 4.890401954232770 0.246 -5.730505644580720 23.966785168390300 
2.0 0.023516666666680 4.890401954232770 1.000 -14.825128739818800 14.872162073152200 
PPRightW4 1.0 2.0 -7.561180639730640 3.959237695657250 0.226 -19.582547630213200 4.460186350751930 
3.0 -1.306795454545470 3.959237695657250 1.000 -13.328162445028000 10.714571535937100 
2.0 1.0 7.561180639730640 3.959237695657250 0.226 -4.460186350751930 19.582547630213200 
3.0 6.254385185185170 3.959237695657250 0.405 -5.766981805297390 18.275752175667700 
3.0 1.0 1.306795454545470 3.959237695657250 1.000 -10.714571535937100 13.328162445028000 
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2.0 -6.254385185185170 3.959237695657250 0.405 -18.275752175667700 5.766981805297390 
PPRightR4 1.0 2.0 -2.009730555555560 5.186596737636700 1.000 -17.757707213577400 13.738246102466200 
3.0 -3.585760317460330 5.186596737636700 1.000 -19.333736975482100 12.162216340561500 
2.0 1.0 2.009730555555560 5.186596737636700 1.000 -13.738246102466200 17.757707213577400 
3.0 -1.576029761904780 5.186596737636700 1.000 -17.324006419926600 14.171946896117000 
3.0 1.0 3.585760317460330 5.186596737636700 1.000 -12.162216340561500 19.333736975482100 
2.0 1.576029761904780 5.186596737636700 1.000 -14.171946896117000 17.324006419926600 
PPRightS4 1.0 2.0 -6.802989880952380 4.830051124578150 0.538 -21.468393075874300 7.862413313969490 
3.0 -9.763684788359790 4.830051124578150 0.184 -24.429087983281700 4.901718406562090 
2.0 1.0 6.802989880952380 4.830051124578150 0.538 -7.862413313969490 21.468393075874300 
3.0 -2.960694907407400 4.830051124578150 1.000 -17.626098102329300 11.704708287514500 
3.0 1.0 9.763684788359790 4.830051124578150 0.184 -4.901718406562090 24.429087983281700 
2.0 2.960694907407400 4.830051124578150 1.000 -11.704708287514500 17.626098102329300 
PPRightW5 1.0 2.0 -4.818644871794870 4.093161754948570 0.772 -17.246643236635700 7.609353493045920 
3.0 -2.546611959336950 4.093161754948570 1.000 -14.974610324177700 9.881386405503840 
2.0 1.0 4.818644871794870 4.093161754948570 0.772 -7.609353493045920 17.246643236635700 
3.0 2.272032912457920 4.093161754948570 1.000 -10.155965452382900 14.700031277298700 
3.0 1.0 2.546611959336950 4.093161754948570 1.000 -9.881386405503840 14.974610324177700 
2.0 -2.272032912457920 4.093161754948570 1.000 -14.700031277298700 10.155965452382900 
PPRightR5 1.0 2.0 -5.469666767029260 6.652157389590390 1.000 -25.667500644603900 14.728167110545400 
3.0 -3.541745007770000 6.652157389590390 1.000 -23.739578885344600 16.656088869804600 
2.0 1.0 5.469666767029260 6.652157389590390 1.000 -14.728167110545400 25.667500644603900 
3.0 1.927921759259260 6.652157389590390 1.000 -18.269912118315400 22.125755636833900 
3.0 1.0 3.541745007770000 6.652157389590390 1.000 -16.656088869804600 23.739578885344600 
2.0 -1.927921759259260 6.652157389590390 1.000 -22.125755636833900 18.269912118315400 
PPRightS5 1.0 2.0 -9.216421618566620 4.084339436005740 0.118 -21.617632924414900 3.184789687281700 
3.0 -
10.706331256613800 
4.084339436005740 0.058 -23.107542562462100 1.694880049234570 
2.0 1.0 9.216421618566620 4.084339436005740 0.118 -3.184789687281700 21.617632924414900 
3.0 -1.489909638047130 4.084339436005740 1.000 -13.891120943895400 10.911301667801200 
3.0 1.0 10.706331256613800 4.084339436005740 0.058 -1.694880049234570 23.107542562462100 
2.0 1.489909638047130 4.084339436005740 1.000 -10.911301667801200 13.891120943895400 
PPRightW6 1.0 2.0 -5.515622784437790 5.719487538264990 1.000 -23.067467436607700 12.036221867732200 
3.0 0.579778092463066 5.719487538264990 1.000 -16.972066559706900 18.131622744633000 
2.0 1.0 5.515622784437790 5.719487538264990 1.000 -12.036221867732200 23.067467436607700 
3.0 6.095400876900860 5.453317397392040 0.847 -10.639626371193500 22.830428124995200 
3.0 1.0 -0.579778092463066 5.719487538264990 1.000 -18.131622744633000 16.972066559706900 
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2.0 -6.095400876900860 5.453317397392040 0.847 -22.830428124995200 10.639626371193500 
PPRightR6 1.0 2.0 -2.821026923076930 5.264278883298790 1.000 -18.804868576685200 13.162814730531400 
3.0 -1.824567663817680 5.264278883298790 1.000 -17.808409317426000 14.159273989790600 
2.0 1.0 2.821026923076930 5.264278883298790 1.000 -13.162814730531400 18.804868576685200 
3.0 0.996459259259250 5.264278883298790 1.000 -14.987382394349000 16.980300912867500 
3.0 1.0 1.824567663817680 5.264278883298790 1.000 -14.159273989790600 17.808409317426000 
2.0 -0.996459259259250 5.264278883298790 1.000 -16.980300912867500 14.987382394349000 
PPRightS6 1.0 2.0 -9.431259537037040 4.509315501455090 0.162 -23.122818540509500 4.260299466435410 
3.0 -9.411350013227520 4.509315501455090 0.163 -23.102909016700000 4.280208990244930 
2.0 1.0 9.431259537037040 4.509315501455090 0.162 -4.260299466435410 23.122818540509500 
3.0 0.019909523809520 4.509315501455090 1.000 -13.671649479662900 13.711468527282000 
3.0 1.0 9.411350013227520 4.509315501455090 0.163 -4.280208990244930 23.102909016700000 
2.0 -0.019909523809520 4.509315501455090 1.000 -13.711468527282000 13.671649479662900 
*. The mean difference is significant at the 0.025 level. 
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APPENDIX E: Bonferroni Adjustment ANOVA & T-Test Charts 
 
EMG with Bonferroni - ANOVA 
 
ANOVA < .025   
CH1 Walking Running Skipping 
2 0.864 0.044 0.004 
3 0.728 0.026 0.002 
4 0.269 0.001 0.002 
5 0.539 0.075 0.079 
6 0.014 0.025 0.001 
CH2    
2 0.001 0.000 0.000 
3 0.001 0.000 0.000 
4 0.006 0.000 0.000 
5 0.002 0.000 0.000 
6 0.000 0.000 0.000 
CH3    
2 0.031 0.011 0.000 
3 0.053 0.007 0.001 
4 0.055 0.002 0.001 
5 0.010 0.004 0.001 
6 0.027 0.010 0.000 
CH4    
2 0.692 0.103 0.052 
3 0.934 0.151 0.014 
4 0.762 0.040 0.026 
5 0.472 0.054 0.013 
6 0.094 0.080 0.014 
 
 
 
 
 
 
 
 
 
 
 
    
Appendix E – Bonferroni Adjustment ANOVA & T-Test Charts 
 
 
EMG with Bonferroni – T-Tests 
 
MARTIAN 0.025   LUNAR    
CH1 Walking Running Skipping CH1 Walking Running Skipping 
2 0.9977 0.1656 0.012 2 0.6724 0.0304 0.0078 
3 0.5283 0.1656 0.0184 3 0.4455 0.0175 0.0038 
4 0.6746 0.0134 0.0196 4 0.1492 0.0011 0.004 
5 0.6905 0.1841 0.1114 5 0.2861 0.0588 0.0807 
6 0.2586 0.1148 0.0069 6 0.9246 0.0155 0.0018 
CH2    CH2    
2 0.0114 0.0025 1.55E-04 2 0.0038 0.0011 1.27E-05 
3 0.0172 2.83E-04 0.0022 3 0.0046 7.19E-05 5.64E-04 
4 0.0397 4.39E-04 0.004 4 0.0134 8.82E-05 0.0014 
5 0.0162 4.29E-04 0.0018 5 0.0058 9.52E-05 2.97E-04 
6 0.0025 0.0023 8.40E-04 6 0.0016 5.80E-04 7.60E-05 
CH3    CH3    
2 0.0681 0.0492 0.0046 2 0.0278 0.0215 1.30E-03 
3 0.202 0.0391 0.0126 3 0.0251 0.0156 5.20E-03 
4 0.1727 0.0185 0.0106 4 0.0352 0.0082 0.0046 
5 0.0609 0.0243 0.0127 5 0.013 0.0107 2.50E-03 
6 0.0709 0.0366 0.0048 6 0.0321 0.0233 7.71E-04 
CH4    CH4    
2 0.513 0.3175 0.0857 2 0.4277 0.0553 5.32E-02 
3 0.731 0.2311 0.0416 3 0.7733 0.1263 2.16E-02 
4 0.7216 0.1093 0.046 4 0.6767 0.0452 3.08E-02 
5 0.7793 0.1707 0.037 5 0.2541 0.0408 1.85E-02 
6 0.2673 0.2036 0.0417 6 0.0368 0.043 1.07E-02 
 
 
    
Appendix E – Bonferroni Adjustment ANOVA & T-Test Charts 
 
 
Dorsiflexion with Bonferroni – ANOVA 
 
ANOVA < .025   
Left Walking Running Skipping 
2 0.637 0.534 0.658 
3 0.806 0.4 0.386 
4 0.324 0.064 0.405 
5 0.056 0.02 0.324 
6 0.333 0.006 0.343 
Right    
2 0.981 0.336 0.071 
3 0.881 0.453 0.106 
4 0.192 0.087 0.215 
5 0.029 0.003 0.003 
6 0.091 0.001 0.661 
 
 
 
 
 
Dorsiflexion with Bonferroni – T-Tests 
 
MARTIAN < .025   LUNAR    
Left Walking Running Skipping Left Walking Running Skipping 
2 0.3507 0.9152 0.73 2 0.4747 0.3503 0.3891 
3 0.5626 0.5108 0.9023 3 0.8813 0.1882 0.2598 
4 1.78E-01 0.3412 0.8744 4 0.4299 0.0473 0.2799 
5 0.0259 0.0797 0.6535 5 0.1137 0.0137 0.1088 
6 0.2074 0.1704 0.6388 6 0.7484 0.0064 0.1495 
Right    Right    
2 0.8238 0.7001 0.0604 2 0.9328 0.3074 0.2024 
3 0.6619 0.7132 0.2254 3 0.9897 0.268 0.0395 
4 1.47E-01 0.3818 0.2563 4 0.073 3.98E-02 0.0752 
5 0.0298 0.0266 0.1887 5 0.1724 6.50E-04 0.0014 
6 0.0876 0.2694 0.7634 6 0.7124 5.73E-04 0.2298 
 
 
 
    
Appendix E – Bonferroni Adjustment ANOVA & T-Test Charts 
 
Plantar flexion with Bonferroni – ANOVA 
 
ANOVA < .025   
Left Walking Running Skipping 
2 0.017 0.292 0.544 
3 0.057 0.544 0.546 
4 0.093 0.556 0.199 
5 0.196 0.859 0.016 
6 0.85 0.982 0.077 
Right    
2 0.043 0.435 0.355 
3 0.075 0.579 0.133 
4 0.159 0.789 0.151 
5 0.515 0.712 0.04 
6 0.576 0.864 0.086 
 
 
 
 
 
 
Plantar flexion with Bonferroni – T-Tests 
MARTIAN < .025   LUNAR    
Left Walking Running Skipping Left Walking Running Skipping 
2 0.0236 0.1377 0.4911 2 0.0049 0.1582 0.2109 
3 0.0392 0.4028 0.4146 3 0.1154 0.2694 0.2175 
4 2.80E-02 0.461 0.1499 4 0.5262 0.2489 0.0291 
5 0.0258 0.6639 0.0288 5 0.9931 0.5873 0.0049 
6 0.3241 0.9291 0.1131 6 0.9182 0.9121 0.0191 
Right    Right    
2 0.0482 0.2637 0.1052 2 0.0101 0.2286 0.3059 
3 0.0545 0.3516 0.0558 3 0.0427 0.3519 0.1045 
4 3.19E-02 0.6496 0.1608 4 0.7619 4.97E-01 0.0518 
5 0.172 0.4158 0.056 5 0.5751 5.38E-01 0.0141 
6 0.2586 0.4655 0.0523 6 0.9246 7.63E-01 0.0602 
 
 
 
